

## Lehne's Pharmacotherapeutics 3rd Edition PDF

Visit the link below to download the full version of the ebook

# [DOWNLOAD NOW](#)



Scan to Download  
or Type the Link

[ebook.ac/lehne3e](http://ebook.ac/lehne3e)

ROSENTHAL • BURCHUM

**LEHNE'S**  
**PHARMACOTHERAPEUTICS**  
for Advanced Practice Nurses  
and Physician Assistants

THIRD EDITION



Evolve\*


Student Resources on Evolve  
Access Code Inside

Evolve®

# YOU'VE JUST PURCHASED MORE THAN A TEXTBOOK!

## Enhance your learning with Evolve Student Resources.

These online study tools and exercises can help deepen your understanding of textbook content so you can be more prepared for class, perform better on exams, and succeed in your course.



Activate the complete learning experience that comes with each NEW textbook purchase by registering with your scratch-off access code at

<http://evolve.elsevier.com/Rosenthal/pharmacotherapeutics/>

If your school uses its own Learning Management System, your resources may be delivered on that platform. Consult with your instructor.

If you rented or purchased a used book and the scratch-off code at right has already been revealed, the code may have been used and cannot be re-used for registration. To purchase a new code to access these valuable study resources, simply follow the link above.



## REGISTER TODAY!



You can now purchase Elsevier products on Evolve!  
Go to [evolve.elsevier.com/shop](http://evolve.elsevier.com/shop) to search and browse for products.

# CONTENTS

## UNIT I Introduction

---

- 1 Prescriptive Authority, 1
- 2 Rational Drug Selection and Prescription Writing, 6
- 3 Promoting Positive Outcomes of Drug Therapy, 10

## UNIT II Basic Principles of Pharmacology

---

- 4 Pharmacokinetics, Pharmacodynamics, and Drug Interactions, 15
- 5 Adverse Drug Reactions and Medication Errors, 36
- 6 Individual Variation in Drug Responses, 44
- 7 Genetic and Genomic Considerations in Pharmacotherapeutics, 48

## UNIT III Drug Therapy Across the Life Span

---

- 8 Drug Therapy During Pregnancy and Breastfeeding, 53
- 9 Drug Therapy in Pediatric Patients, 59
- 10 Drug Therapy in Geriatric Patients, 63

## UNIT IV Peripheral Nervous System Drugs

---

- 11 Basic Principles of Neuropharmacology, 69
- 12 Physiology of the Peripheral Nervous System, 73
- 13 Muscarinic Agonists and Cholinesterase Inhibitors, 83
- 14 Muscarinic Antagonists, 92
- 15 Adrenergic Agonists, 100
- 16 Adrenergic Antagonists, 109
- 17 Indirect-Acting Antiadrenergic Agents, 120

## UNIT V Central Nervous System Drugs

---

- 18 Introduction to Central Nervous System Pharmacology, 125
- 19 Drugs for Parkinson Disease, 127
- 20 Drugs for Alzheimer Disease, 144
- 21 Drugs for Seizure Disorders, 152
- 22 Drugs for Muscle Spasm and Spasticity, 169

## UNIT VI Drugs for Pain

---

- 23 Local Anesthetics, 177
- 24 Opioid Analgesics, Opioid Antagonists, and Nonopioid Centrally Acting Analgesics, 181
- 25 Drugs for Headache, 192

## UNIT VII Psychotherapeutic Drugs

---

- 26 Antipsychotic Agents and Their Use in Schizophrenia, 201
- 27 Antidepressants, 212
- 28 Drugs for Bipolar Disorder, 226
- 29 Sedative-Hypnotic Drugs, 232
- 30 Management of Anxiety Disorders, 241

- 31 Central Nervous System Stimulants and Attention-Deficit/Hyperactivity Disorder, 246

## UNIT VIII Substance Use Disorders

---

- 32 Substance Use Disorders I: Basic Considerations, 253
- 33 Substance Use Disorders II: Alcohol, 258
- 34 Substance Use Disorders III: Nicotine and Smoking, 265
- 35 Substance Use Disorders IV: Major Drugs of Misuse Other Than Alcohol and Nicotine, 270

## UNIT IX Drugs That Affect the Heart, Blood Vessels, Blood, and Blood Volume

---

- 36 Review of Hemodynamics, 281
- 37 Diuretics, 286
- 38 Drugs Acting on the Renin-Angiotensin-Aldosterone System, 293
- 39 Calcium Channel Blockers, 304
- 40 Vasodilators, 309
- 41 Drugs for Hypertension, 312
- 42 Drugs for Heart Failure, 321
- 43 Antidysrhythmic Drugs, 333
- 44 Prophylaxis of Atherosclerotic Cardiovascular Disease: Drugs That Help Normalize Cholesterol and Triglyceride Levels, 345
- 45 Drugs for Angina Pectoris, 360
- 46 Anticoagulant and Antiplatelet Drugs, 368
- 47 Drugs for Deficiency Anemias, 385

## UNIT X Drugs for Endocrine Disorders

---

- 48 Drugs for Diabetes, 393
- 49 Drugs for Thyroid Disorders, 416

## UNIT XI Reproductive Health

---

- 50 Estrogens and Progestins: Basic Pharmacology and Noncontraceptive Applications, 425
- 51 Birth Control, 437
- 52 Androgens, 447
- 53 Drugs for Benign Prostatic Hyperplasia, 453
- 54 Drugs for Sexual Dysfunction, 457
- 55 Transgender Health, 466

## UNIT XII Antiinflammatory, Antiallergic, and Immunologic Drugs

---

- 56 Review of the Immune System, 475
- 57 Childhood Immunization, 484
- 58 Antihistamines, 495
- 59 Cyclooxygenase Inhibitors, Nonsteroidal Antiinflammatory Drugs, and Acetaminophen, 500
- 60 Glucocorticoids in Nonendocrine Disorders, 510

## **UNIT XIII Drugs for Bone and Joint Disorders**

---

- 61** Drug Therapy for Rheumatoid Arthritis, 519
- 62** Drug Therapy for Gout, 534
- 63** Drugs Affecting Calcium Levels and Bone Mineralization, 540

## **UNIT XIV Respiratory Tract Drugs**

---

- 64** Drugs for Asthma and Chronic Obstructive Pulmonary Disease, 557
- 65** Drugs for Allergic Rhinitis, Cough, and Colds, 577

## **UNIT XV Gastrointestinal Drugs**

---

- 66** Drugs for Peptic Ulcer Disease, 585
- 67** Laxatives, 594
- 68** Other Gastrointestinal Drugs, 601

## **UNIT XVI Nutrition and Complementary Therapies**

---

- 69** Vitamins, 611
- 70** Drugs for Obesity, 621
- 71** Complementary and Alternative Therapy, 630

## **UNIT XVII Therapy for Infectious and Parasitic Diseases**

---

- 72** Basic Principles of Antimicrobial Therapy, 645
- 73** Drugs That Weaken the Bacterial Cell Wall I: Penicillins, 656
- 74** Drugs That Weaken the Bacterial Cell Wall II: Other Drugs, 663
- 75** Bacteriostatic Inhibitors of Protein Synthesis, 670
- 76** Aminoglycosides: Bactericidal Inhibitors of Protein Synthesis, 677

- 77** Sulfonamide Antibiotics and Trimethoprim, 682
- 78** Drug Therapy for Urinary Tract Infections, 689
- 79** Drug Therapy for Tuberculosis, 694
- 80** Miscellaneous Antibacterial Drugs, 707
- 81** Antifungal Agents, 711
- 82** Antiviral Agents I: Drugs for Non-HIV Viral Infections, 721
- 83** Antiviral Agents II: Drugs for HIV Infection, 745
- 84** Drug Therapy for Sexually Transmitted Infections, 764
- 85** Anthelmintics, 773

## **UNIT XVIII Cancer Therapy**

---

- 86** Introduction to Immunomodulators, 779
- 87** Supportive Care of Patients Receiving Anticancer Drugs, 782
- 88** Drugs for Cancer Pain, 811

## **UNIT XIX Drugs for Eyes, Ears, and Skin**

---

- 89** Drugs for Disorders of the Eye, 819
- 90** Drugs for Disorders of the Skin, 830
- 91** Drugs for Disorders of the Ear, 855

## **UNIT XX Drug Therapy in Acute Care**

---

- 92** Agents Affecting the Volume and Ion Content of Body Fluids, 863
- 93** Management of ST-Elevation Myocardial Infarction, 867
- 94** Drugs for Acute Care, 872

**Appendix: Canadian Drug Information, 883**

**Index, 887**



# **LEHNE'S** **PHARMACOTHERAPEUTICS**

for Advanced Practice Nurses  
and Physician Assistants

**THIRD EDITION**

**LAURA D. ROSENTHAL, DNP, RN, ACNP-BC, FAANP**

Professor, College of Nursing  
University of Colorado Anschutz Medical Campus  
Aurora, Colorado

**JACQUELINE ROSENJACK BURCHUM, DNSc, FNP-BC, CNE**

Associate Professor, College of Nursing  
Department of Advanced Practice and Doctoral Studies  
University of Tennessee Health Science Center  
Memphis, Tennessee



Elsevier  
3251 Riverport Lane  
St. Louis, Missouri 63043

LEHNE'S PHARMACOTHERAPEUTICS FOR ADVANCED PRACTICE  
NURSES AND PHYSICIAN ASSISTANTS, THIRD EDITION

ISBN: 978-0-323-93606-4

Copyright © 2026 by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Publisher's note: Elsevier takes a neutral position with respect to territorial disputes or jurisdictional claims in its published content, including in maps and institutional affiliations.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: [www.elsevier.com/permissions](http://www.elsevier.com/permissions).

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

#### Notice

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds or experiments described herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. To the fullest extent of the law, no responsibility is assumed by Elsevier, authors, editors or contributors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

Previous editions copyrighted 2021 and 2018.

*Executive Content Strategist:* Lee Henderson  
*Senior Content Development Manager:* Lisa P. Newton  
*Publishing Services Manager:* Julie Eddy  
*Senior Project Manager:* Rachel E. McMullen  
*Design Direction:* Renee Duenow

Printed in India

Last digit is the print number: 9 8 7 6 5 4 3 2 1



*In remembrance of Victoria "Vicki" Erickson,  
a nursing leader, mentor, colleague, and friend.*

*You are missed by many.*

**LDR**

*To my remarkable students.*

*It excites me to know that the future of nursing is in your most capable hands.*

**JRB**

# ACKNOWLEDGMENTS

We would like to acknowledge the support of our colleagues at Elsevier, including Lee Henderson, Executive Content Strategist; Lisa Newton, Senior Content Development Manager; and Rachel McMullen, Senior Project Manager. Finally, we would like to acknowledge the foundational work by Richard A. Lehne. His dedication to the Lehne Pharmacology series made this text possible.

# ABOUT THE AUTHORS



**Laura D. Rosenthal, DNP, RN, ACNP-BC, FAANP**, has been a registered nurse since graduating with her Bachelor of Science degree in Nursing from the University of Michigan in 2000. She completed her Master of Science degree in Nursing in 2006 at Case Western Reserve University in Cleveland, Ohio. She finished her nursing education at the University of Colorado, College of Nursing, graduating with her Doctor of Nursing Practice degree in 2011. Her background includes practice in acute care and inpatient medicine. While working as a nurse practitioner at the University of Colorado Hospital, she assisted in developing one of the first fellowships for advanced practice clinicians in hospital medicine.

Dr. Rosenthal serves as a professor at the University of Colorado College of Nursing, where she teaches within the undergraduate and graduate programs and serves as the director of the DNP program. She received the Dean's Award for Excellence in Teaching in 2013 and the AANP State Award for Excellence in 2015.

In her spare time, Dr. Rosenthal enjoys running, skiing, and fostering retired greyhounds for Colorado Greyhound Adoption.



**Jacqueline Rosenjack Burchum, DNSc, FNP-BC, CNE**, has been a family nurse practitioner since earning her Master of Science in Nursing degree in 1996. She completed her Doctor of Nursing Science degree in 2002. As a nurse practitioner, Dr. Burchum's work centers on addressing the needs of vulnerable populations with a particular focus on providing care for immigrants and refugees.

Dr. Burchum currently serves as an associate professor for the University of Tennessee Health Science Center (UTHSC) College of Nursing. She is credentialed as a certified nurse educator (CNE) by the National League for Nursing. She is a three-time recipient of the UTHSC Student Government Association's Excellence in Teaching Award and a recipient of the 2014 UT Alumni Association's Outstanding Teacher Award. Dr. Burchum was also the 2016–2017 Faculty Innovation Scholar for the UTHSC Teaching and Learning Center.

Dr. Burchum has a special interest in online teaching and program quality. To this end, she serves as an on-site evaluator for the Commission on Collegiate Nursing Education (CCNE), a national agency that accredits nursing education programs. In addition, she is a Master Reviewer for Quality Matters, a program that certifies the quality of online courses.

In her spare time, she enjoys spending time with family, designing and making quilts, and working on the family hobby farm.

# CONTRIBUTOR AND REVIEWERS

## CONTRIBUTOR

---

**Courtney Charles, BSP, BCGP**  
Lecturer, College of Pharmacy and Nutrition  
University of Saskatchewan, Saskatoon  
Saskatoon, Saskatchewan, Canada  
*Appendix: Canadian Drug Information*

## REVIEWERS

---

**Kathryn S. Tierney, MSN, APRN, FNP-BC, FAANP**  
Medical Director, Middlesex Health Center for Gender  
Medicine and Wellness  
Middlesex Health  
Division of Endocrinology  
Middletown, Connecticut

**Chris Paxos, PharmD, BCPP, BCPS, BCGP**  
Director, Pharmacotherapy  
Associate Professor, Pharmacy Practice  
Associate Professor, Psychiatry  
Northeast Ohio Medical University  
Rootstown, Ohio

**Reamer L. Bushardt, PharmD, PA-C, DFAAPA**  
Professor, Provost & Vice President for Academic Affairs  
MGH Institute of Health Professions  
Boston, Massachusetts

# PREFACE

Pharmacology and pharmacotherapeutics pervade all phases of advanced practice nursing and physician assistant practice and relate directly to patient care and education. Despite their importance, many students—and even some teachers—are often uncomfortable with these subjects because traditional textbooks have stressed *memorizing* rather than *understanding*. In this book, the guiding principle is to establish further understanding of drugs and their use in patient care.

This textbook has two major objectives: to help you establish a continued knowledge base in the basic science of drugs and to show you how that knowledge can be applied in clinical practice. The methods by which these goals are achieved are described here.

## LAYING FOUNDATIONS IN BASIC PRINCIPLES

To understand drugs, you need a solid foundation in basic pharmacologic principles. To help you establish that foundation, the book has major chapters on the following topics: basic principles that apply to all drugs (Chapters 4 through 7), basic principles of drug therapy across the life span (Chapters 8 through 10), basic principles of neuropharmacology (Chapter 11), and basic principles of antimicrobial therapy (Chapter 72).

## REVIEWING PHYSIOLOGY AND PATHOPHYSIOLOGY

To understand the actions of a drug, it is useful to understand the biological systems that the drug influences. Accordingly, for all major drug families, relevant physiology and pathophysiology are reviewed. In almost all cases, these reviews are presented at the beginning of each chapter rather than in the systems review at the beginning of a unit. This juxtaposition of pharmacology, physiology, and pathophysiology is designed to help you understand how these topics interrelate.

## TEACHING THROUGH PROTOTYPES

Within each drug family, we can usually identify a prototype—that is, a drug that embodies characteristics shared by all members of the group. Because other family members are similar to the prototype, to know the prototype is to know the basic properties of all family members.

The benefits of teaching through prototypes can be appreciated with an example. Let's consider the nonsteroidal antiinflammatory drugs (NSAIDs), a family that includes aspirin, ibuprofen (Motrin), naproxen (Aleve), celecoxib (Celebrex), and more than 20 other drugs. Traditionally, information on these drugs is presented in a series of

paragraphs describing each drug in turn. When attempting to study from such a list, you are likely to learn many drug names and little else; the important concept of similarity among family members is easily lost. In this book, the family prototype—*aspirin*—is discussed first and in depth. After this, the small ways in which individual NSAIDs differ from aspirin are pointed out. This approach is not only more efficient than the traditional approach but also more effective, in that similarities among family members are emphasized.

## USING CLINICAL REALITY TO PRIORITIZE CONTENT

This book contains two broad categories of information: pharmacology (i.e., basic science about drugs) and therapeutics (i.e., clinical use of drugs). To ensure that content is clinically relevant, we use evidence-based treatment guidelines as a basis for deciding what to stress and what to play down. Unfortunately, clinical practice is a moving target: When effective new drugs are introduced and clinical trials reveal new benefits or new risks of older drugs, the guidelines change—and so we must work hard to keep this book current. Despite our best efforts, the book and clinical reality may not always agree. We therefore encourage you to use this book as a textbook in order to understand how particular drug classes are used therapeutically, but to rely on continually updated drug resources for day-to-day prescribing.

## SPECIAL FEATURES

**Summary of Key Prescribing Considerations:** These summaries provide guidance for safe prescribing practices and include information such as baseline data collection, monitoring needs, identification of high-risk patients, and evaluation for therapeutic effects.

**Prototype Drugs:** Denoted in teal boxes; these key drugs are easy to locate.

**Black Box Warnings:** This feature draws the reader's attention to important safety concerns related to contraindications and adverse effects.

**Patient Education:** These boxes offer important information to provide to patients regarding their therapy.

**Person-Centered Care Across the Life Span:** These boxes in many chapters highlight care concerns for patients throughout their lives, from infancy to older adulthood.

**Canadian trade names** are identified by a **maple leaf icon**.

## TEACHING SUPPLEMENTS FOR INSTRUCTORS

The Instructor Resources are available online and include a **Test Bank**, a **PowerPoint Collection**, and an **Image Collection**.

## STUDENT RESOURCES

Student Resources: New online student resources include one **Case Study** and **Review Questions** per textbook section.

## WAYS TO USE THIS TEXTBOOK

Thanks to its focus on essentials, this book is especially well suited to serve as the primary text for a course dedicated specifically to pharmacology and pharmacotherapeutics. In addition, the book's focused approach makes it a valuable resource for pharmacologic instruction within an integrated curriculum and for self-directed learning by students, teachers, and practitioners.

How is this focus achieved? Four primary techniques are employed: (1) teaching through prototypes, (2) limiting discussion of adverse effects and drug interactions to information that matters most, and (3) using evidence-based clinical guidelines to determine what content to stress.

Students often feel that pharmacology is one of the most difficult classes to master. Pharmacotherapeutics can be an unpopular subject because of the vast and rapidly changing area of content. We hope that this book makes the subjects of pharmacology and pharmacotherapeutics easier for you to master and more enjoyable for you to understand by allowing you to focus on the most important umbrella concepts of pharmacology and pharmacotherapeutics as they relate to the care and safety of patients and the management of their health problems.

**Laura D. Rosenthal**  
**Jacqueline Rosenjack Burchum**

# CONTENTS

## UNIT I Introduction

- 1 Prescriptive Authority, 1
- 2 Rational Drug Selection and Prescription Writing, 6
- 3 Promoting Positive Outcomes of Drug Therapy, 10

## UNIT II Basic Principles of Pharmacology

- 4 Pharmacokinetics, Pharmacodynamics, and Drug Interactions, 15
- 5 Adverse Drug Reactions and Medication Errors, 36
- 6 Individual Variation in Drug Responses, 44
- 7 Genetic and Genomic Considerations in Pharmacotherapeutics, 48

## UNIT III Drug Therapy Across the Life Span

- 8 Drug Therapy During Pregnancy and Breastfeeding, 53
- 9 Drug Therapy in Pediatric Patients, 59
- 10 Drug Therapy in Geriatric Patients, 63

## UNIT IV Peripheral Nervous System Drugs

- 11 Basic Principles of Neuropharmacology, 69
- 12 Physiology of the Peripheral Nervous System, 73
- 13 Muscarinic Agonists and Cholinesterase Inhibitors, 83
- 14 Muscarinic Antagonists, 92
- 15 Adrenergic Agonists, 100
- 16 Adrenergic Antagonists, 109
- 17 Indirect-Acting Antiadrenergic Agents, 120

## UNIT V Central Nervous System Drugs

- 18 Introduction to Central Nervous System Pharmacology, 125
- 19 Drugs for Parkinson Disease, 127
- 20 Drugs for Alzheimer Disease, 144
- 21 Drugs for Seizure Disorders, 152
- 22 Drugs for Muscle Spasm and Spasticity, 169

## UNIT VI Drugs for Pain

- 23 Local Anesthetics, 177
- 24 Opioid Analgesics, Opioid Antagonists, and Nonopioid Centrally Acting Analgesics, 181
- 25 Drugs for Headache, 192

## UNIT VII Psychotherapeutic Drugs

- 26 Antipsychotic Agents and Their Use in Schizophrenia, 201
- 27 Antidepressants, 212
- 28 Drugs for Bipolar Disorder, 226
- 29 Sedative-Hypnotic Drugs, 232
- 30 Management of Anxiety Disorders, 241

- 31 Central Nervous System Stimulants and Attention-Deficit/Hyperactivity Disorder, 246

## UNIT VIII Substance Use Disorders

- 32 Substance Use Disorders I: Basic Considerations, 253
- 33 Substance Use Disorders II: Alcohol, 258
- 34 Substance Use Disorders III: Nicotine and Smoking, 265
- 35 Substance Use Disorders IV: Major Drugs of Misuse Other Than Alcohol and Nicotine, 270

## UNIT IX Drugs That Affect the Heart, Blood Vessels, Blood, and Blood Volume

- 36 Review of Hemodynamics, 281
- 37 Diuretics, 286
- 38 Drugs Acting on the Renin-Angiotensin-Aldosterone System, 293
- 39 Calcium Channel Blockers, 304
- 40 Vasodilators, 309
- 41 Drugs for Hypertension, 312
- 42 Drugs for Heart Failure, 321
- 43 Antidysrhythmic Drugs, 333
- 44 Prophylaxis of Atherosclerotic Cardiovascular Disease: Drugs That Help Normalize Cholesterol and Triglyceride Levels, 345
- 45 Drugs for Angina Pectoris, 360
- 46 Anticoagulant and Antiplatelet Drugs, 368
- 47 Drugs for Deficiency Anemias, 385

## UNIT X Drugs for Endocrine Disorders

- 48 Drugs for Diabetes, 393
- 49 Drugs for Thyroid Disorders, 416

## UNIT XI Reproductive Health

- 50 Estrogens and Progestins: Basic Pharmacology and Noncontraceptive Applications, 425
- 51 Birth Control, 437
- 52 Androgens, 447
- 53 Drugs for Benign Prostatic Hyperplasia, 453
- 54 Drugs for Sexual Dysfunction, 457
- 55 Transgender Health, 466

## UNIT XII Antiinflammatory, Antiallergic, and Immunologic Drugs

- 56 Review of the Immune System, 475
- 57 Childhood Immunization, 484
- 58 Antihistamines, 495
- 59 Cyclooxygenase Inhibitors, Nonsteroidal Antiinflammatory Drugs, and Acetaminophen, 500
- 60 Glucocorticoids in Nonendocrine Disorders, 510

### UNIT XIII Drugs for Bone and Joint Disorders

---

- 61 Drug Therapy for Rheumatoid Arthritis, 519
- 62 Drug Therapy for Gout, 534
- 63 Drugs Affecting Calcium Levels and Bone Mineralization, 540

### UNIT XIV Respiratory Tract Drugs

---

- 64 Drugs for Asthma and Chronic Obstructive Pulmonary Disease, 557
- 65 Drugs for Allergic Rhinitis, Cough, and Colds, 577

### UNIT XV Gastrointestinal Drugs

---

- 66 Drugs for Peptic Ulcer Disease, 585
- 67 Laxatives, 594
- 68 Other Gastrointestinal Drugs, 601

### UNIT XVI Nutrition and Complementary Therapies

---

- 69 Vitamins, 611
- 70 Drugs for Obesity, 621
- 71 Complementary and Alternative Therapy, 630

### UNIT XVII Therapy for Infectious and Parasitic Diseases

---

- 72 Basic Principles of Antimicrobial Therapy, 645
- 73 Drugs That Weaken the Bacterial Cell Wall I: Penicillins, 656
- 74 Drugs That Weaken the Bacterial Cell Wall II: Other Drugs, 663
- 75 Bacteriostatic Inhibitors of Protein Synthesis, 670
- 76 Aminoglycosides: Bactericidal Inhibitors of Protein Synthesis, 677

- 77 Sulfonamide Antibiotics and Trimethoprim, 682
- 78 Drug Therapy for Urinary Tract Infections, 689
- 79 Drug Therapy for Tuberculosis, 694
- 80 Miscellaneous Antibacterial Drugs, 707
- 81 Antifungal Agents, 711
- 82 Antiviral Agents I: Drugs for Non-HIV Viral Infections, 721
- 83 Antiviral Agents II: Drugs for HIV Infection, 745
- 84 Drug Therapy for Sexually Transmitted Infections, 764
- 85 Anthelmintics, 773

### UNIT XVIII Cancer Therapy

---

- 86 Introduction to Immunomodulators, 779
- 87 Supportive Care of Patients Receiving Anticancer Drugs, 782
- 88 Drugs for Cancer Pain, 811

### UNIT XIX Drugs for Eyes, Ears, and Skin

---

- 89 Drugs for Disorders of the Eye, 819
- 90 Drugs for Disorders of the Skin, 830
- 91 Drugs for Disorders of the Ear, 855

### UNIT XX Drug Therapy in Acute Care

---

- 92 Agents Affecting the Volume and Ion Content of Body Fluids, 863
- 93 Management of ST-Elevation Myocardial Infarction, 867
- 94 Drugs for Acute Care, 872

Appendix: Canadian Drug Information, 883

Index, 887

## Prescriptive Authority

Our purpose in writing this book is to prepare advanced practice providers to provide safe and competent medication therapy to patients. This role requires the ability to select, prescribe, and manage medications. In this chapter we examine issues surrounding prescriptive authority and how those issues affect this fundamental aspect of comprehensive patient care.

### WHAT IS PRESCRIPTIVE AUTHORITY?

*Prescriptive authority* is the legal right to prescribe drugs. Full prescriptive authority affords the legal right to prescribe independently and without limitation. Physicians have full prescriptive authority. For nonphysician providers, the degree of prescriptive authority varies. Some have full prescriptive authority; however, for many, prescriptive authority is restricted. Limitations are generally tied to oversight by a doctor of medicine (MD) or doctor of osteopathy (DO) as part of the provider's scope of practice.

Recall that there are two components of prescriptive authority: (1) the right to prescribe independently and (2) the right to prescribe without limitation. The provider who prescribes independently is not subject to rules requiring physician supervision or collaboration. The provider who prescribes without limitation may prescribe any drugs, including controlled drugs, with the exception of schedule I drugs, which have no current medical use.

Full practice authority is sometimes interpreted differently for advanced practice registered nurses (APRNs) and physician assistants<sup>a</sup> (PAs) because supervisory requirements vary for the two professions. PAs are required to have an affiliation with a physician in order to practice and prescribe. All PAs, including those in a solo practice, must establish a relationship with physician who serves in a supervisory or collaborative role and who can be reached by telephone or other means of telecommunication. (See *PA State Laws and Regulations* available at <https://www.aapa.org/advocacy-central/state-advocacy/state-laws-and-regulations> for additional information.) If the PA–physician arrangement does not limit drugs that may be prescribed and if the law allows the PA to prescribe schedule II to V drugs, the PA may enjoy a type of quasifull prescriptive authority. Indeed, some have referred to this as full prescriptive authority; however,

the issue of being affiliated with a physician still applies. Hence PAs do not have the legal right to prescribe without the PA–physician arrangement. Even for those in solo practice, there is always the possibility of dissolution of the PA–physician arrangement. In the event this occurs, the PA must affiliate with another physician or physician group to continue prescribing.

Whether APRNs possess full prescriptive authority depends on their legal right to prescribe without a supervisory or collaborative requirement. APRNs are *educated* to practice and prescribe independently without supervision; however, some state laws require that they practice in collaboration with or under the supervision of a physician. In these situations, some physicians limit the types of drugs that the APRN can prescribe. State laws may place additional restrictions with regard to controlled drugs.

Table 1.1 provides prescriptive authority status for certified midwives and nurse practitioners. Table 1.2 provides prescriptive authority status for PAs. Table 1.3 provides this information for certified registered nurse anesthetists. Information regarding the right to prescribe controlled drugs is available at <http://www.deadiversion.usdoj.gov/drugreg/practioners>.

### PRESCRIPTIVE AUTHORITY REGULATIONS

Prescriptive authority is determined by state law. As a result of differences from state to state, advanced practice providers may have full prescriptive authority in some states yet face significant restrictions in other states. The stark differences particularly affect providers who serve in *locum tenens* (temporary) staffing positions or who have practices in two contiguous states.

The regulation of prescriptive authority is under the jurisdiction of a health professional board. This may be the State Board of Nursing, the State Board of Medicine, or the State Board of Pharmacy, as determined by each state.

Although the federal government controls drug regulation, it has no control over prescriptive authority. However, several organizations have appealed for changes that would place scope of practice and prescriptive authority under federal regulation in an effort to expand prescriptive authority and the scope of practice of advanced practice providers. For example, National Academy of Medicine (formerly the Institute of Medicine or IOM) advocated for federal regulation in their report, *The Future of Nursing: Leading Change, Advancing Health*. After noting problems with the “patchwork of state regulations,” they wrote:

*Some states have kept pace with the evolution of the health care system by changing their scope-of-practice regulations to allow nurse practitioners to see patients and prescribe medications without a physician's supervision or collaboration. However, the majority of state laws lag behind in this regard. ... The federal government*

<sup>a</sup>In May, 2021, the AAPA (American Association of Physician Associates, formerly American Association of Physician Assistants) passed a resolution adopting the name physician associate as the official title for PAs. The reason we use physician assistant in this book is based on AAPA advice which states, “PAs should continue to use ‘physician assistant’ or ‘PA’ as their official legal title in a professional capacity ... until the jurisdiction governing their licensure and practice has formally adopted the title of ‘physician associate.’” (See <https://www.aapa.org/title-change/general-faqs>.)

**TABLE 1.1 Advanced Practice Registered Nurse: Nurse Midwife and Nurse Practitioner Practice and Prescriptive Authority by State**

State	Scheduled Drugs	Physician Relationship Required	Transition to Independent Practice and Prescribing Period Required	Full Independent Practice Authority but Physician Relationship Required for Prescriptive Authority	Full Independent Practice Authority but Transition to Independent Prescribing Period	Full Independent Practice and Prescriptive Authority
AL	III-V, limited II	CNM, NP				
AK	II-V					CNM, NP
AZ	II-V					CNM, NP
AR	III-V, limited II		NP			CNM
CA	II-V		NP	CNM		
CO	II-V				CNM, NP	
CT	II-V		NP			CNM
DE	II-V					CNM, NP
FL	II-V		CNM, NP			
GA	III-V	CNM, NP				
HI	II-V					CNM, NP
ID	II-V					CNM, NP
IL	II-V		CNM, NP			
IN	II-V (within limits)	CNM, NP				
IA	II-V					CNM, NP
KS	II-V					CNM, NP
KY	II-V			CNM, NP		
LA	III-V, limited II	CNM, NP				
ME	II-V		NP			CNM
MD	II-V		NP			CNM
MA	II-V				NP	CNM
MI	II-V	NP		CNM		
MN	II-V		NP			CNM
MS	II-V	CNM, NP				
MO	III-V, limited II	CNM, NP				
MT	II-V					CNM, NP
NE	II-V	CNM	NP			
NV	II-V					CNM, NP
NH	II-V					CNM, NP
NJ	II-V	CNM		NP		
NM	II-V					CNM, NP
NY	II-V		NP			CNM
NC	II-V	CNM, NP				
ND	II-V					CNM, NP
OH	II-V	CNM, NP				
OK	III-V			CNM, NP		
OR	II-V					CNM, NP
PA	II-V	CNM, NP				
RI	II-V					CNM, NP
SC	II-V	CNM, NP				
SD	II-V					CNM, NP
TN	II-V	CNM, NP				
TX	III-V, limited II	CNM, NP				
UT	II-V			CNM		NP
VT	II-V		CNM, NP			
VA	II-V		CNM, NP			
WA	II-V					CNM, NP
WV	II-V				CNM, NP	

**TABLE 1.1 Advanced Practice Registered Nurse: Nurse Midwife and Nurse Practitioner Practice and Prescriptive Authority by State—cont'd**

State	Scheduled Drugs	Physician Relationship Required	Transition to Independent Practice and Prescribing Period Required	Full Independent Practice Authority but Physician Relationship Required for Prescriptive Authority	Full Independent Practice Authority but Transition to Independent Prescribing Period	Full Independent Practice and Prescriptive Authority
WI	II–V	CNM, NP				
WY	II–V					CNM, NP

CNM, Certified nurse midwife; NP, certified nurse practitioner.

Adapted from U.S. Health Resources and Services Administration (HRSA). (2023). *NCSL Scope of Practice Policy Advanced Practice Registered Nurses: Nurse Practitioner Practice Authority*. <https://scopeofpracticepolicy.org/practitioners/advanced-practice-registered-nurses/sop/nurse-practitioner-practice-authority>; HRSA. *NCSL Scope of Practice Policy Advanced Practice Registered Nurses: Certified Nurse Midwife Practice Authority*. (2023). <https://scopeofpracticepolicy.org/practitioners/advanced-practice-registered-nurses/sop/certified-nurse-midwife-practice-authority>; and Drug Enforcement Agency. *Mid-Level Practitioners—Controlled Substance Authority by Discipline Within State*. (2023). [https://www.deadiversion.usdoj.gov/drugreg/practitioners/mlp\\_by\\_state.pdf](https://www.deadiversion.usdoj.gov/drugreg/practitioners/mlp_by_state.pdf).

**TABLE 1.2 Physician Assistant Practice and Prescriptive Authority by State<sup>a</sup>**

State	Scheduled Drugs	Physician Supervision Required for Practice and Prescriptive Authority	Physician Collaboration Allowed for Practice and Prescriptive Authority	Supervision or Collaboration Not Required for Practice or Prescriptive Authority
AL	II–V	✓		
AK	II–V		✓	
AZ	II–V		✓	
AR	II–V	✓		
CA	II–V	✓		
CO	II–V		✓	
CT	II–V	✓		
DE	II–V		✓	
FL	II–V	✓		
GA	III–V	✓		
HI	III–V	✓		
ID	II–V		✓	
IL	II–V		✓	
IN	II–V		✓	
IA	II–V			✓
KS	II–V	✓		
KY	None	✓		
LA	II–V	✓		
ME	II–V		✓	
MD	II–V		✓	
MA	II–V	✓		
MI	II–V		✓	
MN	II–V		✓	
MS	II–V	✓		
MO	III–V	✓		
MT	III–V			✓
NE	II–V	✓		
NV	II–V	✓		
NH	II–V		✓	
NJ	II–V	✓		
NM	II–V		✓	
NY	II–V	✓		
NC	II–V	✓		
ND	II–V			✓
OH	II–V	✓		
OK	II–V	✓		
OR	II–V		✓	

Continued

TABLE 1.2 Physician Assistant Practice and Prescriptive Authority by State—cont'd

State	Scheduled Drugs	Physician Supervision Required for Practice and Prescriptive Authority	Physician Collaboration Allowed for Practice and Prescriptive Authority	Supervision or Collaboration Not Required for Practice or Prescriptive Authority
PA	II–V	✓		
RI	II–V		✓	
SC	II–V	✓		
SD	II–V	✓		
TN	II–V		✓	
TX	III–V	✓		
UT	II–V			✓
VT	II–V		✓	
VA	II–V		✓	
WA	II–V	✓		
WV	III–V		✓	
WI	II–V		✓	
WY	II–V			✓

<sup>a</sup>Physician assistants (PAs) are required to have a PA–physician relationship that is detailed in a written practice agreement.

Adapted from Health Resources and Services Administration. (2023). *NCSL Scope of Practice Policy*. <https://scopeofpracticepolicy.org/practitioners/physician-assistants>; and Drug Enforcement Agency. (2023). *Mid-Level Practitioners—Controlled Substance Authority by Discipline Within State*. [https://www.deadiversion.usdoj.gov/drugreg/practioners/mlp\\_by\\_state.pdf](https://www.deadiversion.usdoj.gov/drugreg/practioners/mlp_by_state.pdf).

TABLE 1.3 Certified Registered Nurse Anesthetist Prescriptive Authority by State

State	Physician Relationship Required or Prescriptive Authority Limited	Independent Prescriptive Authority	No Prescriptive Authority
AL			✓
AK		✓	
AZ	✓		
AR	✓		
CA			✓
CO	✓		
CT	✓		
DE		✓	
FL	✓		
GA			✓
HI		✓	
ID		✓	
IL	✓		
IN			✓
IA		✓	
KS			✓
KY	✓		
LA	✓		
ME	✓		
MD		✓	
MA	✓		
MI	✓		
MN		✓	
MS			✓
MO	✓		
MT		✓	
NE			✓
NV			✓
NH		✓	
NJ	✓		
NM		✓	
NY			✓
NC			✓

TABLE 1.3 Certified Registered Nurse Anesthetist Prescriptive Authority by State—cont'd

State	Physician Relationship Required or Prescriptive Authority Limited	Independent Prescriptive Authority	No Prescriptive Authority
ND		✓	
OH	✓		
OK	✓		
OR		✓	
PA			✓
RI			✓
SC			✓
SD		✓	
TN	✓		
TX	✓		
UT			✓
VT		✓	
VA	✓		
WA		✓	
WV	✓		
WI	✓		
WY		✓	

Adapted from American Association of Nurse Anesthesiology (AANA) State Government Affairs Division. (2023). *Prescriptive Authority Map*. <https://www.aana.com/wp-content/uploads/2023/04/CRNA-Prescriptive-Authority-1.png>.

*has a compelling interest in the regulatory environment for health care professions because of its responsibility to patients covered by federal programs. ... Equally important is the responsibility to all American taxpayers who fund the care provided under these programs to ensure that their tax dollars are spent efficiently. ... Scope-of-practice regulations in all states should reflect the full extent not only of nurses but of each profession's education and training.* (<https://nap.nationalacademies.org/download/12956>)

## THE CASE FOR FULL PRESCRIPTIVE AUTHORITY

- Advanced practice providers complete rigorous programs of study, largely in accredited programs that meet stringent national standards. Although there are differences in each program, all include common components. For example, they require extensive education focused on assessment, diagnosis, and management of health problems. Diagnostic reasoning, critical thinking, and procedural skills are evaluated in both didactic and clinical courses. National examinations validate the ability to provide safe and competent care. Licensure ensures that providers comply with standards of practice that promote public health and safety. In short, advanced practice providers are prepared to fully implement the advanced practice role in their profession.
- Limited prescriptive authority creates numerous barriers to quality, affordable, and accessible patient care. For example, restrictions on the distance of the APRN or PA from the physician providing supervision or collaboration may prevent outreach to areas of greatest need. A requirement to obtain the physician's cosignature on prescriptions can increase patient waits. Despite the use of terms such as *collaborative* arrangement, these relationships create a situation in which one partner holds the power. In the event of dissolution of the arrangement, the ultimate loss is commonly assumed by the advanced practice provider rather than the physician.
- In 2021, the Association of American Medical Colleges released a report projecting the future of the physician workforce, *The Complexities of Physician Supply and Demand: Projections from 2019 to*

2034 (<https://www.aamc.org/media/54681/download>). Several key findings have important implications for nonphysician providers.

- By 2034, the shortage of physicians is projected to range between 37,800 and 124,000. In primary care alone, a 17,800 to 48,000 physician shortage is anticipated. (*The lower numbers on these ranges reflect an increase in APRNs and PAs used to help offset physician shortages.*)
- The report notes, "The supply of advanced practice registered nurses (APRNs) and physician assistants (PAs) continues to grow rapidly, along with improved understanding of their value in care delivery and in helping improve access to care for underserved populations" and "A growing body of literature, both in the United States and internationally, indicates APRNs and PAs provide high-quality care, increase physician productivity, and, in some specialties, perform many of the same functions as physicians ..."
- In the wake of this realization, implementation of the Affordable Care Act has increased the demand for provider coverage. The recent and ongoing COVID-19 (coronavirus disease identified in 2019) crisis has also highlighted the necessity of preparing for an uncertain future.
- In these scenarios, in which physician demands are excessive, requiring oversight for other providers may be untenable. To adequately meet the demands for future health care needs, APRNs and PAs will need broader practice privileges than some states currently allow. This includes an imperative to allow full prescriptive authority.

## PRESCRIPTIVE AUTHORITY AND RESPONSIBILITY

The possession of full prescriptive authority requires a somber responsibility. Whether you are reading this book as a student or as a practicing provider, it is essential to recognize the full obligation this requires. The safe and competent practice of prescribing and managing medications requires a sound understanding of drugs and the conditions that they are used to manage. It is our goal to help you lay that foundation. In the coming chapters, you will read about rational drug selection, writing prescriptions, and promoting positive outcomes. Then we will delve into the heart of pharmacology through a study of pharmacokinetics and pharmacodynamics as we prepare you for the study of individual drug categories.

# Rational Drug Selection and Prescription Writing

## RESPONSIBILITY OF PRESCRIBING

As a practitioner, you will assume great responsibility when caring for patients. The ability to prescribe medications is both a privilege and a burden. Although you may be familiar with many drugs through your previous practice as a registered nurse or other member of the health care field, giving medications and prescribing medications are two very different things. There are many different issues to consider when writing a prescription, many of which we discuss in this chapter or in the previous chapter regarding prescriptive authority.

The best way to keep your patients (and yourself) safe is to be prudent and deliberate in your decision-making process. Have a documented provider–patient relationship with the person for whom you are prescribing. Do not prescribe medications for family or friends or for yourself. Document a thorough history and physical examination in your records. Include any discussions you have with the patient regarding risk factors, side effects, or therapy options. Have a documented plan regarding drug monitoring or titration, if applicable. If you consult additional providers, note that you did so. Finally, use the references provided in [Box 2.1](#) to assist in safely and rationally choosing one medication over another.

## DRUG SELECTION

### Cost

The cost of medications in the United States has risen steeply within the past 10 years. Increasing cost is related to multiple factors, including corporate competition. It is also noted that one of the reasons people do not adhere to their prescribed medication regimen is its excessive cost. Often, we are so concerned with obtaining the right diagnosis and making our patient well that we overlook key pieces of information, including patient financial status. When patients cannot afford the drug you prescribe, they may not get well, even though they want to be compliant. It is of critical importance that providers ask patients if they have difficulty obtaining their medication because it is cost prohibitive.

If you find that your patient is having difficulty purchasing the prescribed medications, consider changing pharmacies or drug regimens. The cost of a drug can vary widely between pharmacies, even within the same city. Many corporations have created generic \$4 lists or special prescription programs that allow patients to fill their medications for a reasonable cost. In addition, all health plans through the Affordable Care Act (ACA) are required to include prescription drug coverage, although these vary greatly. As a prescriber, you need to be familiar with the local resources for medication assistance and low-cost medications.

### Guidelines

When in doubt, follow current guidelines for the treatment of a particular disease or symptom. Almost all medical and nursing societies

have published guidelines, including the American Heart Association, the American College of Cardiology, the Infectious Diseases Society of America, and the American Diabetes Association. It is the provider's responsibility to keep abreast of new recommendations or changes in guidelines and to incorporate these into their prescribing practices. Although closely following the guidelines is desirable, we must always take into account that our patients may not fit well into these guidelines and that individualized care is always best. In these cases, it is important to document the rationale for deviating from standard of care.

### Availability

Every facility and pharmacy provides drugs according to a formulary. This formulary is selected by a panel of pharmacists and providers and may be subject to following guidelines created by regulatory agencies, such as the Centers for Medicare and Medicaid Services (CMS). The formulary may also depend on regional and national drug supplies, drug costs and available rebates, and the presence of generic medications on the market.

In short, the drug you want may not be available in your facility or at a specific pharmacy. This can affect your choice in medications. Become familiar with the formulary where you are employed and know that it can change over time. Often there are substitutes or similar medications you can order in place of what you originally intended. For example, omeprazole may be indicated for the treatment of erosive esophagitis, but the formulary contains esomeprazole instead.

### Interactions

As noted throughout this text, there are few medications that do not interact with either another medication or a food. Polypharmacy greatly increases the risk for interactions. Some of these interactions are negligible, but some can have life-threatening consequences. It is of crucial importance to ask the patient about *all* current drugs, including over-the-counter (OTC) medications and herbal preparations. Many patients do not consider OTC or alternative pharmaceuticals as “medications” and may not mention them unless you ask specifically.

When adding a new medication to a patient regimen, check for significant interactions. There are many resources that allow checks for interactions between multiple medications or foods at one time. If there is a low-risk interaction identified, you may find it acceptable to discuss this with your patient, document the conversation, and then prescribe the medication. If there is a relative or absolute contraindication to the proposed drug combination, it is best to choose an alternative if at all possible.

### Side Effects

All drugs have side effects. Some are adverse, and some may be beneficial. In addition, one patient may experience adverse effects to a

### BOX 2.1 Helpful Applications and Websites for Safe Prescribing

#### Websites

Epocrates: <http://www.epocrates.com/>  
 LexiComp: <http://online.lexi.com/action/home>  
 Pepid: <http://www.pepid.com/>  
 Physicians' Desk Reference (PDR): <http://www.pdr.net/>  
 UptoDate: <http://www.uptodate.com/contents/search>

#### Applications for Tablets, Phones

Centers for Disease Control and Prevention Antibiotic Guidelines  
 Elsevier Clinical Pharmacology  
 Epocrates  
 Pepid  
 Prescriber's Letter

medication, whereas another patient may not. It is important to note the pertinent side effects for each medication and to ask your patients about presence of symptoms after initiating, stopping, or changing a medication dose. When assessing the risk-to-benefit ratio of a medication, one must consider the severity of the side effects. If a patient started on a new antihypertensive medication has a decreased blood pressure, and therefore improvement in hypertension, but experiences fainting, a decrease in dose or a different medication should be considered.

### Allergies

At times, guidelines may suggest a particular drug for a specific ailment. Unfortunately, your patient may have an allergy to that medication or class of drug. It is of critical importance to determine the type of reaction and to document in the patient's chart. Then, selection of an appropriate drug may begin.

In the case of severe allergy, such as anaphylaxis or swelling of the face, these drugs are absolutely contraindicated, but in the case of the patient who experienced vomiting or other similar reactions, the drug may be used again if necessary. The desired choice would be to use an alternate medication that is just as effective. For example, a patient with pyelonephritis who is allergic to penicillin can benefit from a fluoroquinolone instead.

### Hepatic and Renal Function

Many drugs are metabolized and eliminated by the liver and kidneys. If these systems are impaired, this can lead to increased adverse effects and possible medication overdose. Frequently, drugs have special decreased doses or different dosing schedules for patients with hepatic or renal impairment. This is known as *hepatic dosing* or *renal dosing*. Despite the known safety of decreasing doses in some drugs, if there is a different option available, it is prudent to choose a different medication. For example, morphine sulfate is highly metabolized by the kidneys. For patients with renal impairment, morphine can be used to treat pain, but the better choice would be fentanyl because fentanyl does not require a dose reduction in patients with renal impairment. Although some drugs are safe to give or can be used with caution in patients with hepatic or renal dysfunction, other drugs are contraindicated in these patients and must be avoided at all costs.

### Need for Monitoring

Some drugs require frequent monitoring at initiation or throughout the duration of treatment. Examples of these medications include warfarin, lithium, opioids, and immunosuppressive therapies (tacrolimus, sirolimus). When levels of these drugs are not within therapeutic range, serious patient harm can occur. If a patient does not have the ability to attend frequent laboratory appointments, cannot take their medications reliably, or is not easily reachable by phone or electronically, it may be best to try and avoid these medications if possible.

### Special Populations

Populations that deserve special mention when thinking about medications include pregnant or nursing mothers and older adults. These populations are addressed in depth in Unit III, Drug Therapy Across the Life Span. In addition, Life Span Tables are present in many of the chapters throughout the text to alert you to special considerations.

## PRESCRIPTIONS

### Necessities

When writing any prescription, there are key elements that must be present to compose a complete prescription. An example of a common template for a written prescription is provided in Fig. 2.1. These elements include the following:

- Prescriber name, license number, and contact information

UNIVERSITY CLINIC  
 Robert Smith, FNP-BC  
 1777 E. 17th Avenue  
 Las Vegas, CO 87777  
 Phone: 777-777-7777 Fax: 777-777-7778

---

Patient Name: \_\_\_\_\_ Date: \_\_\_\_\_  
 Allergies: \_\_\_\_\_  
 Medical Record#: \_\_\_\_\_ Date of Birth: \_\_\_\_\_  
 Medication: \_\_\_\_\_ Strength: \_\_\_\_\_ Quantity: \_\_\_\_\_  
 Directions for Use: \_\_\_\_\_ 0 DAW

Indication for use: \_\_\_\_\_ Refills: \_\_\_\_\_  
 Prescriber Signature: \_\_\_\_\_ DEA# \_\_\_\_\_  
 License# \_\_\_\_\_ NPI # \_\_\_\_\_  
 Contact #/Pager # \_\_\_\_\_

**Fig. 2.1** Common Example of a Written Prescription. *DAW*, dispense as written; *DEA*, U.S. Drug Enforcement Administration; *NPI*, National Provider Identifier.

- Prescriber U.S. Drug Enforcement Administration (DEA) number, if applicable
- Patient name and date of birth
- Patient allergies
- Name of medication
- Indication of medication (e.g., atenolol for hypertension)
- Medication strength (e.g., 25 mg, 500 mg/mL)
- Dose of medication and frequency (e.g., 12.5 mg once daily)
- Number of tablets or capsules to dispense
- Number of refills
- If using an electronic medical record (EMR) to complete prescriptions, many of these elements will be mandatory for the provider, although many will already be completed by the EMR, including prescriber name and contact information. It is important to note the indication for the medication because many drugs are used for more than one purpose. This allows for the patient as well as other providers to understand your intent for prescribing this particular drug.

## Types of Prescriptions

### Telephone

A common and convenient way to create a new prescription or prescription refill is by telephone. A prescription can be called in to a pharmacy by you or a specified designee. This is often done by leaving a message with the correct information. Although this is a different way of prescribing, the necessities remain the same (see earlier section “Necessities”). Certain medications cannot be prescribed or refilled by telephone. These include medications within the schedule II category. Patients must have a written prescription for these medications. The only exception to this rule is during an emergency. In this case a telephone order can be used for a limited amount of medication, but a written prescription must be presented to the pharmacy within 7 days.

### Written

Providers have been writing prescriptions in the United States since the 1700s. Patients even received scripts during Prohibition in the 1920s to purchase alcohol for medicinal use (Fig. 2.2). Interestingly enough, these paper scripts did not look much different than they do nowadays. This is because the required elements for a complete

prescription have not changed over the years. Although health care is making the transition to electronic prescriptions, many providers still use written scripts to prescribe medication. Written prescriptions, like telephone calls or electronic scripts, contain all the necessary elements as described earlier in this chapter. Although all the correct prompts for information may be prepopulated on your script, there are still some important points to consider. If you use a script with a different provider name or a generic script, make sure your name and contact information are printed legibly on the paper. Write all prescriptions in ink or indelible pencil. Avoid abbreviations such as U (units), MSO<sub>4</sub> (morphine), or QD (daily) because these can increase errors and are therefore no longer acceptable. For a list of abbreviations to avoid, see Table 2.1.

In addition, never write prescriptions on presigned scripts or pre-sign blank scripts for other providers or staff. Although this may seem like a convenient way to ensure availability to patients at all times, it is ultimately an unsafe practice. Finally, many facilities provide tamper-resistant scripts, and some states require their use, especially in the prevention of substance misuse and abuse. A few tamper-resistant security features include Hidden Message Technology, which appears when the script is copied on a copy machine; Anti-Copy Coin Rub, which appears when rubbed with a coin; and distinctive security backgrounds.

### E-Prescribing

With the advent of the EMR, many pharmacies currently have capabilities to accept electronic prescriptions. In fact, CMS provides incentives for using an EMR to prescribe medications. This program, called *Meaningful Use*, is thought to contribute to increased patient safety and improved patient outcomes.

Using an EMR allows the provider to select a specific, patient-selected pharmacy. After the correct medication information is entered, the prescription is automatically sent to the selected pharmacy. This is beneficial because there is direct transmission of information, making error less likely. In addition, the prescription can be ready for the patient when the patient leaves the facility—the patient does not need to drop off the paper script and then wait for a medication fill. Before the advent of two-factor authentication software, limitations to e-prescribing included scheduled medications. Currently, many companies like




Fig. 2.2 Prohibition Era Prescription for Alcohol.

**TABLE 2.1 Abbreviations and Figures to Avoid**

Do Not Use	Preferred
U	Units
IU	International units
QD	Daily
QOD	Every other day
Trailing zero (X.0 mg)	Never trail (X mg)
Lack of leading zero (.X mg)	Always lead with a zero before a decimal point (0.X mg)
MS, MSO <sub>4</sub> , MgSO <sub>4</sub>	Morphine sulfate, magnesium sulfate
AS, AD, AU	Left ear, right ear, both ears
OS, OD, OU	Left eye, right eye, both eyes

Duo, Nexmo, and OneLogin provide an extra layer of security through use of a smartphone to verify identity at the time of prescribing. These programs are incorporated into the EMR, allowing electronic prescribing of scheduled medications directly to the pharmacy. Unfortunately, many health care organizations still do not have a functional EMR, and many pharmacies still do not have the software capabilities to process these requests. In these cases, paper prescriptions are still necessary.

### Refills

There are a few things to consider when refilling a prescription. Questions you should ask yourself include the following:

- Is this a newer medication for this patient?
- Am I changing dose or frequency of the medication?
- Am I adding new medications to their regimen?
- Is the patient having undesired side effects?
- When do I expect to follow up with this patient?
- If the patient is requesting a refill by telephone, when was the last time I saw this patient? Do I need to see the patient again before refill?
- Is this a schedule II medication?

If the answer to any of these questions is “yes,” consider a shorter time between refills (1 to 3 months). The exception to this question is with schedule II medications. These are not eligible for refills and must have a new prescription each renewal period. When changing or

adding to current medication regimens, it is prudent to follow up with the patient by phone or in person to assess changes. This time can be used to discuss new or increased side effects, check vital signs, obtain laboratory work, or make further adjustments. When a medication, such as warfarin, requires frequent monitoring with drug levels, an even shorter refill allotment is reasonable. If the patient has been maintained on the current dose of a medication for some time and remains stable, it is likely acceptable to continue to refill that medication for a longer time period (e.g., 12 months).

## ASSISTANCE

### Applications for Tablets and Phones

This textbook will be paramount in your learning, but it may not be convenient to carry around in the clinical setting. Although we encourage you to use this text to the fullest extent, there are many new applications and websites available to assist providers with safe prescribing (Box 2.1). However, it must be noted that all these tools still require common sense and good judgment on the part of the prescriber. As stated previously, one must take into account the individual patient and multiple other factors, including cost, side effects, and medication formularies. An application can assist you with the basic suggestions in dosing and duration, but ultimately there is no substitute for sound practice.

### Collaboration

As reflected in this chapter, writing a prescription safely can be complicated. It is strongly encouraged that you use all available resources, including your colleagues. Developing a relationship with your pharmacist can be one of the most helpful and fruitful relationships you cultivate. Because this is their specialty, pharmacists will likely have additional information on formulary and drug interactions, as well as suggestions for adequate medication dosing. In some practices, pharmacists are responsible for medication initiation and titration based on standardized protocols.

Infectious disease (ID) specialists can also be a helpful resource. Choosing an appropriate antimicrobial agent for a specific infectious process is often difficult for a new practitioner. A local ID specialist can provide guidance on resistance patterns, common local microbial flora, and correct doses, as well as on duration of treatment for specific infections.

# Promoting Positive Outcomes of Drug Therapy

Selecting and prescribing the most appropriate drug (see Chapter 2) is just the first step in providing safe and competent medication therapy. Ensuring positive outcomes requires establishing a medication education plan, monitoring positive and negative patient responses, identifying and addressing issues of nonadherence, and managing the patient's complete medication regimen.

## MEDICATION EDUCATION

Probably no other provider action influences the patient's commitment to carry out a medication plan more than medication education. This provides an opportunity to not only explain the importance of the medication but also dispel rumors about medications that often lead to therapy failures. Moreover, education reduces medication errors by empowering patients with accurate information and clear guidelines.

### Medication Education Components

There are basic components that should be included when teaching about any new medication. These are (1) medication name, (2) purpose, (3) dosing regimen, (4) administration, (5) adverse effects, (6) any special storage needs, (7) associated laboratory testing, (8) food or drug interactions, and (9) duration of therapy. Each of these is discussed in the following sections.

#### Medication Name

Patients need to know the name of the medication they are taking. Unfortunately, when taking a medication history, we still have patients who refer to medications by their understood purpose (e.g., "blood pressure pill") rather than by their name. This creates a challenge for the provider who needs to select appropriate therapy. It also increases the risk for medication errors. If we teach patients the medication names, we can avoid this concern.

Patients should be encouraged to keep a list of their medications on their person at all times. Both the generic name and brand (trade) name should be included. This can be especially important for the patient who travels and may be treated by providers unfamiliar with the patient's history.

#### Purpose

Patients are more likely to participate in activities when they know those activities produce positive outcomes. The same is true of taking medications. Knowing why the medication is prescribed promotes follow-through with the medication plan.

#### Dosing

The dosing regimen needs to be reviewed with the patient even though it is written on the prescription label. Doing this ensures that the

patient understands how to take the medication and provides an opportunity for the patient to ask questions.

It is important to be specific when explaining the dosing regimen. For example, "four times a day" may be interpreted in various ways by different people. Can the medication be taken every 4 hours for four doses, or does it need to be spaced out evenly to every 6 hours? Does "once a day" mean that it can be taken at any time, or is it better to take the medication in the morning or evening hours? Patients need to know what to do if a dose is accidentally skipped. This is also a good time to explain why drugs should be taken exactly as prescribed.

#### Administration

A common patient concern is whether medication should be taken with or without food. This routine information should be provided for all drugs.

Patients also need to be informed of common administration needs that many of us take for granted. For example, suspensions should be shaken (or rolled, if shaking causes foaming) to equally disperse ingredients before administration.

Finally, some drugs require a special apparatus for administration. Inhaled drugs are a common example. Patients need to see how these are administered and should be able to repeat a demonstration before leaving with a prescription. Many manufacturers provide a device without medication for teaching purposes.

#### Adverse Effects

Some providers and other health care workers hesitate to discuss a drug's potential adverse effects for fear that doing so will lead to a patient's refusal to take the medication. Although that concern is understandable and the consequences may well be true, patients have a right to know of potential harms that may result from therapy. Therefore providers are ethically obligated to divulge adverse effects and other risks. That said, often the approach used in discussing these can make a difference in how patients view them.

When discussing adverse effects, focus on the adverse effects that are common and avoid undue attention on rare and unanticipated effects. If complex effects such as liver injury or pancytopenia may occur, teach patients the signs and symptoms to report. Let patients know that many adverse effects—most commonly nausea and sedation—are usually temporary and go away with continued medication use. In these discussions, it is also beneficial to emphasize benefits over risks. Patients are often willing to endure short-term adverse effects for long-term health improvement.

#### Storage

Storage is an important concern for some drugs. For example, some antibiotic suspensions, insulins, and rectal suppositories need to be

refrigerated. Medications such as sublingual nitroglycerin and dabigatran (Pradaxa) need to be stored in their original container to prevent drug breakdown and loss of potency.

### Laboratory Testing

Laboratory testing is sometimes necessary to determine whether a medication remains safe and effective. For example, liver enzymes may need to be checked periodically for drugs that can cause liver damage. Serum drug levels may need to be checked when maintaining therapeutic levels is challenging.

Patients need to know if special testing will be needed. They also need to know why the monitoring is necessary because those who understand the purpose are more likely to adhere to testing schedules. We recommend teaching what, when, where, why, and how when giving instructions (Box 3.1).

### Food or Drug Interactions

Many medications interact with certain foods or other drugs (including alcohol and other recreational drugs). Patients need to know of any potential interactions and the consequence of those interactions. They also need to know if the problem with interactions can be solved by taking substances further apart or whether they need to avoid an interacting food or drug for the duration of therapy. For example, antacids may be taken with most drugs as long as administration is separated by 2 hours; however, patients taking oral metronidazole must avoid alcohol for the duration of therapy.

### Duration of Therapy

It is important to let the patient know if medication therapy is being prescribed for a short time (e.g., antibiotics for an acute infection) or whether ongoing long-term medication therapy is anticipated (e.g., thyroid hormone therapy for hypothyroidism). Failure to recognize the need for prolonged therapy is a common reason patients stop medications prematurely when a prescription runs out.

#### BOX 3.1 Patient Teaching for Drug Monitoring

When testing is needed for monitoring, include the following when providing patient teaching.

**What:** What test is needed?

Patients like to know what test is needed. Rather than telling them that a blood test is needed, let them know the type of blood test (e.g., a test of thyroid function or cholesterol levels).

**When:** When is testing required?

Testing can disrupt normal routines. Patients need to know, in advance, how often testing is needed so that they can make plans.

**Where:** Where will testing take place?

In some practices, testing takes place at locations other than the primary clinic. Patients who are unfamiliar with the area need directions to the testing site and where to go after arrival.

**Why:** Why is testing necessary?

Testing is often expensive and disruptive to daily lives. These barriers are common reasons that patients miss appointments. If they understand the need for testing, they are more likely to adhere to testing schedules.

**How:** How does the patient prepare for testing?

Some tests require special preparation. For example, many blood tests require fasting. If exercise testing is needed, patients should be told to bring comfortable shoes. It is important to let patients know of anything they need to do before arrival.

### Written Instructions

Medication information is notoriously easy to forget, especially for patients taking numerous medications. We recommend accompanying all verbal education with written instructions. For those who are unable to read due to literacy or vision problems, video or audio instructions can be used.

The Patient Protection and Affordable Care Act of 2010, Title V, defines health literacy as “the degree to which an individual has the capacity to obtain, communicate, process, and understand basic health information and services to make appropriate health decisions.” Low levels of health literacy can impair a patient’s ability to understand medication instructions. Best practices in developing written patient education materials abound in the literature. Table 3.1 provides a list of those for which there is greatest consensus. An excellent resource for writing patient education materials is available at [http://www.cdc.gov/healthliteracy/pdf/Simply\\_Put.pdf](http://www.cdc.gov/healthliteracy/pdf/Simply_Put.pdf).

## MONITORING

As mentioned in Chapter 2, monitoring is an important consideration in medication therapy. Ongoing monitoring of positive and negative patient responses—and acting on those responses in ways that increase benefit or decrease risk—is essential to ensure optimal outcomes.

There are three primary reasons for drug monitoring: (1) determining therapeutic dosage, (2) evaluating medication adequacy, and (3) identifying adverse effects. Each of these purposes is discussed in the following sections. Table 3.2 provides some common examples of drugs that require periodic laboratory monitoring.

### Determining Therapeutic Dosage

Many drugs have a narrow therapeutic index (NTI) (see Chapter 4). Examples include carbamazepine, digoxin, lithium, phenytoin, and theophylline. For these drugs, the difference between an effective dose and a lethal dose is small.

To ensure safety, periodic measurement of serum drug levels is needed when drugs with an NTI are prescribed. This determines whether the drug is in a therapeutic range and also provides an

TABLE 3.1 Best Practices in Developing Written Patient Education Materials

Practice	Rationale
Limit content	Focus on main points. Include only the most important-to-know content.
Place important information first	People tend to remember the first things they read and may become distracted toward the end.
Write in active voice	Active voice is more direct. Passive voice is less dynamic and may be confusing.
Include adequate white space	White space does not contain text or images. White space makes the page feel less cluttered and less overwhelming.
Use meaningful illustrations	Illustrations are a useful way to break up text. Select images or drawings that have a purpose or that reinforce a point in the handout.
Avoid professional terminology	Use common terms in short, simple sentences that patients can easily understand.
Check for readability	Materials should be written at a lower education level that can be understood by most patients. Information for increasing readability is available at <a href="http://www.cdc.gov/healthliteracy/pdf/Simply_Put.pdf">http://www.cdc.gov/healthliteracy/pdf/Simply_Put.pdf</a> .

**TABLE 3.2 Selected Medications That Require Periodic Laboratory Monitoring**

Drug or Drug Category	Laboratory Testing	Reason for Monitoring
ACEIs and ARBs	Potassium Serum creatinine	These drugs can cause hyperkalemia. Renal perfusion is dependent on angiotensin in some patients; increased creatinine may require change in medication.
Amiodarone	Liver function Thyroid function Pulmonary function and chest radiographs	Hepatotoxicity is an adverse effect. Either hypothyroidism or hyperthyroidism may occur. Pulmonary toxicity is not uncommon; effects may be permanent.
Antiseizure drugs	Serum drug levels	Determination of therapeutic dosage is needed. Some have narrow therapeutic index.
Antidiabetic drugs	Serum glucose Hemoglobin A <sub>1c</sub>	Determination of glucose control is needed.
Digoxin	Digoxin level Serum electrolytes if at risk	This drug has a narrow therapeutic index. Hypokalemia, hypomagnesemia, and hypercalcemia can increase toxicity risk. Hypocalcemia can render the drug ineffective.
Diuretics, potassium-sparing	Serum electrolytes	Hyperkalemia can reach dangerous levels. Hypocalcemia and hypomagnesemia may occur.
Diuretics, thiazide and loop	Serum electrolytes	Hypokalemia, hypomagnesemia, and hyponatremia are common. Thiazide diuretics can cause hypercalcemia; loop diuretics can cause hypocalcemia.
Lithium	CBC Lithium level Thyroid function Renal function	Lithium can cause leukocyte elevation. The drug has a narrow therapeutic index. Both hypothyroidism and hyperthyroidism may occur. Renal damage is a serious adverse effect.
Methotrexate	Serum electrolytes CBC Liver function Renal function	Nephrogenic diabetes insipidus may occur; hyponatremia can create complications. Pancytopenia, or a decrease of any of the blood cell types, may occur. Hepatotoxicity is an adverse effect. Renal toxicity is an adverse effect.
NSAIDs (long-term use)	CBC Serum creatinine Liver function	Anemia may occur, especially if there is bleeding, which may be occult. Prostaglandin inhibition may decrease renal perfusion, causing injury. Rare but serious liver injury has occurred.
Statins	Liver function Creatine kinase	Elevations in liver enzymes may be associated with injury. Creatine kinase can determine whether muscle pain is caused by injury secondary to drug use.
Thiazolidinediones	Lipid panel Liver function	Lipids are checked to determine effect. These drugs are associated with a risk for hepatotoxicity.
Thyroid hormone	TSH, T <sub>4</sub>	Monitoring is needed to optimize therapy.
Warfarin	PT/INR	Monitoring is needed to maintain therapeutic range.

ACEI, Angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CBC, complete blood count; NSAIDs, nonsteroidal antiinflammatory drugs; PT/INR, prothrombin time/international normalized ratio; T<sub>4</sub>, thyroxine TSH; thyroid-stimulating hormone.

opportunity for fine-tuning the dosage. If a drug is nearing a toxic level or a subtherapeutic level, the provider will make a dosage adjustment accordingly. How often monitoring is needed varies for each drug. In addition, patient factors such as poor liver or renal function may determine the frequency of drug level monitoring.

For some drugs with an NTI, a therapeutic dosage is determined by means other than the serum drug level. Warfarin is a drug that illustrates this method. Instead of ordering a serum warfarin level, optimal dosing is determined by measures of prothrombin time with international normalized ratio (PT/INR).

### Evaluating Medication Adequacy

For some drugs, evaluation of effectiveness can be determined easily. For example, if an analgesic is given, effectiveness is determined by asking the patient to rate the pain on a scale of 0 to 10. Similarly, the adequacy of an antihypertensive medication can be evaluated by checking the patient's blood pressure. However, evaluating medication adequacy is not so simple for some conditions.

Some conditions do not cause obvious signs or symptoms. Hyperlipidemia is a common example; signs and symptoms often do not appear until after decades of accumulated damage have occurred. Other conditions may be manifested by signs and symptoms that are not easily quantifiable. A common example of this condition is hyperglycemia associated with diabetes. Some people display obvious signs and symptoms when hyperglycemic, whereas for others, the evidence is much more subtle. For conditions such as hyperlipidemia and hyperglycemia, laboratory testing offers a precisely quantifiable measure that can be used to gauge the effectiveness of medication therapy. For example, a hemoglobin A<sub>1c</sub> level can be used to evaluate glucose control, and lipid panels can be used to determine the effectiveness of hyperlipidemia management.

### Identifying Adverse Effects

One of the most common uses of drug monitoring is that of monitoring for harm. This is a proactive undertaking to identify problems early, before they progress to the point of harm.

Many drugs are potentially dangerous. For these, monitoring depends on the type of potential injury. For example, if a drug can cause liver injury, periodic monitoring of liver enzymes (and possibly other tests of liver function) is needed. If a drug can cause bone marrow suppression, periodic monitoring of a complete blood count to assess for anemia, leukopenia, or thrombocytopenia is warranted. In addition, baseline laboratory studies are done before initiating therapy.

## ADHERENCE

Medication nonadherence costs the U.S. health care system approximately \$290 billion each year. It is often directly responsible for disease exacerbations, avoidable hospitalizations, transitioning to long-term (i.e., “nursing home”) care, and premature deaths.

Medication adherence can be defined as the extent to which patients take their medications as prescribed by the provider and agreed to by the patient.<sup>a</sup> The patient who adheres to the agreed-on medication regimen takes the medication in the prescribed dose at the prescribed frequency for the length of time indicated.

To determine the underlying reasons behind nonadherence, the National Community Pharmacists Association (NCPA) surveyed a random sample of 1020 adults aged 40 years or older with long-term medical conditions for which they were prescribed medications. Their findings were released as *Medication Adherence in America: A National Report Card* (available at [http://www.ncpa.co/adherence/AdherenceReportCard\\_Full.pdf](http://www.ncpa.co/adherence/AdherenceReportCard_Full.pdf)). The NCPA report identifies six nonadherent behaviors. They are, in the percentage of frequency, as follows:

- Missed a dose (57%)
- Forgot to take a dose (30%)

- Did not refill the medication in time (28%)
- Took a lower than prescribed dose (22%)
- Did not refill the medication (20%)
- Stopped taking the medication (14%)

The reasons given by patients to explain their nonadherence provide additional insight. Again, in the frequency of occurrence, they are as follows:

- Forgot to take it (42%)
- Ran out (34%)
- Was away from home (27%)
- Was trying to save money (22%)
- Didn't like the side effects (21%)
- Was too busy (17%)
- The medicine wasn't working (17%)
- Didn't believe the medicine was necessary (16%)
- Didn't like taking the medicine (12%)

These documents can offer valuable insight for the health care provider. Moreover, they beg the question, “What could the provider have done differently to address issues of nonadherence proactively?”

In examining these, five primary patterns emerge. These are (1) forgetfulness, (2) lack of planning, (3) cost, (4) dissatisfaction, and (5) altered dosing. An honest and open discussion that respects both the patient and provider perspectives can be an important facilitator to promoting positive outcomes. Individualized solutions that address the specific patient's concerns are those most likely to be successful (Table 3.3). Finally, provide positive feedback that reinforces how adherence has resulted in improved outcomes or health maintenance.

<sup>a</sup>The addition of “agreed to by the patient” distinguishes the definition of medication adherence from medication compliance. The concept of medication compliance has fallen out of favor because it views the provider from the perspective of an authoritarian who dictates treatment rather than a provider who makes decisions that consider the patient's preferences and values.

## MANAGING MEDICATION THERAPY

In addition to the medication review undertaken at each patient encounter, a more comprehensive and deliberate review is needed periodically (at least annually). This review should be approached with the intent purpose of determining whether there are better options for

**TABLE 3.3 Interventions to Address Nonadherence**

Forgetfulness	Schedule medications to align with daily activities to establish habits. Use memory aids such as medication organizers. Employ digital reminder apps on electronic devices. Develop a personalized medication administration record for home use. Simplify medication regimens by prescribing combination drugs. Use once-a-day formulations when feasible.
Lack of planning	Have the patient use a pharmacy that sends reminder messages regarding medication refills. Have the patient use a pharmacy that offers delivery services. Reduce the need to refill frequently by writing 90-day prescriptions.
Cost	Prescribe generic drugs, drugs on formularies, or drugs that are part of a discount pharmacy program to reduce out-of-pocket costs. Assist the patient in enrolling in prescription assistance programs (PAPs) when an expensive drug is needed <sup>a</sup> (see Table 3.4).
Dissatisfaction	Discuss medication concerns at each encounter. Determine if the problem can be addressed by simple interventions (e.g., taking medications with food to reduce nausea and gastrointestinal distress or changing to a sustained-release drug to address problems with inconvenient dosing). Explore consequences of not taking the drug and whether the patient is willing to assume those risks.
Altered dosing	Review drugs at each encounter and ask whether they are taken as prescribed. Identify the reasons why doses are altered and address those reasons specifically. Explain that drugs must reach a therapeutic level to be effective. A subtherapeutic dose is no better than no dose at all! Discuss dangers of low doses (e.g., for some antimicrobial drugs, subtherapeutic levels may cause harm if the bacteria develop resistance). Explain that increasing drug dosage can be dangerous and may increase adverse effects.

<sup>a</sup>Warn patients to beware of discount cards that are not affiliated with known reputable organizations. Unfortunately, some criminals use applications for fake cards for illegal purposes.

**TABLE 3.4 Patient Assistance Programs****Pharmaceutical Patient Assistance Programs**

Allergan	<a href="https://www.allergan.com/Home/patient-assistance-programs">https://www.allergan.com/Home/patient-assistance-programs</a>
AstraZeneca	<a href="http://www.astrazeneca-us.com/medicines/help-affording-your-medicines">http://www.astrazeneca-us.com/medicines/help-affording-your-medicines</a>
Boehringer Ingelheim	<a href="https://www.boehringer-ingelheim.us/our-responsibility/patient-assistance-program">https://www.boehringer-ingelheim.us/our-responsibility/patient-assistance-program</a>
Johnson & Johnson	<a href="http://www.jjpaf.org">http://www.jjpaf.org</a>
Merck	<a href="http://www.merckhelps.com">http://www.merckhelps.com</a>
Novartis	<a href="http://www.patientassistancenow.com">http://www.patientassistancenow.com</a>
Pfizer	<a href="http://www.pfizer.com/health/financial_assistance_programs/patient_assistance_programs">http://www.pfizer.com/health/financial_assistance_programs/patient_assistance_programs</a>
Takeda	<a href="https://www.takeda.com/en-us/what-we-do/patient-services/">https://www.takeda.com/en-us/what-we-do/patient-services/</a>

**Government Programs**

Medicare	<a href="https://www.medicare.gov/pharmaceutical-assistance-program">https://www.medicare.gov/pharmaceutical-assistance-program</a>
State-run programs	<a href="http://www.ncsl.org/research/health/state-pharmaceutical-assistance-programs.aspx">http://www.ncsl.org/research/health/state-pharmaceutical-assistance-programs.aspx</a>

**Nonprofit Organizations**

National Council on Aging	<a href="https://www.ncoa.org/age-well-planner/resource/how-to-get-help-with-your-prescription-drug-costs">https://www.ncoa.org/age-well-planner/resource/how-to-get-help-with-your-prescription-drug-costs</a>
NeedyMeds	<a href="http://www.needy meds.org">http://www.needy meds.org</a>
Patient Help Network	<a href="http://www.patienthelpnetwork.org/">http://www.patienthelpnetwork.org/</a>
RxAssist	<a href="http://www.rxassist.org">http://www.rxassist.org</a>
RxHope	<a href="https://www.rxhope.com/Patient/MedSearchHome.aspx">https://www.rxhope.com/Patient/MedSearchHome.aspx</a>
RxOutreach Online Nonprofit Pharmacy	<a href="https://rxoutreach.org">https://rxoutreach.org</a>

medication therapy. Inherent questions that must be asked about each drug include the following:

- Is each medication accomplishing its intended purpose?
- Is each medication still necessary?
  - Has the patient's condition changed?
  - Do adverse effects or risks outweigh the benefits that some drugs provide?
  - What would happen if some medications were no longer prescribed?
- What problems does each medication create for the patient?
  - Is a medication problem amplified by other drugs the patient is taking?
  - If a medication is necessary but problematic, are drugs with fewer adverse effects available?
- If polypharmacy is an issue, are there ways to decrease the number of medications?
  - Will a combination drug simplify management?
  - Is a single drug available (and desirable) for management of two different conditions?

Ideally, these reviews should be carried out in collaboration with the patient or patient's family so that nothing is overlooked. Medication regimens can then be optimized to eliminate unnecessary drugs, add new drugs, if necessary, and ultimately improve patient satisfaction with care.

**SUMMARY**

We have examined four opportunities to promote positive outcomes in drug therapy. Patients need adequate drug education to take drugs correctly and to avoid complications associated with therapy. Monitoring provides a method of ensuring safe and effective therapy. Promoting adherence, by addressing common causes of nonadherence proactively, can ensure ongoing therapy without interruption. Finally, scheduled medication reviews with the intent to optimize medication regimens, based on patient experiences and needs, can help promote positive outcomes.

# Pharmacokinetics, Pharmacodynamics, and Drug Interactions

## PHARMACOKINETICS

Pharmacodynamics is defined as the study of the biochemical and physiologic effects of drugs on the body and the molecular mechanisms by which those effects are produced. In essence, pharmacokinetics is the study of drug movement throughout the body. There are four basic pharmacokinetic processes: absorption, distribution, metabolism, and excretion (Fig. 4.1). *Absorption* is the drug's movement from its site of administration into the blood. *Distribution* is the drug's movement from the blood to the interstitial space of tissues and from there into cells. *Metabolism* (biotransformation) is the enzymatically mediated alteration of drug structure. *Excretion* is the movement of drugs and their metabolites out of the body. The combination of metabolism and excretion is called *elimination*. The four pharmacokinetic processes, acting in concert, determine the concentration of a drug at its sites of action.

By applying knowledge of pharmacokinetics to drug therapy, we can help maximize beneficial effects and minimize harm. Recall that the intensity of the response to a drug is directly related to the concentration of the drug at its site of action. To maximize beneficial effects, a drug must achieve concentrations that are high enough to elicit desired responses; to minimize harm, we must avoid concentrations that are too high. This balance is achieved by selecting the most appropriate route, dosage, and dosing schedule.

## PASSAGE OF DRUGS ACROSS MEMBRANES

All four phases of pharmacokinetics—absorption, distribution, metabolism, and excretion—involve drug movement. To move throughout the body, drugs must cross membranes. Drugs cross membranes as they pass from the site of administration into the bloodstream and, subsequently, as they leave the vascular system to reach the site of action. In addition, drugs must cross membranes to undergo metabolism and excretion. Accordingly, the factors that determine the passage of drugs across biologic membranes have a profound influence on all aspects of pharmacokinetics.

Biologic membranes are composed of layers of individual cells. The cells composing most membranes are close to one another—so close, in fact, that drugs must usually pass *through* cells, rather than between them, to cross the membrane. Hence the ability of a drug to cross a biologic membrane is determined primarily by its ability to pass through single cells.

## Three Ways to Cross a Cell Membrane

The three most important ways by which drugs cross cell membranes are (1) passage through channels or pores, (2) passage with the aid of a transport system, and (3) direct penetration of the membrane. Of the three, direct penetration of the membrane is most common.

### Channels and Pores

Few drugs cross membranes through channels or pores. The channels in membranes are extremely small and are specific for certain molecules. Consequently, only the smallest of compounds, such as potassium and sodium, can pass through these channels and then only if the channel is the right one.

### Transport Systems

Transport systems are carriers that can move drugs from one side of the cell membrane to the other side. All transport systems are selective. Whether a transporter will carry a particular drug depends on the drug's structure.

A number of drugs could not reach intracellular sites of action without a transport system to move them across the cell membrane. One transporter, known as *P-glycoprotein* (PGP) or *multidrug transporter protein*, deserves special mention. PGP is a transmembrane protein that transports a wide variety of drugs *out* of cells.

### Direct Penetration of the Membrane

For most drugs, movement throughout the body is dependent on the ability to penetrate membranes directly because (1) most drugs are too large to pass through channels or pores and (2) most drugs lack transport systems to help them cross all of the membranes that separate them from their sites of action, metabolism, and excretion.


A general rule in chemistry states that “like dissolves like.” Membranes are composed primarily of lipids; therefore, to directly penetrate membranes, a drug must be *lipid soluble* (lipophilic).

## POLAR MOLECULES AND IONS


Certain kinds of molecules are *not* lipid soluble and therefore cannot penetrate membranes. This group consists of *polar molecules* and *ions*.

### Polar Molecules

Polar molecules are molecules that have no *net* charge; however, they have an uneven *distribution* of electrical charge. That is, positive and



**Fig. 4.1** The Four Basic Pharmacokinetic Processes. Dotted lines represent membranes that must be crossed as drugs move throughout the body. *GI*, Gastrointestinal.



**Fig. 4.2** Polar Molecules. (A) Stippling shows the distribution of electrons within the water molecule. As indicated at the lower right, water's electrons spend more time near the oxygen atom than in the vicinity of the two hydrogen atoms, making the area near the oxygen atom somewhat negative and the area near the hydrogen atoms more positive. (B) Gentamicin is a polar drug. The 2-OH groups of gentamicin attract electrons, thereby causing the area around these groups to be more negative than the rest of the molecule.

negative charges within the molecule tend to congregate separately from one another. Water is the classic example. As depicted in Fig. 4.2, the electrons (negative charges) in the water molecule spend more time in the vicinity of the oxygen atom than in the vicinity of the two hydrogen atoms. As a result, the area around the oxygen atom tends to be negatively charged, whereas the area around the hydrogen atoms tends to be positively charged. In accord with the “like dissolves like” rule, polar molecules will dissolve in *polar* solvents (such as water) but not in *nonpolar* solvents (such as lipids).

## Ions

Ions are defined as molecules that have a *net electrical charge* (either positive or negative). Except for tiny molecules, *ions are unable to cross membranes*; therefore they must become nonionized to cross from one side to the other. Many drugs are either weak organic acids or weak organic bases, which can exist in charged and uncharged forms.

Whether a weak acid or base carries an electrical charge is determined by the pH of the surrounding medium. Acids tend to ionize in basic (alkaline) media, whereas bases tend to ionize in acidic media. Therefore drugs that are weak acids are best absorbed in an acidic environment such as gastric acid because they remain in a nonionized form. When aspirin molecules pass from the stomach and proximal small intestine into the more distal small intestine, where the environment is relatively alkaline, more of the molecules change to their ionized form. As a result, absorption of aspirin from the more distal intestine is impeded.

## pH Partitioning (Ion Trapping)

Because the ionization of drugs is pH dependent, when the pH of the fluid on one side of a membrane differs from the pH of the fluid on the other side, drug molecules tend to accumulate on the side where the pH most favors their ionization. Accordingly, because acidic drugs tend to ionize in basic media and because basic drugs tend to ionize in

- Glucocorticoids (*Continued*)  
 therapeutic uses in nonendocrine disorders, 512–513  
 topical, 830–831, 831t  
 withdrawal, 515–517
- Glucosamine and chondroitin, 638
- Glucose  
 alcohol effects on, 259  
 blood level testing, 395  
 homeostasis, and estrogens, 427–428  
 intolerance, oral contraceptives and, 441  
 self-monitoring, 395
- Glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide receptor agonist (GLP-1 RA), 411–413
- Glucose-6-phosphate dehydrogenase (G6PD) deficiency, 36
- $\alpha$ -glucosidase inhibitors, 408
- Glucuronidation, 20
- Glutamate antagonism, 154
- Glycogenolysis, 114
- Glycoprotein IIb/IIIa receptor antagonists, 869, 875
- Goiter  
 lithium, 229  
 simple, 421t  
 toxic nodular, 419
- Gold salts–auranofin (Ridaura), 527, 527b
- Golimumab, 529
- Gonadotropin-releasing hormone agonists, 797–798
- Gonadotropin-releasing hormone (GnRH) analogues  
 antagonists, 798  
 dosage, 471t  
 puberty suppression, 468
- Gonococcal infections, 765–766, 765f  
 disseminated gonococcal infection (DGI), 765
- Goserelin, 798
- Gout, 534  
 drug therapy  
 for acute gouty arthritis, 535–537  
 colchicine, 536  
 glucocorticoids, 536  
 for hyperuricemia, 537–539, 537f  
 nonsteroidal antiinflammatory drugs, 535–536  
 person-centered care across the life span, 534b  
 preparations and dosages, 535t  
 prototype drugs, 538b  
 pathophysiology of, 534  
 pharmacologic management of, 534
- Gram-negative cell envelope, 656
- Granisetron, 601, 603t
- Granulocytopenia, 726
- Grapefruit juice 34–35  
 nifedipine and, 308
- Graves disease, 419  
 radioactive iodine, 423
- Green tea, 638–639
- Griseofulvin, 720
- Gross malformations, teratogens exposure, 54
- Growth delay, glucocorticoids and, 513
- Guanfacine, 121  
 for attention-deficit/hyperactivity disorder (ADHD), 251
- H**
- Haemophilus influenzae* type b, 486  
 vaccine, 490–491
- Haemophilus vaginalis*, 767
- Hair (*Continued*)  
 cancer chemotherapy and, 788  
 drugs for, 853–854  
 seborrheic dermatitis and dandruff, 853
- Half-life, drug, 23
- digoxin, 330  
 epinephrine, 106
- Hallucinogen persisting perception disorder (HPPD), 278
- Haloperidol, 207, 603t
- Headache, 192–200  
 cluster headaches, 198  
 characteristics, 198  
 drug therapy, 198  
 treatment, 198  
 medication overuse headache (MOH), 198–199  
 migraine, 192–198  
 abortive therapy, 192–196, 193t  
 characteristics, 192  
 oral contraceptives and, 440  
 pathophysiology, 192  
 preventive therapy, 196–198  
 prototype drugs, 195b  
 from nitroglycerin, 362  
 treatment, 193t
- Health care-associated MRSA (HCA-MRSA), 657–658
- Hearing loss  
 aminoglycosides, 679  
 sildenafil and, 461
- Heart  
 adenosine effects on, 878  
 afterload, 282–283  
 amiodarone (Pacerone), 342  
 amiodarone effects on, 878  
 calcium channel blockers, 343  
 calcium channels, 304  
 digoxin, 343  
 diltiazem, 306  
 electrical properties, 333–335  
 lidocaine effects on, 877  
 muscarinic antagonists and, 93  
 oxygen demand and supply, 360  
 preload, 282  
 propranolol, 342  
 Starling law, 283  
 stroke volume, 282  
 verapamil, 304–305
- Heartburn, cimetidine for, 589
- Heart disease  
 antimicrobial drugs and, 654  
 digoxin and, 328  
 hormonal therapy and, 434
- Heart failure, 321–332  
 acute decompensated, 878–879  
 aldosterone antagonists and, 325  
 angiotensin-converting enzyme inhibitors, 296–297, 324  
 angiotensin II receptor blockers, 300, 325  
 $\beta$ 1 activation and, 104  
 $\beta$  blockade, 113  
 $\beta$  blockers, 325–326  
 cardiac remodeling in, 321–322  
 digoxin for, 326–330  
 diuretics for, 323–324  
 dopamine for, 107  
 electrical effects, 328  
 eplerenone for, 302–303  
 hemodynamic benefits, 327  
 increased sympathetic tone with, 321–322  
 loop diuretics, 324  
 management of, 330–332, 331f  
 drugs to avoid, 332  
 drug therapy, 331–332  
 treatment evaluation, 332
- Heart failure (*Continued*)  
 neurohormonal benefits in, 327  
 overview of drugs used to treat, 323–326  
 pathophysiology, 321–323  
 patient education, 328b  
 prototype drugs, 324b  
 renin-angiotensin-aldosterone system, 324–325  
 severity classification, 323  
 signs and symptoms, 323  
 spironolactone for, 291  
 ST-segment elevation myocardial infarction and, 870  
 vasodilators for, 326  
 vicious cycle of “compensatory” physiologic responses in, 322–323  
 water retention and increased blood volume with, 322
- Heart rate, 282  
 $\beta$ 1 activation and, 104
- Helicobacter pylori*, 585  
 first-line regimens for, 589t
- Helminthiasis. *See* Anthelmintics
- Helper T cells (CD4 cells), 475–477, 480–481  
 activation, 481
- Helper T lymphocytes, 475–477
- Hematologic effects  
 oxcarbazepine, 159  
 trimethoprim, 686
- Hematologic systems, glucocorticoids and, 510
- Hemodynamics, 281–285  
 arterial pressure regulation, 284–285  
 cardiac output regulation, 281–284  
 circulatory system overview, 281  
 heart failure and, 324  
 nifedipine, 307–308  
 vasodilators, 309–311  
 verapamil, 305
- Hemoglobin A<sub>1c</sub> measurement, 395–396, 396t
- Hemolytic anemia  
 indirect-acting antiadrenergic agents and, 122  
 sulfonamides and, 683
- Hemophilia, protease inhibitors and, 756
- Hemorrhage  
 abnormal uterine, oral contraceptives and, 440  
 clopidogrel and, 383  
 dabigatran and, 380  
 rivaroxaban, 380  
 unfractionated heparin, 372  
 warfarin, 376–377
- Hemostasis, 368–370  
 adrenergic agonists and antagonists and, 101
- Heparin, 371–375  
 continuous unfractionated heparin  
 intravenous infusion, 874  
 contrasts with warfarin, 377, 379t  
 low-dose unfractionated heparin therapy, 874  
 low-molecular-weight, 374  
 overdose, protamine sulfate for, 874  
 prescribing considerations, 374b  
 ST-segment elevation myocardial infarction and, 869  
 unfractionated  
 adverse effects, 372  
 anticoagulant action, 371–372  
 black box warning, 372b  
 chemistry level, 371  
 drug interactions, 374  
 laboratory monitoring, 374  
 mechanism of action, 373f  
 pharmacokinetics, doses, indications, 375t  
 prescribing considerations, 374b  
 therapeutic uses, 372  
 warnings and contraindications, 372–374
- Heparin-induced thrombocytopenia, 372
- Hepatic dosing, 7

- Hepatic drug-metabolizing enzymes, 19  
phenytoin, 158
- Hepatic function, 7
- Hepatic impairment, rivaroxaban and, 380
- Hepatic metabolism, in neonates and infants, 61
- Hepatitis, 728
- Hepatitis A, 487  
vaccine, 491–492
- Hepatitis B, 487, 734–736  
drugs for, 735t, 736b, 737b  
interferon alfa, 734–737, 736b  
nucleoside analogs for, 736–737  
vaccine, 491
- Hepatitis B reactivation, 529
- Hepatitis C, 729f  
drugs for, 732–733t, 732t  
interferon alfa, 732t, 733–736, 736b  
NS5A inhibitors, 730, 732t  
NS5B inhibitors, 730–733, 732t  
patient-centered care across the life span, 730b  
protease inhibitors, 730, 731t  
ribavirin, 733–734
- Hepatomegaly, with steatosis, 751
- Hepatotoxic drugs, 37, 38t
- Hepatotoxicity  
androgens and, 448  
dantrolene, 172  
divalproex, 231b  
HMG-CoA reductase inhibitors (statins) and, 355  
indirect-acting antiadrenergic agents and, 122  
monoclonal antibodies (MAbs) and, 781  
tetracyclines and, 671  
tizanidine and metaxalone, 174
- Herbal products. *See also* Complementary and alternative therapy; Dietary supplements  
adverse interactions with conventional drugs, 631  
standardization of, 631
- Herceptin, 51
- Heroin, 270. *See also* Opioids, abuse
- Herpes labialis, 725
- Herpes simplex virus (HSV), 768–769  
anogenital warts, 768  
drugs for, 721–725, 722t, 723b, 725b  
mucocutaneous, 721
- High-density lipoproteins (HDLs), 346  
vs. low-density lipoproteins (LDLs), 346
- Highly active antiretroviral therapy (HAART), 745
- Hip replacement, dabigatran and, 380
- His-Purkinje system, 333
- Histamine, 495–499  
distribution, synthesis, storage, and release, 495, 496f  
physiologic and pharmacologic effects, 495
- Histamine-1 receptor antagonists, 495–496, 497t, 498t, 577  
first-generation, 496  
second-generation, 496
- Histamine-2 receptor antagonists, for peptic ulcer disease, 589–590, 589b, 590b
- Histone deacetylase inhibitors, 807
- HMG-CoA reductase inhibitors, 352–355  
adverse effects, 354–355  
beneficial actions, 352–353  
clinical trials, 353  
mechanism of cholesterol reduction, 353  
pharmacokinetics, 354  
pregnancy, 355  
preparations, dosage, and administration, 356t  
prescribing considerations, 356b  
recommendations, 351f  
therapeutic uses, 353–354
- Hookworms, 773
- Host defenses, 652
- Human immunodeficiency virus (HIV), 745–763  
antiretroviral drugs classification, 748, 749t  
baseline data, 763  
characteristics of, 745–747  
drug interactions and, 748  
identifying high-risk patients and, 763  
infection clinical course, 748  
infection management, 761  
infection prophylaxis, 761–763  
mutation and drug resistance, 747  
pathophysiology, 745–748  
prescribing considerations, 763  
replication cycle of, 746, 747f  
replication rate, 746–747  
structure of, 745–746, 746f  
target cells, 745  
therapeutic goals, 763  
transmission of, 747  
vaccines, 763
- Human insulin analogs, 396
- Human leukocyte antigen (HLA), 51
- Human papillomavirus (HPV), 485–486  
vaccine, 493–494
- Humoral immunity, 478
- Hydralazine, 46, 309–310
- Hydrochlorothiazide, 290–291
- Hydrocodone, 186, 186b
- Hydrocortisone, 512t
- Hydromorphone, 184t, 185  
black box warning, 185b
- Hydroxychloroquine (Plaquenil), 526–527
- Hydroxyurea, 792
- Hydroxyzine, 497t, 498t, 603t
- Hyperalgesia, 192
- Hyperbilirubinemia, vitamin K and, 616
- Hypercalcemia, 542
- Hypercholesterolemia, 353
- Hyperglycemia, 12  
 $\beta_2$  receptors, 104  
epinephrine and, 106  
glucocorticoids and, 513  
protease inhibitors and, 754
- Hyperglycemic agents, 401
- Hyperglycemic hyperosmolar nonketotic syndrome (HHNS), 414–415
- Hyperkalemia, 865–866, 866t  
aliskiren and, 302  
angiotensin-converting enzyme (ACE) inhibitors and, 298  
eplerenone and, 303  
in oral contraceptives, 438  
spironolactone and, 291–292  
triamterene, 292  
trimethoprim, 686
- Hyperlipidemia, 12  
protease inhibitors and, 755–756
- Hypermagnesemia, 866
- Hyperosmolar hyperglycemic state (HHS), 414–415
- Hyperparathyroidism, 542–543  
alendronate and, 548–550, 549t  
primary, 542  
secondary, 542–543
- Hypersensitivity  
in abacavir, 751  
enfuvirtide and, 759–760  
oxcarbazepine, 159  
PCSK9 inhibitors and, 359  
with sulfonamides, 683, 684b
- Hypertension. *See also* Blood pressure  
adrenergic agonists and antagonists and, 103  
adrenergic antagonists and, 109  
angina pectoris and, 366
- Hypertension (*Continued*)  
angiotensin-converting enzyme (ACE) inhibitors for, 296  
angiotensin II receptor blockers for, 300  
antihypertensive mechanisms and, 314–316  
basic considerations, 312  
 $\beta$  blockade, 113  
centrally acting  $\alpha_2$  agonist, 121  
diltiazem for, 308  
drug therapy, 312–316  
fundamentals of, 316–317  
initial drug selection, 316  
treatment algorithm, 316  
eplerenone for, 302  
individualizing therapy for, 317–319  
management of chronic, 312–319  
oral contraceptives and, 440  
orthostatic,  $\alpha$  blockade and, 109  
person-centered care across the life span, 318b  
in pregnancy, 319–320  
chronic hypertension, 319–320  
preeclampsia and eclampsia, 320  
primary, 312  
prototype drugs, 313b  
regulation of blood pressure, 314  
secondary, 312  
in special populations, 317–319  
spironolactone for, 291  
step-down therapy, 317  
type 1 diabetes (T1D), 394  
types of, 312
- Hypertensive crisis  
dietary tyramine, 221  
epinephrine and, 106  
monoamine oxidase inhibitors (MAOIs), 221  
patient education, 221b
- Hypertensive emergencies  
clevidipine for, 880  
drugs for, 879–880  
epinephrine and, 106  
fenoldopam for, 880  
labetalol for, 880  
monoamine oxidase-B (MAO-B) inhibitors, 140  
sodium nitroprusside for, 879–880
- Hyperthyroidism, 419  
anticholinergic drugs and, 85  
 $\beta$  blockade, 113  
drugs for, 421–423
- Hypertonic contraction, 863–864
- Hypertrichosis, minoxidil and, 310–311
- Hyperuricemia  
cancer chemotherapy and, 789  
drugs for, 537–539, 537f
- Hypnotics, for insomnia, 238–239
- Hypocalcemia, 542
- Hypochloremia, 289
- Hypoglycemia, 400–401  
 $\beta$  blockade, 114  
insulin and, 400–401  
patient education, 401b  
sulfonyleurea and, 405  
unawareness, 401
- Hypoglycemic agents, 312–320  
insulin and, 401
- Hypogonadism  
female, 428  
male, 448
- Hypokalemia, 401, 865, 865t  
digoxin and, 328  
furosemide, 289  
insulin and, 401
- Hypomagnesemia, 866  
omeprazole and, 591
- Hypomaneic episodes, 226
- Hypomethylating agents, 791

- Hyponatremia  
 furosemide, 289  
 oxcarbazepine, 159  
 selective serotonin reuptake inhibitors (SSRIs), 217  
 vasopressin receptor antagonists for, 882
- Hypoparathyroidism, 542
- Hypotension  
 excessive, 880  
 furosemide, 289  
 orthostatic, 285  
 levodopa and, 142  
 monoamine oxidase inhibitors (MAOIs), 221  
 opioids and, 184  
 regulation of arterial pressure and, 285  
 second-generation (atypical) antipsychotics, 209  
 tricyclic antidepressants (TCAs), 218  
 patient education, 184b  
 sildenafil and, 461
- Hypotensive drugs, nitroglycerin and, 362
- Hypothalamus, thyroid regulation and, 416
- Hypothyroidism  
 in adults, 418  
 in infants, 418–419  
 lithium, 229  
 methimazole and, 422  
 during pregnancy, 418  
 thyroid hormone preparations for, 419–421
- Hypotonic contraction, 863–864
- I**
- Iatrogenic Cushing syndrome, glucocorticoids and, 514
- Iatrogenic disease, 36
- Ibexafungerp, 720
- Ibuprofen, 504, 505, 506t, 873
- Icosapent ethyl (Vascepa), 359
- Idiosyncratic effect, 36
- Imatinib, 803
- Imipenem, 665–667
- Imiquimod, 846
- Immune system, 475–483  
 cell-mediated immunity *versus* antibody-mediated (humoral) immunity, 475  
 cells of, 475–477, 476t  
 characteristic features, 478  
 diversity, 478  
 memory, 478  
 natural immunity *versus* specific acquired immunity, 475  
 phases, 479  
 activation phase, 479  
 antigen recognition, 479  
 effector mechanisms, 479  
 recognition phase, 479  
 specificity, 478  
 time limitation, 478, 478f
- Immunization, childhood, 484–494. *See also* Vaccine Adverse Event Reporting System (VAERS)  
 adverse effects of, 484–485, 489t  
 definitions in, 484  
 general considerations, 484–485  
 killed vaccines *versus* live vaccines, 484  
 records, 484  
 schedule, 485  
 specific immune globulins, 484  
 specific vaccines and toxoids, 488–494, 488t  
 target diseases, 485–488
- Immunogenicity  
 monoclonal antibodies (MAbs) and, 780  
 PCSK9 inhibitors and, 359
- Immunomodulators, 609–610, 779–781  
 immunotherapy of future, 781  
 monoclonal antibodies (MAbs), 779, 780t  
 adverse reaction to, 780–781  
 for asthma, 779  
 definition and creation, 779, 780f  
 immunotherapy, 780t  
 for infectious disease, 779  
 for migraine prevention, 779  
 proteasome inhibitors, 780t, 781  
 tyrosine kinase inhibitors, 780t, 781
- Immunostimulants, 807–808, 807t  
 aldesleukin, 807–808  
 Bacillus Calmette-Guérin vaccine, 808
- Immunosuppressants, 609  
 glucocorticoids and, 511  
 topical, 844–845
- Impaired glucose tolerance, 394
- Impetigo, 850–851, 851t
- Implantable testosterone pellets, 451
- Impulse conduction, 333
- Inactivated influenza vaccine, 738
- Inactivation, drug, 20
- Indirect-acting antiadrenergic agents, 120–124  
 centrally acting  $\alpha_2$  agonist, 120–123
- Indirect-acting sympathomimetic drugs  
 monoamine oxidase inhibitors (MAOI) and, 223  
 tricyclic antidepressants (TCAs) and, 218–220
- Indomethacin, 535t
- Infants. *See also* Breastfeeding; Neonates  
 aminoglycosides and, 679b  
 antiemetics in, 605b  
 antifungal agents and, 718b  
 antihistamines in, 497b  
 antimicrobial drugs in, 653b  
 blood-brain barrier in, 61  
 carbapenems and, 667b  
 cephalosporins in, 667b  
*Chlamydia trachomatis* in, 764–765, 765t  
 drug absorption in, 59–60  
 drug distribution in, 60–61  
 hepatic metabolism in, 61  
 hypothyroidism in, 418–419  
 intramuscular administration, 60  
 laxatives in, 594b  
 oral administration, 59  
 penicillins for, 660b  
 peptic ulcer disease in, 592b  
 pharmacokinetics in, 59–61  
 renal excretion in, 61  
 selective serotonin reuptake inhibitors (SSRIs), 217  
 sulfonamides in, 685b  
 transdermal absorption in, 60  
 urinary tract infections in, 692b
- Infections  
 diarrhea, 606–607  
 glucocorticoids and, 513  
*Helicobacter pylori*, 585  
 HIV. *See* Human immunodeficiency virus  
 impetigo, 850–851, 851t  
 influenza, 487  
 meningococcal, 487  
 pneumococcal, 487  
 sexually transmitted, 764–772  
 site of, 652–653  
 tetracyclines for, 670  
 urinary tract. *See* Urinary tract infections  
 vaccines for target, 485–488  
 viral, 654
- Infectious conjunctivitis, 825, 825–826t, 825b
- Infiltration anesthesia, 180
- Inflammatory bowel disease, 608–610, 609t  
 5-aminosalicylates, 608–609
- Inflammatory bowel disease (*Continued*)  
 glucocorticoids for, 512, 609  
 immunosuppressants for, 609
- Infliximab (Remicade), 528–529, 529b, 610
- Influenza, 487  
 acute otitis media and, 858  
 adamantanes, 740  
 antiviral drugs for, 740–741, 740t, 741t  
 neuraminidase inhibitors, 740–741  
 oseltamivir, 740  
 prevention and treatment of, 858  
 vaccines, 493, 738–740, 739t  
 zanamivir, 740–741
- Inhalants, 280
- Inhaled human insulin, 397
- Inhaler, nicotine, 268
- Injectable local anesthetics, 178t, 180
- Innervation, control patterns and, 74
- Inorganic (physical) screens, 851
- Inotropic action, 326–327
- Inotropic agents, for acute decompensated heart failure, 878–879
- Insomnia, 142. *See also* Sleep disturbances  
 antihistamines for, 497  
 barbiturates, 238  
 benzodiazepines, 233  
 major drugs for, 239t  
 management, 238–239  
 nondrug therapy for, 238
- Institute for Safe Medical Practice (ISMP), 41
- Institute of Medicine (IOM), 1–5, 59
- Insulin, 396–401  
 administration, 396–399  
 $\beta$ -adrenergic blocking agents, 401  
 $\beta$  blockade, 116  
 deficiency, metabolic consequences, 396  
 dosage, 399–400  
 dosing schedules, 400, 400f  
 drug interactions, 401  
 glucocorticoids and, 514  
 metabolic actions, 396, 397t  
 mixing, 399b, 399t  
 patient education, 399b  
 physiology, 396  
 preparations, 396–399  
 prescribing considerations, 401b  
 replacement, in type 1 diabetes, 394  
 sources, 396  
 therapeutic use, 399–401  
 therapy complications, 400–401  
 types, 397–399, 397t, 398t
- Insulin degludec, 399
- Insulin detemir, 399
- Insulin glargine (U-100), 399
- Insulin glargine (U-300), 399
- Insulin receptor substrate-2 (IRS-2), 393
- Insulins aspart, 397
- Insulins glulisine, 397
- Insulins lispro, 397
- Integrase strand transfer inhibitors, 757–759, 757t, 758t
- Intensification of effects, 31
- Intensive basal/bolus strategy, 400
- Interactions, drug, 15–35, 32–33t, 216–217, 387  
 acarbose, 408  
 ACL inhibitors, 359  
 alcohol, 260–261  
 aminoglycosides, 680  
 amiodarone, 343  
 of amphotericin, 713  
 angiotensin-converting enzyme (ACE) inhibitors, 299  
 angiotensin II receptor blockers (ARBs), 301  
 atomoxetine, 251  
 basic mechanisms of, 31–34

- Interactions, drug (*Continued*)  
 benzodiazepines, 234  
 bupropion, 223–224  
 calcium channel blockers, 343  
 cephalosporins, 664–665  
 cevimeline, 86  
 cholinesterase inhibitors, 88–89, 147  
 cimetidine, 590  
 clopidogrel and, 383  
 colessevelam, 357  
 creation of unique response, 31  
 dabigatran and, 380  
 with daptomycin, 710  
 dietary supplements, 631  
 digoxin, 329, 344  
 dobutamine, 107  
 dopamine, 107  
 epinephrine and, 106  
 eplerenone and, 303  
 ergotamine, 196  
 erythromycin, 673–674  
 estrogens, 428  
 ezetimibe, 357  
 first-generation (conventional)  
   antipsychotics, 207  
 food and, 6, 11  
   absorption, 34  
   drug action, 35  
   drug metabolism, 34–35  
   drug toxicity, 35  
   levodopa/carbidopa, 133  
   monoamine oxidase inhibitors, 222t  
   tetracyclines, 671–672  
   timing of drug administration with respect  
     to meals and, 35  
   verapamil and diltiazem, 307  
 gemfibrozil, 358  
 heparin, 374  
 HMG-CoA reductase inhibitors (statins)  
   and, 355  
 human immunodeficiency virus (HIV)  
   and, 748  
 hydralazine, 310  
 hydrochlorothiazide, 291  
 individual variation in drug responses and, 46  
 insulin, 401  
 intensification of effect, 31  
 iron, 387  
 isoproterenol, 107  
 levodopa and, 132–133  
 levothyroxine, 420  
 lithium, 229–230  
 loop diuretics, 290t  
 low-molecular-weight (LMW) heparins, 374  
 marijuana, 277  
 memantine, 149  
 metformin, 405  
 methylnaltrexone, naloxegol, and  
   naldemedine, 188  
 modafinil, 248  
 monoamine oxidase inhibitors (MAOIs),  
   221–223, 222f  
 morphine, 182t, 184  
 muscarinic antagonists, 94–95  
 nifedipine, 308  
 nitroglycerin, 362  
 oral contraceptives, 441  
 oxcarbazepine, 159–160  
 phenytoin, 158–159  
 pioglitazone, 407–408  
 pramipexole, 136  
 propranolol, 116  
 quinidine, 340  
 ramelteon, 236  
 ranolazine, 364
- Interactions, drug (*Continued*)  
 reduction of effects, 31  
 rivaroxaban, 380  
 second-generation (atypical) antipsychotics, 209  
 sildenafil, 462  
 sitagliptin, 408–409  
 sodium-glucose co-transporter 2 inhibitors, 410  
 spironolactone, 292  
 sulfonylureas, 406  
 sumatriptan and, 195  
 suvorexant (Belsomra), 237  
 thiazide diuretics, 290t  
 tirzepatide, 411–413  
 tramadol, 189  
 tricyclic antidepressants (TCAs), 218–220  
 ubrogepant, 196  
 verapamil, 306  
 warfarin, 377, 378t
- Interferon alfa, 732t, 733–734  
 black box warning, 736b
- Interferon  $\gamma$ , 481
- Interleukin antagonists, 843
- Interleukin-5 antagonists, 566–567
- Interleukin-1 receptor antagonist, 531
- Interleukin-4 receptor antagonists, 567
- Interleukin-6 receptor antagonists, 530–531
- International System of Units, 884
- Interpatient variability, in drug responses, 29–30  
 clinical implications of, 30  
 ED<sub>50</sub>, 30
- Intestinal fluke infestations, 775
- Intestinal hypertonicity and hypermotility,  
 atropine, 93
- Intracavernous injection, alprostadil, 463
- Intracranial pressure, reduction of, mannitol  
 for, 881
- Intramuscular (IM) administration  
 analgesia and, 873  
 in neonates and infants, 60
- Intramuscular testosterone esters, 451
- Intranasal cromolyn sodium, for allergic  
 rhinitis, 579–580
- Intraocular pressure elevation, atropine, 94
- Intrauterine devices (IUDs), 444  
 as emergency contraception, 445
- Intravenous (IV) administration  
 analgesia and, 873  
 nitroglycerin, 879  
 regional anesthesia, 872–873  
 vasodilators, 879
- Intrinsic activity, 27
- Intrinsic sympathomimetic activity (partial  
 agonist activity), 117
- Iodinated radiocontrast media  
 metformin and, 405
- Iodine  
 nonradioactive iodine, 423  
 radioactive iodine, 422–423
- Iodine deficiency, thyroid function and, 416–417
- Ions, 15–17  
 trapping, 16–17
- Ipilimumab, 807
- IPLDGE Program, 836
- Ipratropium, 572–573
- Ipratropium bromide, 95, 581
- Irbesartan, 300
- Iron  
 biochemistry and physiology of, 385–386  
 carbonyl, 387–388  
 daily requirements, 385–386  
 deficiency, 385–388  
   causes, 386  
   consequences, 386  
   diagnosis, 386  
   duration of therapy, 388
- Iron (*Continued*)  
 fate in body, 385  
 guidelines for treating, 388  
 therapeutic combinations, 388  
 dextran, 880, 880b  
 metabolic functions of, 385  
 parenteral, 880–881  
 preparations, oral, 386–388, 388t  
   tooth staining from, 386b  
 recommended dietary allowances, 387t  
 sucrose, 881
- Irreversible cholinesterase inhibitors, 89–90
- Irritable bowel syndrome, drugs for,  
 607–608, 608t  
 nonspecific, 607  
 specific, 607–608
- Isoniazid, 699t, 700t  
 black box warning, 701b
- Isoproterenol, 72, 107  
 adverse effects, 107  
 therapeutic uses, 107
- Isosorbide dinitrate (ISDN), 46, 326, 331–332, 363
- Isosorbide mononitrate, 363
- Isotonic contraction, 863
- Isotretinoin, 835–836, 835b, 836b
- Istradefylline, 141–142
- Itraconazole, 714  
 black box warning, 714, 714b
- Ivabradine (Corlanor), 326
- Ivermectin, 775–776t, 777, 850, 850b
- Ixazomib, 807
- J**
- Janus kinase inhibitors, 531–533, 531b
- K**
- Karnofsky Performance Scale, 789–790, 789t
- Kava, 644
- Keratolytic agents, for skin, 832
- Kernicterus, 683–685
- Ketamine, 872
- Ketoconazole, 799
- Ketorolac, 873
- Key Potentially Inappropriate Drugs in  
 Pediatrics (KIDs) List, 59
- Kidney disease, 44
- Kidneys  
 acute uncomplicated pyelonephritis, 689–690  
 alcohol effects on, 259  
 anatomy and physiology and, 286–287  
 disease, 44  
 individual variation in drug responses, 44  
 function during pregnancy, 53  
 renin-angiotensin-aldosterone system  
   (RAAS), 284  
 retention of water, 284–285
- Killed vaccines, 484
- Kinase II, 295
- Kinase inhibitors, 802–805  
 anaplastic lymphoma, 804–805  
 BCR-ABL tyrosine, 803  
 BRAF V600E, 804  
 epidermal growth factor receptor (EGFR)  
   tyrosine, 802–803  
 mammalian target of rapamycin (mTOR), 804  
 multi-tyrosine, 803–804
- Korsakoff psychosis, 258
- Kunecatechins, 846
- L**
- Labeling  
 sunscreens, 851–852  
 supplement, 630
- Labetalol, for hypertensive emergencies, 880

- Laboratory testing, 12t  
 HIV and, 761, 762b  
 information, 11
- Lack of planning, adherence and, 13t
- $\beta$ -Lactamases, 656–657
- Lactation. *See also* Breastfeeding  
 alcohol effects on, 260  
 benzodiazepines and, 234  
 lithium and, 229  
 methimazole and, 422–423  
 nicotine effects, 266  
 trimethoprim and, 686
- Lactic acidosis, 405, 751
- Lactitol, 598
- Lactulose, 598
- Lamivudine, 736
- Lamotrigine, 231  
 adverse reactions, 231b
- Lapatinib, 796
- Latanoprost, 820–821
- Latent tuberculosis, 697–699, 698t
- Laxatives, 594–600  
 abuse, 600  
 basic pharmacology of, 596–600  
 bisacodyl, 597  
 bowel cleansing products for colonoscopy, 599–600, 599t  
 bulk-forming, 596, 597t  
 castor oil, 597  
 classification schemes, 595–596, 595t, 596t  
 colon function and, 594  
 combination products, 599–600  
 constipation, 594, 595t  
 general considerations, 594–596  
 indications for, 594–595  
 lactulose, 598  
 lubiprostone, 598  
 osmotic, 598  
 patient-centered care across the life span, 594b  
 plecanatide, 598  
 polyethylene glycol, 598  
 precautions and contraindications to, 595  
 prescribing considerations, 600b  
 prototype drugs, 596b  
 prucalopride, 598–599  
 salts, 598  
 senna, 597  
 sodium phosphate products, 599  
 stimulant, 597  
 surfactant, 596  
 trade names, dosage forms, and dosages, 597t
- Lecanemab, 151
- Leflunomide (Arava), 524
- Lenalidomide, 809
- Lennox-Gastaut syndrome, 153
- Lesbian, 467b
- Letrozole, 795
- Leukotriene modifiers, 562–564, 564t
- Leuprolide, 797–798
- Leuprolide acetate, 470
- Levocetirizine, 497t, 498t, 579t
- Levodopa, 129–134  
 acute loss of effect, 129  
 adverse effects, 132  
 alteration of central nervous system function, 130f  
 beneficial effect, 129  
 carbidopa combination, 133–134  
 combinations, 134b  
 drug interactions, 132–133, 133t  
 food interactions, 133  
 mechanism of action, 129–130  
 monoamine oxidase-B (MAO-B) inhibitors, 140  
 motor complications, 130t  
 patient education, 132b
- Levodopa (*Continued*)  
 pharmacokinetics, 130–132  
 preparations, 133–134  
 prescribing considerations, 134b
- Levofloxacin, 699t, 700t
- Levomefolate, 441
- Levomilnacipran, 217
- Levorphanol, 184t, 185
- Levothyroxine ( $T_4$ ), 419–421  
 prescribing considerations, 421b
- Lewy bodies, 127
- Lidocaine, 179  
 acute care, 877, 877t  
 for cancer pain, 816
- Lifestyle modifications  
 diabetes, 393  
 high low-density lipoprotein cholesterol and, 350  
 hypertension and, 313
- Linaclootide, 608t
- Lindane, 849–850, 850b
- Linezolid, 674–676, 675t
- Liothyronine ( $T_3$ ), 418
- Lipase inhibitor, 625–627
- Lipid solubility, 17  
 blood-brain barrier and, 17–18
- Lipodystrophy, protease inhibitors and, 754–755
- Lipohypertrophy, 401  
 insulin and, 401
- Lipoproteins. *See also* Cholesterol  
 apolipoprotein, 345  
 basic structure, 345  
 classes, 345–346  
 colesevelam effect on, 356  
 function, 345  
 plasma, 346f  
 very-low-density lipoproteins (VLDLs), 346
- Liraglutide, 627–628, 627b
- Lisdexamfetamine, 246
- Lithium, 217, 229b  
 adverse effects, 229  
 angiotensin-converting enzyme (ACE) inhibitors and, 299  
 black box warning, 229b  
 chemistry, 228  
 dosage and administration, 230  
 drug interactions, 229–230  
 mechanism of action, 228  
 pharmacokinetics, 228–229  
 plasma levels monitoring, 228–229  
 preparations, 230t  
 prescribing considerations, 230b  
 therapeutic uses, 228  
 toxicity, 229b
- Live attenuated influenza vaccine, 738
- Liver  
 alcohol effects on, 259  
 disease, 44  
 individual variation in drug responses, 44  
 injury, gemfibrozil and, 358  
 toxicity, amiodarone, 343b
- Liver failure, tolcapone and, 139b
- Liver fluke infestations, 775
- Live vaccines, 484
- Loading *versus* maintenance doses, 24
- Local anesthetics, 177–180  
 absorption and distribution, 178  
 basic pharmacology, 177–179  
 chloroprocaine, 179  
 classification, 177  
 clinical use, 179–180  
 cocaine, 179  
 injectable, 178t, 180  
 lidocaine, 179  
 mechanism of action, 177
- Local anesthetics (*Continued*)  
 patient education, 177b  
 pharmacokinetics, 178  
 prescribing considerations, 180b  
 properties of individual, 179  
 prototype drugs, 179b  
 selectivity, 177  
 for skin, 854  
 time course, 177–178  
 topical, 178t  
 topical administration, 180  
 with vasoconstrictors, 178
- Long-acting contraceptives, 443–444
- Longevity, alcohol effects on, 260
- Long-term course of schizophrenia, 201–202
- Loop diuretics, 289–290  
 adverse effects, 290t  
 black box warning, 290b  
 furosemide, 289–290  
 for heart failure, 324  
 oral routes, time course, and dosage, 290t  
 patient education, 289b  
 prescribing considerations, 290b
- Loop of Henle, 286–287
- Loperamide, 606
- Loratadine, 497t, 498t, 579t, 582t
- Lorazepam, 603t
- Losartan, 300
- Lovaza, 359
- Low-density lipoprotein (LDL), 345, 346.  
*See also* Heparin  
 atherosclerosis, 346–347  
 vs. high-density lipoprotein cholesterol, 346  
 prototype drug, 352b  
 role in atherosclerosis, 346–347  
 treatment of, 350  
 type 1 diabetes, 394
- Low-dose unfractionated heparin therapy, 874
- Low-molecular-weight (LMW) heparins, 374  
 administration, dosing, and monitoring, 374  
 group properties, 374  
 individual preparations, 374  
 mechanism of action, 373f, 374  
 therapeutic use, 374
- Loxapine, 210
- Lozenges, nicotine, 268
- Lubiprostone, 598, 608t
- Lugol solution, 423
- Lungs, drugs excretion, 22
- Luteinizing hormone (LH), 425
- Lymphatic filarial infestation, 774
- Lymphogranuloma venereum, 764
- Lymphokines, 479
- d*-Lysergic acid diethylamide (LSD), 278
- Lysis of target cells, 481
- ## M
- Macrolides, 672–674  
 erythromycin, 672–674  
 routes of administration, 673t
- Macrophages, 477, 481, 745
- Mafenide, 684t, 685–686
- Magnesium, 866t  
 hypermagnesemia, 866  
 hypomagnesemia, 866  
 imbalances, 866
- Magnesium hydroxide, 593
- Magnesium salicylate, 505–506
- Ma huang, 644
- Major depression, 212  
 atypical antidepressants, 223–224  
 clinical features, 212  
 drugs used for, 212–224  
 monoamine oxidase inhibitors (MAOI), 220–223

- Major depression (*Continued*)  
 pathogenesis, 212  
 prototype drugs, 212b  
 selective serotonin reuptake inhibitors (SSRIs), 214–217  
 serotonin-norepinephrine reuptake inhibitors, 217  
 treatment overview, 212  
 tricyclic antidepressants, 218–220
- Major depressive episode, in bipolar disorder, 226
- Major histocompatibility complex (MHC) molecules, 478, 479
- Malathion, 849
- Males, biosynthesis and elimination, 426
- Male sexual dysfunction, 457  
 erectile dysfunction (ED), 457–463  
 premature ejaculation (PE), 463–464
- Mammalian target of rapamycin (mTOR) kinase inhibitors, 804
- Mannitol, 881
- Maraviroc, 51, 760
- Marijuana, 275–277, 639  
 behavioral and subjective effects, 275–276  
 drug interactions, 277  
 legal status, 277  
 mechanism of action, 275  
 medical research, 276–277, 277b  
 pharmacokinetics, 275  
 physiologic effects, 276–277  
 psychoactive substance, 275  
 source, 275  
 synthetic, 277
- Mast cells, 477
- Mast cell stabilizer, 564–565
- Maternal-fetal drug transfer, 18–19
- Maximal efficacy, 25
- Meaningful Use*, 8
- Measles, 486  
 vaccine, 488–489
- Mebendazole, 775–776t, 777
- Meclizine, 603t
- Medical marijuana, 277
- Medical transition, 467b
- Medication Adherence in America: A National Report Card*, 13
- Medication Error Reporting (MER) Program, 42
- Medication Guides, 40
- Medication reconciliation, 41, 42b
- Medullary thyroid carcinoma (MTC), exenatide and, 411
- Megaloblastic anemia, 389–390
- Meglitinides, 406, 407t  
 prescribing considerations, 406b
- Melatonin, 240, 639–640
- Melatonin agonist, 236
- Memantine, 149  
 mechanism of action, 150f  
 patient education, 149b  
 prescribing considerations, 149b
- Membrane attack complexes, 481
- Meningococcal infection, 487  
 vaccine, 492–493
- Menopause. *See also* Estrogens; Menstrual cycle  
 androgen replacement therapy in, 448  
 genitourinary syndrome of, 427  
 hormonal therapy (HT), 431–436, 432t  
 benefits and risks of, 432, 432t  
 discontinuing, 434–435  
 drug products for, 435–436  
 inappropriate uses of, 434  
 intravaginal estrogens for, 434t  
 oral drugs for, 435t  
 progestins, 436b  
 recommendations on, 432–435  
 transdermal drugs, 436t
- Menopause (*Continued*)  
 use for approved indications, 433  
 physiologic alterations accompanying, 427–429  
 symptom management algorithm, 433f  
 testosterone therapy in, 448
- Menstrual cycle, 425, 426f  
 progestin therapy and, 430, 436b
- Menstrually associated migraine, 197–198
- Meperidine, 140
- Mepolizumab, 779
- Mercaptopurine, 609
- Mescaline, 279
- Metabolic acidosis, 864
- Metabolic actions, estrogens, 427
- Metabolic alkalosis, 864
- Metabolic effects, 34–35, 35t  
 antipsychotic drugs and, 208–209  
 benzodiazepines, 233  
 folic acid, 391  
 glucocorticoids, 510, 511  
 iron, 385
- Metabolic syndrome, 350–352
- Metabolic tolerance, 45
- Metabolism, 15  
 accelerated renal drug excretion, 20  
 age, 20  
 alcohol, 260  
 altered, 32  
 competition between drugs and, 20  
 drug inactivation, 20  
 enterohepatic recirculation, 20  
 enzyme induction and inhibition, 20  
 first-pass effect, 20  
 in geriatric patients, 63  
 glucocorticoids, 510, 511  
 hepatic drug-metabolizing enzymes, 19  
 hydralazine, 309  
 increased/decreased toxicity, 20  
 increased therapeutic action, 20  
 local anesthetics, 178  
 in neonates and infants, 61  
 nitroglycerin, 362  
 nutritional status, 20  
 prodrug activation, 20  
 therapeutic consequences, 20
- Metaxalone, 174
- Metered-dose inhalers (MDIs), 558–559
- Metformin, 403–405  
 black box warning, 405b
- Methadone, 185  
 black box warnings, 185b, 271b  
 for opioid addiction, 271
- Methamphetamine, 246–247, 274–275  
 adverse effects, 247  
 adverse psychological effects, 274  
 mechanism of action, 246  
 patterns of use, 274  
 pharmacologic effects, 246–247  
 subjective and behavioral effects, 274  
 therapeutic uses, 247
- Methemoglobinemia, 179
- Methenamine, 692t, 693
- Methicillin-resistant *Staphylococcus aureus* (MRSA), 657–658  
 community-associated, 658  
 health care-associated, 657–658
- Methimazole, 421–423  
 prescribing considerations, 422b
- Methocarbamol, 174
- Methotrexate, 523–524, 523b, 609, 842  
 for Crohn disease, 609
- Methyl dopa, 121–123
- Methyldopate, 121–123
- 3, 4-Methylenedioxymethamphetamine (MDMA), 279–280
- Methylnaltrexone, 188
- Methylphenidate, 247
- Methylprednisolone, 512t, 603t
- Methylxanthines, 247–248, 570–572, 571t, 572b  
 caffeine, 247–248
- Metoclopramide, 603t, 604, 610
- Metoprolol, 116
- Metronidazole, 588, 709  
 black box warning, 709b
- Mexiletine, 340–342
- Microbial mechanisms of drug resistance, 647–648
- Microglial cells, 745
- Midazolam, 872–873
- Mifepristone, as emergency contraception, 445
- Migraine headache, 192–198  
 abortive therapy, 192–196, 193t  
 analgesics, 193  
 calcitonin gene-related peptide receptor antagonists, 196  
 ergot alkaloids, 195–196  
 serotonin<sub>1B/1D</sub> receptor agonists (Triptans), 193–195  
 characteristics, 192  
 menstrually associated, 197–198  
 pathophysiology, 192  
 preventive therapy, 196–198  
 prophylaxis,  $\beta$  blockade and, 113  
 prototype drugs, 195b  
 stroke in women with, oral contraceptives and, 440
- Migraine with aura, 192
- Migraine without aura, 192
- Milrinone, 879
- Mind-altering drugs, 253
- Minimum effective concentration (MEC), 22  
 in pediatric patients, 59
- Minocycline, 670
- Minoxidil, 310–311  
 topical, 853
- Mirtazapine, 224
- Misoprostol, 592–593, 592b
- Misuse  
 barbiturates, 238  
 buspirone, 242
- Mitotane, 792
- Mitotic inhibitors, 791–792
- Mixed episode in bipolar disorder, 226
- Modafinil, 248
- Moderna, 742
- Modified occupancy theory, 27
- Molnupiravir, 744
- Mometasone, 579t
- Monitoring, drug, 11–13, 11b  
 allergic conjunctivitis treatment drugs, 827b  
 aminoglycosides, 680  
 androgens, 452b  
 antimicrobial drugs, 655  
 determining therapeutic dosage by, 11–12  
 diabetes treatment, 395–396  
 evaluating medication adequacy, 12  
 glaucoma treatment drugs, 824b  
 heparins, 374  
 identifying adverse effects, 12–13  
 need for, 7  
 PDE-5 inhibitors, 455b  
 warfarin, 376
- Monoamine oxidase (MAO), 100
- Monoamine oxidase-B (MAO-B) inhibitors, 139–140
- Monoamine oxidase inhibitors (MAOIs), 216–217, 220–223  
 adverse effects, 220–221  
 dietary tyramine and, 220  
 dopamine and, 107  
 drug interactions, 221–223, 222f

- Monoamine oxidase inhibitors (MAOIs) (*Continued*)  
 epinephrine and, 106  
 foods that can interact with, 222t  
 levodopa, 132–133  
 mechanism of action, 220–223  
 oral, 220–223  
 prescribing considerations, 223b  
 therapeutic uses, 220  
 transdermal, 223  
 tricyclic antidepressants (TCAs) and, 218  
 triptans and, 195
- Monoclonal antibodies (MAbs), 149–151, 350, 565–567, 565t, 566b, 566t, 779, 780t  
 adverse reaction to, 780–781  
 for asthma, 779  
 definition and creation, 779, 780f  
 dupilumab, 582  
 immunotherapy, 780t  
 omalizumab, 582  
 for infectious disease, 779  
 for migraine prevention, 779
- Monokines, 479
- Montelukast (Singulair), 564, 581–582
- Mood stabilizers, 226b, 227  
 lithium, 228
- Morphine, 181–184  
 adverse effects of, 182–184  
 drug interactions, 184  
 patient education, 182b  
 pharmacologic actions, 182  
 preparations, 182t  
 for relief of pain, 182  
 ST-segment elevation myocardial infarction and, 868  
 tolerance and physical dependence, 184  
 toxicity, 184
- Mortality, perioperative,  $\beta$  blockade and, 113
- Motion sickness, antihistamines for, 497, 605–606
- Motor symptom, in Parkinson disease management, 127–128  
 pathophysiology, 127
- Moxifloxacin, 699t, 700t
- Mucocutaneous reactions, 529
- Mucolytics, 583
- Mucus, stomach, 585
- Multidrug transporter protein, 15
- Multiorgan hypersensitivity reactions, 159
- Multiple sclerosis, 276
- Multi-tyrosine kinase inhibitors, 803–804
- Mumps, 486  
 vaccine, 488–489
- Mupirocin, 675t
- Muscarinic agonists, 83–87  
 bethanechol, 83  
 cevimeline, 85–86  
 patient education, 87b  
 pharmacokinetics, 84t  
 pilocarpine, 86  
 poisoning, atropine, 94  
 preparation and dosage, 84, 84t  
 toxicology, 86–87, 86b
- Muscarinic antagonists (MA), 92–99  
 anticholinergic, 95  
 atropine, 92–95  
 centrally acting anticholinergics, 95  
 dicyclomine, 95  
 ipratropium bromide, 95  
 mydriatic cycloplegics, 95  
 for overactive bladder, 95–98, 96f  
 patient-centered care across the life span, 92b  
 patient education, 98b  
 prescribing considerations, 95b  
 prototype drugs, 92b  
 receptors, 93t
- Muscarinic antagonists (MA) (*Continued*)  
 scopolamine, 95  
 toxicology, 98–99
- Muscarinic receptors, 79
- Muscarinic responses, reversible cholinesterase inhibitors and, 88
- Muscarinic stimulation, reversible cholinesterase inhibitors and, 88
- Muscle spasm, drugs for, 169–176, 170–171t  
 benzodiazepines, 234  
 life span considerations, 173–174b  
 localized, 173  
 pharmacokinetics, 171t  
 prototype drugs, 169b
- Musculoskeletal system. *See also* Bone health  
 myopathy, HMG-CoA reductase inhibitors (statins) and, 354–355
- Mutation, of human immunodeficiency virus (HIV), 747
- Myasthenia gravis, 90–91
- Myasthenic crisis, 90
- Mydriasis, 80  
 adrenergic agonists and antagonists and, 102
- Mydriatic cycloplegics, 95
- Myelosuppression, of colchicine, 536
- Myocardial contractility, 282
- Myocardial infarction (MI)  
 in abacavir, 751  
 angiotensin-converting enzyme (ACE) inhibitors for, 297  
 angiotensin II receptor blockers for, 300  
 aspirin for, 382  
 $\beta$  blockade, 113  
 drugs used to prevent, 365  
 ST-segment elevated, 867–870  
 complications of, 870  
 fibrinolytic therapy, 868–869, 868t, 869t  
 management of, 867–870  
 pathophysiology, 867  
 primary percutaneous coronary intervention, 868  
 reperfusion therapy, 868–869, 868t  
 routine drug therapy, 867–868  
 secondary prevention of, 870–871  
 thrombolytics for, 876t
- Myocarditis, antipsychotic drugs and, 209
- Myocardium, calcium channels, 304
- Myoclonic seizures, 153
- Myopathy  
 of colchicine, 536  
 gemfibrozil and, 358  
 glucocorticoids and, 513  
 HMG-CoA reductase inhibitors (statins) and, 354–355
- Myxedema, 418
- N**
- N-methyl-D-aspartate receptor antagonist, 140–141, 141t, 149
- Naftifine, 713
- Naldemedine, 188
- Naloxegol, 188
- Naloxone, 188  
 for reversal of opioid effects, 873
- Naltrexone, 188  
 for alcohol abstinence maintenance, 263, 264t  
 bupropion and, 628, 628b  
 for opioid addiction, 272
- Naproxen, 504, 535t
- Narcolepsy, amphetamines and, 247
- Narrow therapeutic index (NTI), 11–12
- Nasal congestion,  $\alpha$  blockade, 110
- Nasal decongestion, adrenergic agonists and antagonists and, 101
- Natazia, 441
- Nateglinide, 406, 407t
- National Association of Pharmacy Regulatory Authorities (NAPRA), 884
- National Birth Defects Prevention Study, 53
- National Childhood Vaccine Act, 484
- National Community Pharmacists Association (NCPA), 13
- National Comprehensive Cancer Network (NCCN), 52
- National Coordinating Council for Medication Error Reporting and Prevention (NCC MERP), 40
- National Vaccine Injury Compensation Program (NVICP), 485
- Natriuretic peptides, 285, 322
- Natural immunity, 475
- Natural insulin, 397
- Nausea and vomiting  
 cancer chemotherapy and, 788, 788t  
 chemotherapy-induced, 605  
 levodopa and, 132  
 opioids and, 816  
 of pregnancy, 605
- Nebulizers, 559–561
- Necatoriasis, 773
- Necrosis, with adrenergic agonists and antagonists, 103
- Necrotizing otitis externa, 859
- Nelfinavir, 591
- Nematodes, 773  
 extraintestinal infestations, 774  
 intestinal infestations, 773–774
- Neomycin, 681t
- Neonatal abstinence syndrome (NAS), 216
- Neonates. *See also* Breastfeeding; Infants  
 antipsychotic drugs and extrapyramidal symptoms in, 207  
 apnea in, 248  
 $\beta$  blockade in, 115  
 blood-brain barrier in, 61  
 drug absorption in, 59–60  
 drug distribution in, 60–61  
 gonococcal infection in, 766, 767t  
 hepatic metabolism in, 61  
 incidence and causes of congenital anomalies, 54  
 pharmacokinetics in, 59–61  
 renal excretion in, 61  
 selective serotonin reuptake inhibitors (SSRIs), 216  
 transdermal absorption in, 60
- Neoplastic cells, in cancer, 782
- Neostigmine, 89
- Nephron, 287f
- Nephrosclerosis, 317
- Nephrotoxic drugs, aminoglycosides and, 680
- Nephrotoxicity, 680  
 of amphotericin, 713  
 black box warning, 680b
- Neprilysin Inhibitor, 325
- Nerve block anesthesia, 180
- Nervous system, divisions, 73
- Nesiritide, 879
- Netupitant/palonosetron, 603t
- Neuraminidase inhibitors, 740–741
- Neuritic plaques, in Alzheimer disease, 144
- Neurobiology of substance use disorders, 255
- Neuroendocrine effect, antipsychotic agents, 206
- Neurofibrillary tangles and tau, in Alzheimer disease, 144
- Neuroleptic-induced parkinsonism, 205
- Neuroleptic malignant syndrome (NMS), 206
- Neuroleptics, 202
- Neurologic damage, vitamin B<sub>12</sub> deficiency, 390
- Neurolytic nerve block, 817

- Neuromuscular blockers, 874  
 aminoglycoside-induced, black box warning, 680b  
 reversible cholinesterase inhibitors and, 88
- Neuromuscular blocking agents, 83
- Neuromuscular effects, reversible cholinesterase inhibitors and, 88
- Neuronal degeneration, in Alzheimer disease, 144
- Neuropharmacology, 69–72  
 and basic mechanisms by which neuropharmacologic agents act, 69–71  
 definition, 71  
 how neurons regulate physiologic processes and, 69  
 learning about peripheral nervous system drugs in, 72  
 multiple receptor types and selectivity of drug action, 71–72
- Neuropsychiatric symptoms, 151
- Neurotoxicity, morphine and, 184
- Neurotransmitters  
 central nervous system and, 125, 126b  
 life cycles, 80–82  
 in Parkinson disease, 127  
 peripheral nervous system, 75  
 release, 70  
 storage, 70  
 synthesis, 70  
 termination, 71
- Neutralization of toxins and viruses, 481
- Neutral protamine Hagedorn (NPH) insulin suspension, 397–399
- Neutropenia  
 angiotensin-converting enzyme (ACE) inhibitors and, 299  
 antimicrobial drugs and, 654  
 cancer chemotherapeutic drugs and, 786–787
- Neutrophils, 477
- New Delhi metallo- $\beta$ -lactamase 1 (NDM-1) gene and, 648
- New drugs  
 adverse reactions to, 37–38  
 development process, 884
- New York Heart Association (NYHA) scheme, 323
- Nexplanon, 443
- Niacin, 355, 617
- NicoDerm CQ, 268
- Nicotine  
 acute poisoning, 266  
 angina pectoris and, 366  
 basic pharmacology, 265–266  
 chewing gum, 268  
 dependence, 266  
 inhaler, 268  
 lozenges, 268  
 mechanism of action, 265  
 nasal spray, 268  
 pharmacokinetics, 265  
 pharmacologic effect, 265–266  
 smoking cessation and  
 Bupropion SR, 269, 269b  
 internet-based resources, 267t  
 nicotine replacement therapy (NRT), 267–268  
 pharmacologic aids to, 266–269, 267t  
 prototype drugs, 266b  
 tolerance, 266  
 transdermal systems, 268, 269t
- Nicotine-free product, 269t
- Nicotine replacement therapy (NRT), 267–268
- Nicotinic<sub>M</sub>, 78f, 79
- Nicotinic<sub>N</sub>, 78f, 79t
- Nifedipine, 307–308  
 drug interactions, 308  
 hemodynamic effects, 307–308
- Nifedipine (*Continued*)  
 immediate-release, 308  
 pharmacokinetics, 308
- Nilotinib, 803
- Nilutamide, 798
- Nirmatrelvir, 743–744
- Nitrates, for erectile dysfunction, 462
- Nitrofurantoin, 691–692, 692t
- Nitroglycerin  
 for angina pectoris, 361–362  
 discontinuing, 362  
 intravenous, 879  
 prescribing considerations, 363b  
 sildenafil and, 462  
 ST-segment elevation myocardial infarction and, 868
- Nitrosoureas, 790
- Nonacetylated salicylates, 505–506
- Nonacute reactions, monoclonal antibodies (MAbs) and, 780–781
- Nonadherence, 13  
 forgetfulness and, 13t
- Nonanthracyclines, 791
- Nonarteritic ischemic optic neuropathy, sildenafil and, 461
- Nonaspirin first-generation nonsteroidal antiinflammatory drugs, 504, 505–506, 506t  
 aspirin and, 501–505  
 clinical pharmacology of, 506t  
 diclofenac, 506t  
 diflunisal, 506t  
 etodolac, 506t  
 fenoprofen, 506t  
 flurbiprofen, 506t  
 ibuprofen, 505  
 indomethacin, 506t  
 ketoprofen, 506t  
 ketorolac, 506t  
 mefenamic acid, 506t  
 meloxicam, 506t  
 nabumetone, 506t  
 naproxen, 506t  
 oxaprozin, 506t  
 piroxicam, 506t  
 ST-segment elevation myocardial infarction and, 868  
 sulindac, 506t  
 tolmetin, 506t
- Noncatecholamines, 101, 102f
- Noncompetitive (insurmountable) antagonists, 28, 28f
- Nondiabetic nephropathy and ACE inhibitors, 297–298
- Nondihydropyridines  
 diltiazem, 306–307  
 verapamil, 304–306
- Nondrug therapy  
 chronic stable angina, 360  
 insomnia, 238  
 schizophrenia, 211
- Nonendocrine disorders, glucocorticoids in, 510–518
- Nonergot derivatives, for Parkinson disease, 135–137
- Nongonococcal urethritis (NGU), 769, 770t
- Noninsulin medications, for diabetes, 401–415  
 injectable agents, 410–413, 412t  
 amylin mimetic, 413  
 canagliflozin, 409–410  
 combination, 413  
 dapagliflozin, 410t  
 empagliflozin, 410t  
 exenatide, 411  
 GIP/GLP-1 RA, 411–413
- Noninsulin medications, for diabetes (*Continued*)  
 glucagon-like peptide-1 receptor agonists, 410–411  
 nateglinide, 406, 407t  
 pioglitazone, 407–408  
 saxagliptin, 409t
- oral drugs, 401–410  
 acarbose, 408  
 adjunctive, 410  
 biguanides, 403–405  
 canagliflozin, 409–410  
 combination products, 410  
 dipeptidyl peptidase-4 inhibitors, 408–409  
 $\alpha$ -glucosidase inhibitors, 408  
 linagliptin, 409t  
 meglitinides, 406  
 sitagliptin, 408–409  
 sodium-glucose cotransporter 2 inhibitors, 409–410  
 sulfonyleureas, 405–406  
 thiazolidinedione, 407–408  
 pharmacokinetics, 404t
- Nonmotor symptoms management, in Parkinson disease, 142
- Nonnucleoside reverse transcriptase inhibitors (NNRTIs), 751–761, 752t, 753t, 754b  
 patient education, 754b
- Nonoccupational postexposure prophylaxis, 763
- Nonopioid antitussives, 582–583
- Nonopioid centrally acting analgesic, 188–189
- Nonprescription medications national drug schedules, 884
- Nonradioactive iodine, 423
- Nonselective  $\alpha_1$  blocker, 454t
- Nonsteroidal antiinflammatory drugs (NSAIDs), 75, 80, 193  
 in acute care, 873  
 for acute gouty arthritis, 535–536, 535t  
 alcohol and, 260  
 angiotensin-converting enzyme (ACE) inhibitors and, 299  
 antirheumatic drugs, 522, 522–523t  
 black box warning, 535b  
 for cancer pain, 814  
 classification, 522  
 dosages, 522, 522–523t, 525t  
 first-generation, 500–506, 506b  
 glucocorticoids and, 514  
 interactions with lithium, 229–230  
 nonaspirin first-generation, 505–506, 506t  
 peptic ulcer disease and, 586  
 person-centered care across life span, 504b  
 pharmacokinetics, 523, 526t  
 second-generation, 506–507  
 selection, 522  
 ST-segment elevation myocardial infarction and, 868
- Nonstimulants, attention-deficit/hyperactivity disorder (ADHD), 250–251
- Norepinephrine (NE), 75, 80, 106  
 inactivation inhibition by adrenergic agonists, 100  
 life cycle, 81–82, 81f  
 release promotion by adrenergic agonists, 100  
 reuptake inhibition by adrenergic agonists, 100  
 reuptake inhibition by atomoxetine, 250–251
- Norepinephrine uptake inhibitors, 250–251
- Novavax, 742
- NS5A inhibitors, 730, 732t
- NS5B inhibitors, 730–733, 732t
- Nucleoside analogs, for hepatitis B, 736–737
- Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), 748–752, 750t, 751b, 752b  
 patient education, 752b

- Nutritional status, drug metabolism and, 20  
Nystatin, 713
- O**
- Obesity. *See also* Weight loss  
algorithm for, 624f  
assessment of weight-related health risk, 621  
bariatric surgery, 625  
behavior modification for, 623–624  
body mass index, 621, 622f  
caloric restriction for, 623  
devices, 624–625  
drugs for, 621–629  
    black box warning, 627b, 628b  
    combination, 628  
    glucagon-like peptide-1 agonist, 627–628  
    lipase inhibitor, 625–627  
    pharmacokinetics, 625t  
    preparations and dosage, 626t  
    prescribing considerations for, 628b  
    sympathomimetic amines, 626–627  
exercise for, 623  
health risk and, 621  
overview of treatment for, 623–625, 623b  
pathophysiology, 622–623  
patient-centered care across the lifespan, 627b  
risk status and, 621  
treatment for, 623–625, 623b  
treatment goal, 623  
treatment modalities, 623–625  
waist circumference, 621
- Obsessive-compulsive disorder (OCD), 243–244  
characteristics, 243–244  
treatment, 244
- Obstructive sleep apnea-hypopnea syndrome (OSAHS), 248
- Occupational postexposure prophylaxis, 763
- Ocular decongestants, 828
- Ocular herpes infection, 725
- Ofatumumab, 805
- Olanzapine, 208
- Older adults, 318–319. *See also* Adults  
aminoglycosides and, 679b  
androgens and, 448b  
antiemetics in, 605b  
antifungal agents and, 718b  
antihistamines in, 497b  
antimicrobial drugs and, 653b  
antiviral agents and, 723b  
carbapenems and, 667b  
cephalosporins and, 667b  
drugs for benign prostatic hyperplasia and, 455b  
drugs for erectile dysfunction and, 461b  
glucocorticoids and, 513b  
gout and, 534b  
laxatives in, 594b  
muscle spasm and spasticity in, 173b  
penicillins in, 660b  
peptic ulcer disease in, 592b  
progestins in, 436b  
second-generation (atypical) antipsychotics, 209  
selective serotonin reuptake inhibitors (SSRIs), 217t  
tetracyclines and, 672b  
tuberculosis and, 695b  
urinary tract infections in, 692b
- Olopatadine, 579t
- Omalizumab, 565b, 582, 779
- Omeclamox-Pak, 588
- Omeprazole, 591–592
- OnabotulinumtoxinA, for nonsurgical cosmetic procedures, 852–853
- Onchocerciasis, 774
- Ondansetron, 601–602, 603t
- Onychomycosis, 711
- Ophthalmic effect, amiodarone, 343
- Opioids  
abuse  
    detoxification, 272  
    drugs for long-term management of, 271–272  
    patterns of use, 270  
    preferred drugs and routes of administration, 270  
    subjective and behavioral effects, 270  
tolerance and physical dependence in, 270–271  
treatment of acute toxicity, 271
- agonist-antagonist opioids, 186–187  
buprenorphine, 187  
formulations, 187t  
pentazocine, 187  
pharmacology, 187t
- antagonists, 187–188  
methylnaltrexone, 188  
naldemedine, 188  
naloxegol, 188  
naloxone, 188  
naltrexone, 188
- antitussives, 582  
to avoid, 815  
black box warning, 183b  
for cancer pain, 815–816, 815t  
classification of drugs that act as opioid receptors and, 181  
for diarrhea, 606t  
endogenous opioid peptides, 181  
fentanyl, 184–185  
mechanism of action and classification, 815  
methadone, 185  
moderate to strong opioid agonists, 185–186  
    codeine, 186  
    hydrocodone, 186  
    oxycodone, 186  
    tapentadol, 186  
morphine, 181–184  
as nonspecific antidiarrheal agents, 606  
other strong  
    fentanyl, 184–185  
    hydromorphone, oxymorphone, and levorphanol, 185  
    methadone, 185  
person-centered care across the life span, 191b  
pharmacology, 181–187  
preferred, 815  
prescribing  
    cancer-related pain, 191  
    CDC guidelines for safe, 190–191, 190b  
    chronic, noncancer pain, 189–191  
    considerations, 191  
    efforts to decrease abuse and misuse, 189–190, 189t  
    guidelines, 190–191  
    opioid epidemic, 189  
    prototype drugs, 181b  
    receptors, 181  
REMS to reduce morbidity, mortality, and abuse related to, 189–190  
reversal of effects of, 873  
rotation, 815  
routes of administration, 816  
selection, 815  
with special caution, 815  
terminology, 181
- Opium tincture, 606
- Opsonization of bacteria, 481
- Oral (PO) administration, neonates and infants, 59
- Oral antihistamines, 577
- Oral candidiasis, 711
- Oral contraceptives, 437–442, 745  
absolute and relative contraindications of, 439t  
acne and, 836–837  
combination, 437–442, 438t, 441t, 446  
dosing schedules, 441–442  
drug interactions, 441  
extended-cycle and continuous schedules, 442  
noncontraceptive benefits of, 441  
oxcarbazepine, 160  
progestin-only, 442
- Oral glucose tolerance test, 394t
- Oral hypoglycemics, glucocorticoids and, 514
- Oral iron preparations, 386–388
- Orexin antagonist, 237
- Organic nitrates  
isosorbide mononitrate and isosorbide dinitrate, 363  
nitroglycerin, 361–362  
    discontinuing, 362  
    sildenafil and, 456  
    time course of action, 362t  
    trade names and dosages, 363t
- Organic (chemical) screens, 851
- Organic solvents, 280
- Organ-specific toxicity, 37
- Organ system immaturity, 61
- Oritavancin, 709t
- Orlistat, 625–627
- Orthostatic hypotension, 109, 206  
     $\alpha$  blockade and, 109  
    monoamine oxidase inhibitors (MAOIs), 221  
    nitroglycerin and, 362  
    opioids and, 184  
    patient education, 218b  
    regulation of arterial pressure and, 285  
    second-generation (atypical) antipsychotics, 209  
    tricyclic antidepressants (TCAs), 218
- Oseltamivir, 740
- Osmolality disorders, 863–864
- Osmotic laxatives, 598
- Osteoporosis  
drugs for, 550t  
glucocorticoids and, 513  
raloxifene for  
    patient education, 543b  
    prescribing considerations, 544b  
prevention of, 434
- Otitis externa  
acute, 859–861, 859b, 860f  
fungal, 861  
necrotizing, 859
- Otitis media, 855–858  
acute, 855–858, 855t, 856f, 857t, 858b  
with effusion, 858–859  
recurrent, 858
- Otomycosis, 861
- Ototoxic drugs  
aminoglycosides and, 680  
furosemide and, 289
- Ototoxicity. *See also* Hearing loss  
furosemide, 289
- Ovarian and uterine events, in menstrual cycle, 425
- Overactive bladder, muscarinic antagonists for, 95–98, 96f, 97t, 98t
- Over-the-counter (OTC) medications, 6
- Overweight. *See* Weight loss
- Oxcarbazepine, 159–160
- Oxybutynin, 97t. *See also* Opioids, abuse
- Oxycodone, 186, 186b, 270
- Oxygen  
demand and supply, cardiac, 360  
ST-segment elevation myocardial infarction and, 867

- Oxymetazoline, 581t  
 Oxymorphone, 184t, 185  
   black box warning, 185b
- P**
- Paget disease of bone, 542
- Pain, 276  
   assessment, opioids and, 191  
   barriers to management of, 811b  
   cancer-related, 811–818  
     adjuvant analgesics for, 816–817, 817t  
     antidepressants for, 816  
     antiseizure drugs for, 816  
     assessment and ongoing evaluation in, 811–813  
     bisphosphonates for, 817  
     breakthrough, 816  
     causes of, 811  
     central nervous system stimulants, 817  
     comprehensive initial assessment, 812–813  
     diagnostic tests, 813  
     drug therapy, 813–817, 813f, 814t  
     glucocorticoids for, 817  
     incidence of, 811  
     management strategy, 811, 812f  
     nondrug therapy, 817–818  
     nonopioid analgesics for, 814–815  
     ongoing evaluation, 813  
     opioid analgesics for, 815–816  
     patient education, 818  
     patient self-report of, 812–813  
     physical and neurologic examination, 813  
     psychosocial assessment of, 813  
     topical anesthetics for, 816  
   defined, 811  
   headache. *See* Headache  
   relief, morphine, 182
- Palivizumab, 494, 742
- Palonosetron, 601, 603t
- Pancreas, alcohol effects on, 259
- Pancreatic enzymes, 610
- Pancreatitis  
   divalproex, 231b  
   exenatide and, 411
- Panic disorder, 242–243  
   characteristics, 242–243  
   treatment, 243
- Panitumumab, 802
- Pantothenic acid, 619–620
- Papanicolaou (Pap) test, 487
- Papaverine plus phentolamine, 463
- Para-aminosalicylic acid, 699t, 705
- Paradoxical effects, 36  
   benzodiazepines and, 234
- Parasitic worms, 773. *See also* Anthelmintics  
   classification of, 773  
   drugs of choice, 774t
- Parasympathetic nervous system  
   anatomic considerations, 74–75  
   functions, 73
- Parathyroid analog, 552
- Parathyroid hormone, 541, 542t
- Parenteral preparations, iron, 880–881
- Parenteral therapy, and aminoglycosides, 677
- Parkinson disease (PD), 127–143  
   amantadine for, 140–141  
   catechol-*O*-methyltransferase inhibitors  
     for, 138–139  
   centrally acting anticholinergic drugs for, 142  
   clinical guidelines of, 128  
   dopaminergic drugs for, 129t, 134–139  
   drug selection, 128  
   drugs employed in, 128  
   drugs for, 127–143  
   ergot derivatives, 137–138
- Parkinson disease (*Continued*)  
   initial treatment of, 128  
   levodopa for, 129–134  
   management of motor fluctuations in, 128  
   monoamine oxidase-B (MAO-B) inhibitors  
     for, 139–140  
   motor symptoms, 127  
   nonergot derivatives for, 135–137  
   nonmotor symptoms and their  
     management, 142  
   overview of motor symptom management  
     in, 127–128  
   pathogenesis, 127  
   pathophysiology that underlies motor  
     symptoms, 127  
   patient-centered care across the life span, 139b  
   pharmacokinetics, 130–132  
   pharmacology of drugs used for motor  
     symptoms in, 129–142  
   prototype drugs, 135b  
   therapeutic goal of, 127
- Parkinsonism, antipsychotic drugs and, 205
- Paromomycin, 681t
- Paroxetine, 217, 242
- Partial agonists, 29
- Partial seizures, 152
- Passive tubular reabsorption, 21
- Pathogenesis  
   diabetic ketoacidosis (DKA), 413–414, 414f  
   of major depression, 212  
   peptic ulcers, 585–586
- Pathophysiology  
   acne, 832  
   of allergic conjunctivitis, 826  
   Alzheimer disease (AD), 144  
   anaphylaxis, 104–105  
   angina pectoris, 360–361  
   benign prostatic hyperplasia (BPH), 453  
   of glaucoma, 819  
   of gout, 534  
   heart failure, 321–323  
   human immunodeficiency virus (HIV),  
     745–748  
   and individual variation in drug responses, 44  
   migraine headache, 192  
   in Parkinson disease (PD), 127  
   premature ejaculation (PE), 464  
   ST-segment elevation myocardial infarction, 867  
   of thyroid, 418–419  
   variant angina, 360–361
- Patient education, 10–11  
   acute otitis externa, 859b  
   acyclovir, 723b  
   administration, 10  
   on adverse effects, 10  
   allergic conjunctivitis, 828b  
   androgens, 452b  
   antimicrobial drugs, 653b  
   antipsychotic agents, 206b  
   antipsychotic drugs, 211b  
   antituberculosis drugs, 706b  
   baclofen, 172b  
   bipolar disorder (BPD), 228b  
   centrally acting skeletal muscle relaxants, 172b  
   cold in children, 584b  
   components, 10–11  
   dantrolene, 172b  
   daptomycin, 710b  
   on dietary supplement, 644  
   digoxin, 329b  
   digoxin toxicity, 329b  
   disulfiram, 264b  
   on dosing, 10  
   drug names, 10  
   drug purposes, 10
- Patient education (*Continued*)  
   duration of therapy, 11  
   estrogens, 429b  
   food or drug interactions, 11  
   ganciclovir, 726b  
   gender-affirming hormone therapy  
     (GAHT), 474  
   glaucoma, 824b  
   glucocorticoids, 516b  
   heart failure, 328b  
   hypertensive crisis, 221b  
   hypoglycemia, 401b  
   hypotension, 184b  
   infectious conjunctivitis, 825b  
   insulin, 399b  
   local anesthetics and self-inflicted injury, 177b  
   loop diuretics, 289b  
   methadone toxicity, 185b  
   monoamine oxidase inhibitors (MAOIs), 221b  
   morphine and respiratory depression, 182b  
   opioids and, 191  
   orthostatic hypotension, 218b  
   phosphodiesterase-5 inhibitors, 459b  
   ribavirin, 733b  
   selective serotonin reuptake inhibitors, 216b  
   storage information, 10–11  
   with sulfonamides, 683b  
   testosterone, 452b  
   tetracyclines, 670b, 671b  
   thrombosis and thromboembolism, 439b  
   topical testosterone, 452b  
   with trimethoprim, 686b  
   vasodilators, 309b  
   vitamin supplement, 620b  
   warfarin, 377b  
   written instructions, 11
- Pazopanib, 803–804
- Pediatric patients, drug therapy in, 59–62  
   absorption, 59–60  
   adverse drug reactions, 61  
   dosage determination, 61  
   minimum effective concentration (MEC), 59  
   pharmacokinetics in children 1 year and  
     older and, 61  
   pharmacokinetics in neonates and  
     infants, 59–61  
   promoting adherence to, 61, 61t
- Pediatric Research Equity Act (PREA), 59
- Pediculosis, 847–848, 847t, 848b
- Pediculosis capitis, 847
- Pediculosis corporis, 847–848
- Pediculosis pubis, 848
- Pegloticase, 535t, 536t, 538–539, 539b  
   black box warning, 539b
- Pelvic inflammatory disease (PID), 769–770, 770t
- Penciclovir, 724t
- Penicillamine, 527
- Penicillinases, 656–657
- Penicillin G, 658–660, 659f
- Penicillins, 656–662, 662b, 680. *See also*  
   Antibacterial drugs  
   allergy, 659–660  
   broad-spectrum, 661  
   chemistry of, 658  
   classification of, 658, 658t  
   combined with  $\beta$ -lactamase inhibitor, 662  
   dosage for, 661t  
   extended-spectrum, 661–662  
   introduction to, 656–658  
   mechanism of action of, 656, 657f  
   mechanisms of bacterial resistance and,  
     656–657, 657f  
   patient-centered care across the life span, 660b  
   penicillinase-resistant, 660–661  
   properties of, 658–660

- Penicillin V, 660–662, 661t
- Pentazocine, 187
- Peppermint, 640
- Pepsin, 586
- Peptic ulcer disease (PUD), 585–593
  - aggressive factors, 585–586, 586f
  - alcohol and, 261
  - antacids for, 593, 593t
  - antibacterial drugs for, 588
  - antibiotics for, 588
  - atropine, 93–94
  - cimetidine for, 589–590, 590f
  - defensive factors, 585
  - famotidine for, 589
  - gastric acid and, 586
  - glucocorticoids and, 513–514
  - Helicobacter pylori*-associated, 585
  - histamine-2 receptor antagonists, 589–590
  - misoprostol and, 592–593, 592b
  - nizatidine for, 589
  - nonsteroidal antiinflammatory drugs and, 586
  - pathogenesis of, 585–586
  - patient-centered care across the life span, 592b
  - proton pump inhibitors for, 590–592
  - prototype drugs for, 589b
  - sucralfate and, 592
  - tetracyclines for, 670
  - treatment overview, 586–588, 587t
- Peramivir, 741
- Perampanel, 164t, 166–168t
- Percutaneous coronary intervention, 875
- Performance anxiety,  $\beta$  blockade, 113
- Perindopril, 298
- Periodic limb movements of sleep (PLMS), 142
- Periodontal disease, tetracyclines for, 670
- Peripartum depression, 224–225
- Peripheral nervous system (PNS)
  - anatomic considerations, 74–75
  - autonomic nervous system function and, 73
  - autonomic nervous system regulates
    - physiologic processes, 74
  - and basic mechanisms by which
    - neuropharmacologic agents act, 69–71
  - central nervous system (CNS) and, 73
  - drugs affecting, 72
  - drug sites of action, 71, 72f
  - how neurons regulate physiologic processes and, 69
  - neuropharmacology, 69–72
  - physiology, 73–82
  - receptors, 75–76
  - transmitters, 75, 76f
- Peripheral vascular resistance, 313
- Permethrin, 848
- Perphenazine, 603t
- Persistent pulmonary hypertension of the newborn (PPHN), 216
- Personalized medicine, 48
- Pertussis, 486
  - vaccine, 490, 490t
- Pertuzumab, 796
- Pfizer-BioNTech, 742
- P-glycoprotein (PGP), 15
  - drug-drug interactions and, 33
- Phagocytosis, 477
- Pharmacodynamics, 15–35
  - dose-response relationships, 24–25
  - drug-receptor interactions, 25–29
  - drug responses that do not involve receptors, 29
  - drug-supplement interactions, 35
  - in geriatric patients, 63–64
  - interactions, 33–34
  - interpatient variability in drug responses, 29–30
  - therapeutic index, 30
- Pharmacodynamic tolerance, 44, 45
- Pharmacogenomics
  - application of, 48–51
    - barriers, 51
  - drug metabolism and, 49–50
  - education and competencies, 48
  - individual variation in drug responses, 45–46
  - testing, 51
- Pharmacokinetics, 15–35
  - absorption, 17
  - ACL inhibitors on, 359
  - alcohol, 260
  - alcohol effects on, 260
  - aliskiren, 302
  - aminoglycosides, 677–679, 679t
  - amiodarone (Pacerone), 342
  - angiotensin-converting enzyme (ACE) inhibitors, 296
  - atomoxetine, 250
  - baclofen and, 169
  - benzodiazepines, 233
  - bremelanotide (Vyleesi), 465t
  - bupropion, 223
  - calcitonin gene-related peptide receptor antagonists, 196
  - centrally acting  $\alpha_2$  agonist, 121t
  - of cephalosporins, 663, 664t
  - in children 1 year and older and, 61
  - cimetidine, 589
  - clopidogrel, 383
  - colesevelam, 356
  - digoxin, 329–330
  - diltiazem, 306
  - direct oral anticoagulants, 379t
  - distribution, 17–19
  - disulfiram, 264b
  - epinephrine, 105–106
  - ergotamine, 196
  - erythromycin, 673
  - excretion, 20–22
  - ezetimibe, 357
  - first-generation antiseizure drugs, 156t
  - flibanserin, 465t
  - flibanserin (Addyi), 465t
  - fluoxetine, 215
  - fondaparinux, 375t
  - furosemide, 289
  - in geriatric patients, 63, 64t
  - glucocorticoids, 511–512
  - heparin, 375t
  - HMG-CoA reductase inhibitors, 354
  - hydralazine, 309
  - hydrochlorothiazide, 291
  - injectable noninsulin antidiabetic drugs, 412t
  - interactions, 31–33
  - levodopa, 130–132
  - levothyroxine, 420
  - lithium, 228–229
  - local anesthetics, 178
  - marijuana, 275
  - metabolism, 19–20
  - methimazole, 422, 422t
  - methylxanthone, 188
  - minoxidil, 310
  - modafinil, 248
  - naldemedine, 188
  - naloxegol, 188
  - naloxone, 188
  - neonates and infants, 59–61
  - nicotine, 265
  - nifedipine, 308
  - nitroglycerin, 362
  - oxcarbazepine, 160
  - passage of drugs across membranes, 15
  - PCSK9 inhibitors, 359
- Pharmacokinetics (*Continued*)
  - penicillin G, 659
  - phenytoin, 156–157
  - pramlintide, 413
  - propylthiouracil, 422t
  - ranolazine, 364
  - reversible cholinesterase inhibitors and, 88
  - sedative-hypnotic drugs, 235t
  - sulfonamides, 682, 683t, 684t
  - sumatriptan, 195
  - tetracyclines, 670, 671t
  - time course of drug responses, 22–24
  - tirzepatide, 411
  - tramadol, 189
  - triarterene, 292
  - tricyclic antidepressants (TCAs), 218
  - verapamil, 305–306
  - vorapaxar, 383
  - warfarin, 376t
- Pharmacology
  - agonist-antagonist opioids, 187t
  - alcohol, 258–260
  - amiloride, 292
  - amphetamine, 246–247
  - angiotensin-converting enzyme (ACE) inhibitors, 296
  - angiotensin II receptor blockers (ARBs), 300
  - antidysrhythmic drugs, 340–344
  - antituberculosis drugs, 699–703
  - barbiturates, 237
  - buprenorphine, 187
  - disulfiram, alcohol and, 263
  - drugs used for motor symptoms in Parkinson disease, 129–142
  - estrogens, 428
  - of glucocorticoids, 511–517
  - hydromorphone, oxycodone, and levorphanol, 185
  - laxatives, 596–600
  - local anesthetics, 177–179
  - naloxone, 188
  - nicotine, 265–266
  - opioids, 181–187
  - organic solvents, 280
  - triptans, 194t
  - vasodilators, 309–311
- Pharyngeal infection, gonorrhea, 765–766
- pH-dependent ionization, 21
- Phencyclidine, 279
- Phenobarbital, oxcarbazepine and, 159–160
- Phenothiazines, 497t, 498t, 603–604, 603t
- Phenoxybenzamine, 112–113
- Phentermine, 626–627
- Phentermine/topiramate, 628
- Phentolamine, 112
- Phenylephrine, 107, 581, 581t
- Phenytoin, 156–159
  - black box warning, 158b
  - valproic acid and, 159–160
- Pheochromocytoma
  - adrenergic antagonists, 109
  - $\beta$  blockade, 113–114
- Phone applications, 9
- Phosphodiesterase-4 inhibitors, 567, 845
- Phosphodiesterase-5 inhibitors, 454t, 456, 458–462
  - comparison, 462t
  - patient education, 459b
  - prescribing considerations, 463b
  - sildenafil, 461
- Phosphodiesterase inhibitors, for acute decompensated heart failure, 879
- Photophobia, atropine, 94
- pH partitioning, 16–17
- Physical activity. *See* Exercise

- Physical dependence, 36–37, 254  
 alcohol, 260  
 amphetamine, 246  
 barbiturates, 238, 273  
 benzodiazepines, 234–235  
 centrally acting muscle relaxants, 174  
 central nervous system and, 125–126  
 ergotamine, 196  
 first-generation (conventional)  
 antipsychotics, 207  
 morphine and, 184  
 nicotine, 266  
 opioids, 270–271, 815  
 pentazocine, 187  
 suvorexant (Belsomra), 237
- Physician assistants (PAs)  
 case for full prescriptive authority, 5  
 full practice authority and, 1
- Physiologic effects, *d*-lysergic acid  
 diethylamide, 278
- Physostigmine, 89
- Phytoestrogens, 429
- Pilocarpine, 86, 823, 823t
- Pimavanserin, 132
- Pinworms, 773
- Pioglitazone, 407–408
- Piperacillin, 662
- Piperazine, 497t, 498t
- Piperidine, 498t
- Placebo effect, 45
- Placental drug transfer, 18–19, 19f, 53. *See also*  
 Fetal effects
- Plan B One-Step, 445
- Plasma-derived antithrombin, 875
- Plasma drug levels  
 antiepileptic drugs, 154  
 time course of drug responses and, 22
- Plasma lipoproteins. *See also* Cholesterol  
 ACL inhibitors on, 359  
 ezetimibe effect on, 357  
 gemfibrozil effect on, 358  
 proprotein convertase subtilisin kexin type 9  
 effect on, 358  
 structure, 346f
- Plateau drug levels, 23, 23f  
 decline from, 24
- Platelet aggregation suppression, 502–503
- Platinum compounds, 790
- Plazomicin, 681t
- Plecanatide, 598
- Plummer disease, 419
- Pneumococcal conjugate vaccine (PCV), 492
- Pneumococcal infection, 487  
 acute otitis media and, 858  
 conjugate vaccine, 492
- Pneumocystis jirovecii* pneumonia  
 trimethoprim/sulfamethoxazole, 687
- Pneumonia  
 cimetidine and, 590  
 enfuvirtide and, 759  
 omeprazole and, 591
- Podofilox, 846
- Podophyllin, 845–846
- Poisoning  
 cholinesterase inhibitors, 87, 94  
 nicotine, 266
- Polar molecules, 15–16, 16f
- Poliomyelitis, 486
- Poliovirus vaccine, 490
- Polycystic ovary syndrome (PCOS), 403–405
- Polyene antibiotics, 712, 713, 713t
- Polyethylene glycol, 598  
 electrolyte solutions, 599
- Polygender, 466
- Polypharmacy, 6
- Polyuria, lithium and, 229
- Ponatinib, 803
- Pores, 15
- Pork roundworm infestation, 774
- Postattachment inhibitor, 760–761
- Postexposure prophylaxis, 762–763
- Post-extravasation necrosis, epinephrine and, 106
- Posttraumatic stress disorder (PTSD), 244–245  
 characteristics, 244–245  
 epidemiology, 244–245  
 treatment, 245
- Postural hypotension, 285. *See also* Orthostatic  
 hypotension  
 levodopa and, 132  
 vasodilators, 309
- Potassium  
 hyperkalemia, 291–292, 302, 865–866, 866t  
 hypokalemia, 865, 865t  
 imbalances, 864–865  
 loss, glucocorticoids and, 514  
 potassium binders, 865–866, 866t  
 regulation, 864–865
- Potassium binders, 865–866, 866t
- Potassium channel blockers, 337, 342–343
- Potassium-sparing diuretics, 291–292, 324  
 amiloride, 292  
 names, dosages, and time course of effects, 292t  
 prescribing considerations, 292b  
 spironolactone, 291–292  
 triamterene, 292
- Potency, relative, 25
- Pralidoxime, 90
- Pramipexole, for Parkinson disease, 135–136
- Pramlintide, 413
- Prasugrel, ST-segment elevation myocardial  
 infarction and, 869
- Praziquantel, 775–776t, 777
- Prazosin, 111
- Preanesthetic medication, atropine, 93
- Precision medicine, 48
- Prediabetes, 394
- Prednisolone, 512t
- Prednisone, 512t, 535t
- Preeclampsia, 320
- Preexposure prophylaxis, 761–762
- Pregnancy. *See also* Breastfeeding; Fetal effects  
 alcohol effects on, 259–260  
 aminoglycosides and, 679b  
 androgens and, 448b  
 antifungal agents and, 718b  
 antihistamines in, 497b  
 antimicrobial drugs and, 653b  
 antiviral agents and, 723b  
 benzodiazepines and, 234  
 carbapenems and, 667b  
 cephalosporins and, 667b  
*Chlamydia trachomatis* in, 764, 765t  
 clonidine, 121  
 diabetes, 393–394  
 drugs for benign prostatic hyperplasia and, 455b  
 drugs for erectile dysfunction and, 461b  
 drug therapy during, 53–58  
 adverse reactions to, 53–54  
 basic considerations, 53–54  
 FDA pregnancy and lactation labeling rule  
 and, 56, 57t  
 FDA pregnancy risk categories and, 56, 56t  
 minimizing drug risk with, 56–57  
 misoprostol in, 593b  
 peptic ulcer disease, 592b  
 physiologic changes, 53  
 teratogenesis and, 54  
 folic acid deficiency during, 391  
 glucocorticoids and, 513b  
 gout and, 534b
- Pregnancy (*Continued*)  
 HMG-CoA reductase inhibitors (statins)  
 and, 355  
 hypertension in, 319–320  
 chronic, 319–320  
 hypothyroidism in, 418  
 laxatives in, 594b  
 methamphetamine, 274  
 methimazole and, 422  
 muscle spasm and spasticity in, 173–174b  
 nausea and vomiting of, 605  
 nicotine effects, 266  
 oral contraceptives and, 440  
 penicillins for, 660b  
 phenytoin, 158  
 placental drug transfer, 18–19  
 progestin effects during, 430, 436b  
 ramelteon, 236  
 risk with angiotensin-converting enzyme  
 inhibitors, 324b  
 rivaroxaban and, 380–381  
 selective serotonin reuptake inhibitors  
 (SSRIs), 216  
 sulfonamides in, 685b  
 suvorexant (Belsomra), 237  
 teratogenesis, 195  
 tetracyclines and, 672b  
 trimethoprim and, 686  
 tuberculosis and, 695b  
 urinary tract infections in, 692b
- Pregnancy and Lactation Labeling Rule, 56, 57t
- Prejunctional receptors, 80
- Preload, 282
- Premature ejaculation (PE)  
 definition, 463–464  
 drug therapy, 464  
 selective serotonin reuptake inhibitors  
 (SSRI), 464  
 topical anesthetics, 464  
 management  
 clinical guidelines, 464  
 nonpharmacologic treatments, 464  
 pathophysiology, 464
- Premature epiphyseal closure, 450
- Premature ventricular complex (PVC), 339
- Premixed insulin combinations, 399t
- Preparations  
 angiotensin-converting enzyme (ACE)  
 inhibitors, 299  
 antigout drugs, 535t  
 antihistamines, 497  
 antipsychotic agents, 204t  
 baclofen and, 169  
 bremelanotide (Vyleesi), 465t  
 centrally acting  $\alpha_2$  agonist, 121  
 depot antipsychotic, 210t  
 dipeptidyl peptidase-4 inhibitors, 409t  
 disulfiram, 264b  
 estrogens, 428  
 fentanyl, 183t  
 folic acid, 392t  
 flibanserin, 465t  
 glucocorticoids, 514–515  
 $\alpha$ -glucosidase inhibitors, 409t  
 HMG-CoA reductase inhibitors, 356t  
 hydromorphone, 184t  
 injectable noninsulin antidiabetic drugs, 412t  
 insulin, 396–399  
 levodopa, 133–134, 134t  
 levorphanol, 184t  
 levothyroxine, 420–421  
 lithium, 230t  
 meglitinides, 407t  
 metformin, 405, 405t  
 moderate to strong opioid agonists, 186t

- Preparations (*Continued*)  
 morphine, 182t  
 newer-generation antiepileptic drugs, 164t  
 oral contraceptives, 441  
 oxcarbazepine, 160  
 oxymorphone, 184t  
 phosphodiesterase-5 inhibitors, 460t  
 ranolazine, 364  
 sodium-glucose co-transporter 2 inhibitors, 410t  
 sulfonylureas, 406t  
 thiazolidinedione, 408t  
 thyroid hormone, 419t  
 vasodilators, 310t  
 vitamin B<sub>12</sub>, 390t
- Prescription drug monitoring program (PDMP), 191
- Prescriptions, 6–9  
 abbreviations and figures to avoid, 9t  
 allergic conjunctivitis treatment drugs, 827b  
 androgens, 452b  
 assistance, 9  
 assistance programs, 14t  
 collaboration in, 9  
 common example, 7f  
 Controlled Substances Act (CSA), 256–257  
 drug selection, 6–7  
 electronic, 8–9  
 estrogens, 429b  
 glaucoma treatment drugs, 824b  
 glucocorticoids and, 516–517b  
 helpful applications and websites for, 9  
 historical example, 8f  
 necessities of, 7–8  
 phosphodiesterase-5 inhibitors, 463b  
 progestins, 431b  
 refills, 9  
 responsibility of, 6  
 tablet and phone applications, 9  
 telephone, 8  
 types of, 8–9  
 written, 8
- Prescriptive authority, 1–5  
 case for full, 5  
 components of, 1  
 defined, 1  
 regulations, 1–5  
 responsibility and, 5
- Presynaptic receptors, 80
- Preterm labor delay,  $\beta_2$  activation and, 104
- Priapism, sildenafil and, 461
- Primary (essential) hypertension, 312
- Primary open-angle glaucoma (POAG), 819, 820t, 821f
- Primary percutaneous coronary intervention, 868
- Primary sexual characteristics, 467b
- Primidone, for epilepsy, 156
- Prinzmetal angina, 360–361
- Probenecid, 535t, 536t, 538
- Probiotics, 640–641
- Procainamide, 877–878
- Procaine, 179
- Prochlorperazine, 603t
- Proctitis, 770–771, 771t
- Prodrug activation, 20
- Proerythroblasts, 385
- Progesterone, 425
- Progestin-only emergency contraception pills, 442, 445
- Progestins, 430–431  
 adverse effects of, 431  
 black box warning, 436b  
 for cancer treatment, 809  
 clinical pharmacology of, 430–431  
 imbalance, effects of, 440–441, 440t
- Progestins (*Continued*)  
 in oral contraceptives, 438  
 patient-centered care across the life span, 436b  
 prototype drugs, 432b
- Progressive multifocal leukoencephalopathy, 529–530
- Prokinetic agents, 610
- Promethazine, 497t, 498b, 498t, 603t, 604b
- Propranolol, 114–116, 244, 342
- Proprotein convertase subtilisin/kexin type (PCSK9) inhibitors, 358–359  
 adverse effects, 359  
 effect on plasma lipoproteins, 358  
 mechanism of action, 358  
 pharmacokinetics, 359
- Propylthiouracil, 421, 422t
- Prostaglandin analogs, for glaucoma, 820–821, 821t
- Prostaglandin E<sub>1</sub>, 462–463
- Prostaglandins, in peptic ulcer disease, 585
- Prostate cancer  
 androgen deprivation therapy, 797  
 androgen receptor blockers for, 798  
 androgens and, 450  
 drugs for, 796–799, 797t  
 gonadotropin-releasing hormone agonists for, 797–798  
 gonadotropin-releasing hormone antagonists for, 798  
 sipuleucel-T for, 799
- Prostatitis, acute bacterial, 691
- Protamine sulfate, for heparin overdose, 874
- Protease-activated receptor-1 antagonists, 383–384
- Protease inhibitors, 730, 731t, 732t, 753–757, 754t, 755t, 756b
- Proteasome inhibitors, 780t, 781, 807
- Protein A Column (Prozorba), 527
- Protein binding, 19, 19f  
 competition, 31  
 in neonates and infants, 60–61
- Proton pump inhibitors (PPIs), 590–592, 592b  
 clopidogrel, 383, 591–592  
 omeprazole, 591–592
- Prototype drugs, 87b  
 acne, 832b  
 allergic rhinitis, cough, and colds, 580b  
 angina pectoris, 361b  
 antibacterial drugs, 707b  
 anticoagulant drugs, 368b  
 antidepressants, 212b  
 antidysrhythmic drugs, 340b  
 antifungal agents, 714b  
 antigout, 538b  
 antiplatelet drugs, 368b  
 antipsychotic agents, 201b  
 antituberculosis drugs, 699b  
 anxiety, 241b  
 bacteriostatic inhibitors of protein synthesis, 672b  
 bipolar disorder (BPD), 226b  
 birth control, 438b  
 calcium channel blockers (CCBs), 304b  
 calcium levels and bone mineralization, 548b  
 cephalosporins, 665b  
 diabetes, 396b  
 drugs for HIV infection, 748b  
 estrogens and progestins, 432b  
 eyes, 822b  
 gastrointestinal drugs, 601b  
 hypertension, 313b  
 laxatives, 596b  
 local anesthetics, 179b  
 low-density lipoprotein (LDL), 352b  
 migraine headache, 195b  
 non-HIV viral infections, 723b  
 opioids, 181b
- Prototype drugs (*Continued*)  
 peptic ulcer disease, 589b  
 sedative-hypnotic drugs, 235b
- Proximal convoluted tubule, 286
- Prucalopride, 598–599
- Pseudoephedrine, 581, 581t, 582t
- Psilocin, 279
- Psilocybin, 279
- Psoriasis  
 biologic agents, 842–843  
 conventional agents, 839–842  
 patient-centered care across the life span, 843b  
 phototherapy, 843  
 topical drugs for, 837–839, 840–841t  
 treatment overview, 837, 839t
- Psychedelics, 278–279  
*d*-lysergic acid diethylamide, 278  
 mescaline, psilocin, psilocybin, and dimethyltryptamine, 279  
 salvia, 278–279
- Psychiatric conditions, baclofen and, 172
- Psychological dependence  
 defined, 254  
 substance use disorder and, 254
- Psychological effects, methamphetamine, 274
- Psychologic disturbances, glucocorticoids and, 513
- Psychosis  
 amphetamine and, 247  
 levodopa and, 132  
 in Parkinson disease, 142–143
- Psychostimulants, 273–275  
 abuse, 273–275
- Pubertal transformation, and testosterone, 447
- Puberty  
 induction, 468  
 suppression, 468  
 GnRH analogue effects, 468  
 monitoring during, 468
- Pulmonary embolism, dabigatran for, 380
- Pulmonary toxicity, amiodarone (Pacerone), 343b
- Pure manic episode, 226
- Pure opioid agonists, 181, 183t
- Pure opioid antagonists, 181
- Purine analogs, 790
- Purple glove syndrome, 158
- P2Y<sub>12</sub> adenosine diphosphate receptor antagonists, 382–383
- Pyelonephritis, acute uncomplicated, 689–690
- Pyrantel pamoate, 775–776t, 777
- Pyrazinamide, 699t, 700t, 703, 703b
- Pyrethrins plus piperonyl butoxide, 848–849
- Pyridostigmine, 87–89, 88–89b, 88t
- Pyridoxine, levodopa, 133
- Pyrimidine analogs, 712t, 718–720, 790
- Q**
- QT interval drugs, 37, 39t
- QT prolongation  
 drugs and ranolazine interaction, 364  
 ranolazine, 364
- Quetiapine, 132
- Quinidine, 340  
 digoxin and, 329
- R**
- Race-related variations in drug responses, 46
- Radiation therapy, for cancer pain, 817–818
- Radiation, ultraviolet, 851, 852f
- Radioactive iodine, 422–423  
 prescribing considerations, 423b
- Radiofrequency ablation, premature ejaculation (PE), 464

- Raloxifene, 551–552, 551b  
 comparison with estrogen, 551t  
 patient education, 552b  
 prescribing considerations, 552b
- Raltegravir, 757, 759b
- Ramelteon, 236
- Ramipril, 298
- Ranolazine, 364
- Rasagiline, 140
- Rash, efavirenz and, 752
- Rate of dissolution, 17
- Raynaud disease, adrenergic antagonists and, 109
- Reabsorption, renal, 286
- Rebound acid hypersecretion, omeprazole and, 591
- Rebound cardiac excitation,  $\beta$  blockade, 114
- Rebound congestion, 580
- Rebound hypertension, centrally acting  $\alpha_2$  agonist, 121
- Receptors, 70  
 adrenergic, 76  
 binding, 70  
 direct, 100  
 cholinergic, 76  
 cholinergic drugs, 84t  
 multiple types, 71–72  
 neurons and, 70  
 opioids, 181  
 peripheral nervous system (PNS), 75–76  
 selectivity, 77  
 specificity, 80, 101  
 subtypes, 76–78, 77t  
 locations of, 78  
 types and selectivity of drug action, 71–72
- $\alpha_1$  receptors, 79t, 80  
 adverse effects of activation of, 102–103  
 clinical consequences of activation of, 101–103  
 therapeutic applications of, activation of, 101–102
- $\alpha_2$  receptors, 79t, 80  
 clinical consequences of, 103  
 effects of blockade of, 110–111
- 5- $\alpha$ -reductase inhibitors, 453–455, 454t
- $\beta_1$  receptors, 80  
 adverse effects of activation of, 104  
 clinical consequences of activation of, 104  
 therapeutic applications of, 104
- $\beta_2$  receptors, 80  
 adverse effects of activation of, 104  
 clinical consequences of activation of, 104  
 therapeutic applications, 104
- $\beta_2$  receptors, 80
- $\kappa$  receptors, 181
- $\mu$  receptors, 181
- Recirculating activation, 336
- Recirculation, enterohepatic, 20
- Recombinant human antithrombin, 875
- Recombinant parathyroid hormone, 552
- Recommended dietary allowance (RDA), 611, 612t
- Recreational marijuana, 277
- Recurrent otitis media, 858
- Recurrent urinary tract infections, 690–691
- Red blood cell development, 385. *See also* Anemias stages, 386f
- Reduction of effects, 31
- Reduction of perioperative mortality,  $\beta$  blockade, 113
- Reentrant activation, 337f
- Reentry, 336
- Refills, prescription, 9
- Reflex tachycardia  
 adrenergic antagonists and, 110  
 hydralazine and, 310  
 minoxidil and, 310  
 nitroglycerin and, 362
- Reformulations, opioids, 189
- Regorafenib, 803–804
- Regular insulin, 397
- Regulations, prescriptive authority, 1–5
- Reinforcing properties of drugs, 254
- Relative potency, 25
- Remdesivir, 744
- Remifentanyl, 872
- Renal disease, 317
- Renal dosing, 7
- Renal drug excretion, 20–22  
 altered, 32–33  
 factors that modify, 21–22  
 glomerular filtration, 21  
 in neonates and infants, 61  
 passive tubular reabsorption, 21  
 steps in, 21
- Renal failure  
 angiotensin-converting enzyme (ACE) inhibitors and, 298–299  
 angiotensin II receptor blockers for, 301  
 prophylaxis of, mannitol for, 881  
 tetracyclines and, 671
- Renal impairment  
 exenatide and, 411  
 rivaroxaban and, 380
- Renal processes, 286
- Renal toxicity, lithium, 229
- Renal tubules and blood pressure, 316
- Renin, 316  
 release regulation, 295
- Renin-angiotensin-aldosterone system (RAAS), 284  
 aldosterone antagonists, 302–303  
 aliskiren, 301–302  
 angiotensin-converting enzyme (ACE) inhibitors, 296–299  
 angiotensin II receptor blockers (ARBs) and, 300–301  
 blood pressure regulation, 294f, 295, 314  
 components, 316  
 drugs acting, 293–303, 295b  
 drugs that suppress, 316  
 heart failure and, 324–325  
 person-centered care across the life span, 295b  
 physiology, 293–295
- Repaglinide, 406
- Repeated doses, 23–24, 23f
- Reperfusion therapy, 868–869, 868t  
 adjuncts to, 869–870, 870t
- Replacement therapy, androgen, 448
- Replication cycle, of human immunodeficiency virus (HIV), 746, 747f
- Replication rate, of human immunodeficiency virus (HIV), 746–747
- Reporting of vaccine-preventable diseases, 484
- Reproduction  
 cancer chemotherapy effects on, 788–789  
 marijuana, 276
- Reslizumab, 566–567, 567b, 779
- Respiration, alcohol effects on, 259
- Respiratory acidosis, 864
- Respiratory alkalosis, 864
- Respiratory depression  
 barbiturates, 238  
 benzodiazepines and, 234  
 morphine, 182–183
- Respiratory distress syndrome, glucocorticoids for, 512–513
- Respiratory syncytial virus (RSV), 488, 742  
 vaccine, 494
- Respiratory system  
 depression with morphine, 182–183, 182b  
 depression with opioids, 816  
 glucocorticoids and, 510  
 marijuana, 276
- Restless legs syndrome (RLS), 136
- Resveratrol, 641
- Retepulse, 877
- Reticulocytes, 385
- Retinoids, 834–835  
 for cancer treatment, 808–809
- Retinol, 614
- Reversal of opioid overdose, 188
- Reversible cholinesterase inhibitors, 87–89
- Reward circuit, 255
- Rewarding effects of alcohol, 258
- Reye syndrome, 504
- Rhabdomyolysis, with HMG-CoA reductase inhibitors (statins), 354–355
- Rheumatoid arthritis (RA)  
 drug therapy, 519–533  
 glucocorticoids for, 512  
 nondrug measures, 519  
 pathophysiology, 519  
 progressive joint degeneration, 519, 520f  
 prototype drugs, 528b  
 therapy, 519–522
- Ribavirin, 733–734  
 black box warning, 736b  
 patient education, 733b
- Riboflavin, 617–618
- Rifabutin, 699t, 700t, 703
- Rifampin, 699t, 700t, 701–703, 703b
- Rifapentine, 699t, 700t, 702
- Rimegepant, 196
- Risk assessment  
 for adverse reactions, 40  
 atherosclerotic cardiovascular disease (ASCVD), 347–350  
 opioids and, 191  
 weight-related, 621
- Risk Evaluation and Mitigation Strategies (REMS), 40, 189–190
- Ritonavir, 730b, 743–744
- Rituximab, 529–530, 529b, 805
- Rivaroxaban, 380
- Rivastigmine, 148
- River blindness, 774
- Roflumilast, 839
- Rolapitant, 602, 603t
- Rome IV criteria, for constipation, 595t
- Romidepsin, 807
- Ropinireole, Parkinson disease and, 136–137
- Rotavirus gastroenteritis, 487  
 vaccine, 493
- Rotigotine, Parkinson disease and, 137
- Round worms, 773  
 infestations, 773  
 pork, 774
- Routes of administration  
 antipsychotic drugs, 210  
 characteristics of, 17
- Rubella, 486  
 vaccine, 488–489
- S**
- Sacubitril, 325
- Safinamide, 140
- Salicylates, 501
- Salicylic acid, 832, 835
- Salicylism, 504
- Saliva, drugs excretion, 22
- Salsalate, 505–506
- Salts, laxative, 598
- Sarilumab (Kevzara), 531, 531b
- Saw palmetto, 456, 641–642
- Saxagliptin, 409t
- Scabies, 847t, 848
- Schistosomiasis, 775

- Schizophrenia, 201–202  
 acute episodes, 201  
 clinical presentation, 201–202  
 cognitive symptoms, 201  
 depot antipsychotic preparations for, 210t  
 etiology, 202  
 first-generation (conventional) antipsychotics, 202–207  
 long-term course, 201–202  
 management, 201  
 drug therapy in, 209–211  
 initial therapy, 210  
 maintenance therapy, 210  
 promoting adherence in, 211  
 negative symptoms, 201, 202t  
 nondrug therapy, 211  
 positive symptoms, 201, 202t  
 residual symptoms, 201  
 second-generation antipsychotics, 208–209
- Scopolamine, 95, 603t, 605
- Screening Tool to Alert doctors to Right Treatment (START), 64
- Seborrheic dermatitis, 853
- Secondarily generalized seizures, 152
- Secondary hypertension, 312
- Secondary sexual characteristics, 467b
- Second-generation (atypical) antipsychotics, 208–209  
 clozapine, 208–209  
 prescribing considerations, 209b
- Second-generation (nonsedating) histamine 1 antagonists, 496, 497
- Secretagogues, 405–406
- Sedation  
 antihistamines and, 496, 497  
 morphine and, 184  
 opioids and, 816  
 tricyclic antidepressants (TCAs), 218
- Sedative-hypnotic drugs  
 benzodiazepine-like drugs, 235–236  
 benzodiazepines, 232–235  
 pharmacokinetic properties, 235t  
 prototype drugs, 235b  
 ramelteon, 236  
 suvorexant, 237
- Seizures, 152–168, 206. *See also* Epilepsy  
 absence, 152–153  
 antipsychotic drugs and, 209  
 atonic, 153  
 barbiturates, 238  
 benzodiazepines for, 233  
 drugs for, 152–168  
 febrile, 153  
 generalized, 152–153  
 generation in epilepsy, 152  
 myoclonic seizures, 153  
 partial, 152  
 prototype drugs, 156b  
 status epilepticus (SE), 153  
 tonic-clonic, 152  
 tricyclic antidepressants (TCAs), 218  
 types of, 152–153
- Selection, drug, 6–7  
 allergies, 7  
 availability, 6  
 cost, 6  
 epilepsy and, 154  
 guidelines, 6  
 hepatic and renal function, 7  
 interactions, 6  
 need for monitoring and, 7  
 side effects, 6–7  
 for special populations, 7
- Selective  $\alpha_1$  blocker, 454t
- Selective estrogen receptor modulators (SERMs), 430, 551
- Selective serotonin reuptake inhibitors (SSRIs), 140, 214–217  
 adverse effects, 215–216  
 drug interactions, 216–217  
 fluoxetine, 214–217  
 for generalized anxiety disorder, 242  
 mechanism of action, 214, 215f  
 for obsessive-compulsive disorder (OCD), 244  
 other, 217  
 for panic disorder, 243  
 patient education, 216b  
 pharmacokinetics, 215  
 for posttraumatic stress disorder, 245  
 for premature ejaculation, 464  
 prescribing considerations, 217b  
 for social anxiety disorder (SAD), 244  
 and sumatriptan interactions, 195  
 therapeutic uses, 214, 215t
- Selective toxicity, 645
- Selegiline  
 for major depression, 223  
 Parkinson disease and, 139–140
- Self-inflicted injury, local anesthetics and, 177b
- Self-monitoring of blood glucose (SMBG), 395
- Selzentry, 51
- Senna, 597
- Serotonergic drugs, monoamine oxidase inhibitors (MAOI) and, 223
- Serotonin, 192
- Serotonin<sub>1B/1D</sub> receptor agonists (Triptans), 193–195
- Serotonin/norepinephrine reuptake inhibitors (SNRIs)  
 prescribing considerations, 217b  
 promoting activation of serotonin receptors, 216t  
 and sumatriptan interactions, 195  
 therapeutic uses, 215t  
 venlafaxine, 217
- Serotonin receptor antagonists, 601–602, 602b
- Serotonin syndrome, 173b  
 fluoxetine, 216
- Sertraline, 217
- Serum creatinine levels, 63
- Serum thyroid-stimulating hormone test, 417
- Serum thyroxine test, 417
- Serum transaminases, protease inhibitors and, 756
- Serum triiodothyronine test, 418
- Severe acute respiratory syndrome coronavirus-2 (COVID-19) vaccine, 494
- Severe dysrhythmias, 206–207
- Severe hypoglycemia, 415
- Sex, 467b
- Sexual dysfunction, 457–465  
 antipsychotic drugs and, 206  
 female, 464–465  
 male, 457  
 selective serotonin reuptake inhibitors and, 215–216
- Sexual function, alcohol effects on, 259
- Sexually transmitted diseases (STDs), 764–772  
 acute epididymitis, 770, 771t  
 anogenital warts, 771  
 bacterial vaginosis, 767–768, 768t  
*Chlamydia trachomatis*, 764–765  
 drugs for, 766b, 771–772t  
 genital herpes, 768–769, 769t  
 gonococcal, 765–766  
 incidence of, 764  
 nongonococcal urethritis (NGU), 769, 770t  
 pelvic inflammatory disease (PID), 769–770, 770t
- Sexually transmitted diseases (STDs) (*Continued*)  
 proctitis, 770–771, 771t  
 syphilis, 767, 767f, 768t  
 trichomoniasis, 768, 768t
- Sexual orientation, 467b
- Shift-work sleep disorder (SWSD), 248
- Shock  
 $\beta_1$  activation and, 104  
 dopamine receptor activation and, 104, 107  
 multiple receptor activation in treatment of anaphylactic, 104–105
- Side effects, drug, 6–7, 36. *See also* Adverse drug reactions (ADRs)  
 adaptation of central nervous system to prolonged, 125–126  
 decreased, 125  
 increased therapeutic effects, 125  
 antipsychotic agents, 205t  
 opioids, 816  
 penicillin G, 659
- Sildenafil  
 adverse effects, 461–462  
 drug interactions, 462  
 for erectile dysfunction (ED), 460t, 461  
 mechanism of action of, 461  
 in men with coronary heart disease, 462  
 preparation, dosage, and considerations, 460t  
 sexual benefits, 461
- Sildenafil, 112, 454t
- Silver sulfadiazine, 684t, 685–686  
 black box warning, 730b
- Simple occupancy theory, 27, 27f
- Simple partial seizures, 152
- Single-dose time course, 22f, 23
- Sinoatrial node, 333  
 calcium channels, 304
- Sipuleucel-T, 799
- Sitagliptin, 408–409
- Skeletal-related events (SREs), with breast cancer, 796
- Skin, 830–854  
 acne, 832–837  
 antiacne drugs, 837b  
 estrogens and, 428  
 hormonal agents for, 836–837, 838f  
 oral drugs for, 835–837  
 pathophysiology, 832  
 prototype drugs, 832b  
 sunscreens and, 851–852, 852b, 852f  
 topical drugs for, 832–835, 833–834t, 835b  
 treatment overview, 832, 833t  
 atopic dermatitis, 843–845, 844t, 845b  
 Botox and, 852–853  
 dermis, 830  
 ectoparasites, 849t  
 patient-centered care across the life span, 850b  
 pediculosis, 847–848, 847t, 848b  
 pharmacology of, 848–850  
 prototype drugs, 848b  
 scabies, 847t, 848  
 epidermis, 830  
 glucocorticoids for, 830–831, 831t  
 hair loss, 853–854  
 impetigo, 850–851, 851t  
 keratolytic agents, 832  
 local anesthetics for, 854  
 onabotulinumtoxinA, for nonsurgical cosmetic procedures, 852–853  
 psoriasis  
 biologic agents, 842–843  
 conventional agents, 839–842  
 patient-centered care across the life span, 843b  
 phototherapy, 843

- Skin (*Continued*)  
 topical drugs for, 837–839, 840–841t  
 treatment overview, 837, 839t  
 seborrheic dermatitis and dandruff, 853  
 sunscreens, 851–852  
   benefits of, 851  
   compounds employed as, 851  
   labeling, 851–852  
   sun protection factor, 851–852  
   UVB and UVA radiation and, 851, 852f  
   water and sweat resistance of, 852  
 topical drug formulations for, 830–832  
 warts  
   agents used to remove, 845–846  
   anogenital, 771  
   common, 846  
   venereal, 845–846, 846t
- Sleep disturbances. *See also* Insomnia  
 alcohol and, 258  
 benzodiazepines, 234  
 in Parkinson disease, 142  
 Sleep driving, 234  
 Slow potentials, 335
- Smoking  
 angina pectoris and, 366  
 cessation  
   internet-based resources, 267t  
   nicotine replacement therapy (NRT), 267–268  
   pharmacologic aids to, 266–269, 267t  
   prototype drugs, 266b  
 chronic toxicity, 266  
 peptic ulcer disease and, 586
- Smooth muscle, muscarinic antagonists and, 93
- Social anxiety disorder (SAD)  
 characteristics, 244  
 treatment, 244
- Social determinants of health (SDOH), 46, 47t
- Social factors, substance use disorder and, 254–255
- Social transition, 467b
- Society of PAs in Genetics and Genomics (SPAGG), 48
- Sodium channel blockers, 336, 340–342  
 class IA agents, 340  
 class IB agents, 340–342  
 class IC agents, 342
- Sodium-depleting drugs, oxcarbazepine, 160
- Sodium-ferric gluconate complex, 881
- Sodium-glucose cotransporter 2 (SGLT-2)  
 inhibitors, 326, 409–410, 410b  
 for heart failure, 331
- Sodium influx suppression, 153–154
- Sodium loading, 593
- Sodium nitroprusside, 879–880
- Sodium phosphate products, 599
- Sodium–potassium exchange, 287
- Sodium restriction and hypertension, 313
- Sodium retention, adrenergic antagonists and, 110
- Sodium salicylate, 505–506
- Sofosbuvir, 730–733
- Soft mist inhalers, 559
- Solifenacin, 97t
- Somatic motor system, anatomic considerations, 75, 75f
- Sorafenib, 803–804
- Sotalol, 117
- Soy, 642
- Spasticity, drugs for, 169–173  
 baclofen and, 169  
 contraindications and interactions, 172  
 dantrolene, 172–173  
 diazepam, 174  
 life span considerations, 173–174b  
 pharmacokinetics, 171t
- Special populations. *See also* Adolescents;  
 Children; Infants; Older adults  
 drug selection for, 7
- Specific acquired immunity, 475
- Spermatogenesis, 447
- Spermicides, 444, 444t
- Spinal (subarachnoid) anesthesia, 873
- Spinal/epidural hematoma, rivaroxaban, 380
- Spinosad, 849
- Spironolactone, 303, 325  
 for acne, 837, 838f
- Spontaneous mutations, and acquired resistance, 648
- Sprue, 391
- Stable angina, nitroglycerin for, 362
- Starling law of the heart, 283  
 maintenance of systemic-pulmonary balance, 283–284
- Statins. *See* HMG-CoA reductase inhibitors
- Status epilepticus (SE), 153
- Step-down therapy for hypertension, 317
- Stevens-Johnson syndrome (SJS), 157–158
- Stewardship, antimicrobial, 649
- Stimulant laxatives, 597
- Stimulants, central nervous system, 246–248  
 abuse, 273–275  
 amphetamines, 246–247  
 dexmethylphenidate, 247  
 methylphenidate, 247  
 methylxanthines, 247–248  
 modafinil, 248  
 person-centered care across the life span, 248b  
 prototype drugs, 246b
- St. John's wort, 631, 642–643
- Stomach, alcohol effects on, 259
- Stomatitis, 787
- Straight, 467b
- Streptococcus pneumoniae, 858
- Streptomycin, 681t, 699t, 700t
- Stress response, 510
- Stroke prevention  
 angiotensin-converting enzyme (ACE) inhibitors and, 298  
 angiotensin II receptor blockers for, 300  
 oral contraceptives and, 440
- Stroke volume, 282
- Strongyloidiasis, 774
- ST-segment elevation myocardial infarction (STEMI), 867–871  
 complications of, 870  
 fibrinolytic therapy, 868–869, 868t, 869t  
 management of, 867–870  
 pathophysiology of, 867  
 primary percutaneous coronary intervention, 868  
 reperfusion therapy, 868–869, 868t  
 adjuncts to, 869–870, 870t  
 routine drug therapy, 867–868  
 secondary prevention of, 870–871
- Subdermal etonogestrel implants, 443
- Substance P/neurokinin-1 antagonists, 602, 603t
- Substance use disorder (SUD), 253  
 alcohol. *See* Alcohol  
 Controlled Substances Act (CSA)  
   drug enforcement agency schedules, 256, 257t  
   labeling rules, 257  
   prescriptions, 256–257  
   record keeping, 256  
   state laws, 257  
 diagnostic criteria, 254  
 drug availability, 255  
 factors that contribute to, 254–255  
 heroin, oxycodone, meperidine, 270–280  
 neurobiology, 255
- Substance use disorder (SUD) (*Continued*)  
 physical dependence, 254  
 psychological dependence, 254  
 social factors, 254–255  
 treatment principles, 255  
 vulnerability of the individual, 255
- Succinylcholine, 874
- Sucralfate, 592
- Sufentanil, 872
- Suicide risk, with antiepileptic drugs, 155
- Sulfacetamide, 684t, 685
- Sulfadiazine, 683t, 684t, 685
- Sulfamethoxazole, 683t, 684t, 685
- Sulfasalazine, 524–526, 609
- Sulfisoxazole, 685
- Sulfonamides, 682–686, 688b, 693  
 antimicrobial spectrum of, 682  
 dosages and administration of, 684t  
 drug interactions with, 685  
 hematologic effects of, 683  
 hypersensitivity reactions with, 683, 684b  
 kernicterus, 683–685  
 mechanisms of action of, 682  
 microbial resistance and, 682  
 patient-centered care across the lifespan, 685b  
 pharmacokinetics, 682, 683t, 684t  
 preparations, 685–686  
 renal damage, 685  
 structural relationship, 683f  
 systemic, 685  
 therapeutic uses of, 682  
 topical, 685–686
- Sulfonyleureas, 405–406  
 prescribing considerations, 406b
- Sulfur, for skin, 832
- Sumatriptan, 193–195
- Sun exposure and dermatitis, 207
- Sun exposure, risk, with tetracyclines, 671b
- Sunitinib, 803–804
- Sunscreens, 851–852  
 benefits of, 851  
 compounds employed as, 851  
 labeling, 851–852  
 patient education, 852b  
 sun protection factor, 851–852  
 UVB and UVA radiation and, 851, 852f  
 water and sweat resistance of, 852
- Superinfection, tetracyclines and, 671
- Supraventricular dysrhythmias, 338–339
- Surface area, 17
- Surfactant laxatives, 596
- Surgery  
 antimicrobial drugs in, 654  
 drainage and cleansing, 655  
 omission of surgical drainage, 655
- Sustained hyperglycemia, 393
- Sustained supraventricular tachycardia (SVT), 338–339
- Suvorexant, 237
- Sweat, drugs excretion, 22
- Sympathetic baroreceptor reflex, 314
- Sympathetic ganglia, blood pressure and, 315
- Sympathetic nervous system  
 anatomic considerations, 75, 75f  
 functions, 73
- Sympatholytics (antiadrenergic drugs), 316
- Sympathomimetic amines, 626–627
- Sympathomimetics, 100  
 for acute decompensated heart failure, 878–879  
 for allergic rhinitis, 578t, 580–581, 581t  
 combinations with antihistamines, 581, 582t  
 digoxin and, 329
- Synaptic transmission, 69–70  
 effects of drugs on the steps of, 70–71  
 steps in, 70, 70f

- Synthetic cathinones, 275  
 Synthetic marijuana, 277  
 $\alpha$ -Synuclein, 127  
 Syphilis, 767, 767f, 768t  
 Systemic filling pressure, 283  
 Systemic lupus erythematosus (SLE),  
   glucocorticoids for, 512  
 Systemic lupus erythematosus–like syndrome,  
   hydralazine and, 310  
 Systemic mycoses, 711–712  
   amphotericin B, 712–713  
 Systemic-pulmonary balance, 283–284, 284f
- T**
- Tablet applications, 9  
 Tachycardia  
   adrenergic antagonists and, 110  
   atropine, 94  
 Tachydysrhythmia, 333  
 Tachyphylaxis, 45  
 Tacrolimus ointment, 844–845  
 Tadalafil, 454t, 456, 460t, 462  
 Taeniasis, 775  
 Tamiflu, 740  
 Tamoxifen, 430, 793–794  
   anastrozole comparison with, 795  
 Tamsulosin, 112, 454t  
 Tamsulosin/dutasteride, 454t  
 Tapentadol, 186  
 Tapeworms, 773  
   infestations, 774–775  
 Tapinarof, 839  
 Tardive dyskinesia (TD), 205–206  
 Targeted anticancer drugs, 799–805, 800–801t  
 Targeted disease-modifying antirheumatic drug,  
   531–533, 532–533b, 532b  
 Tars, 839  
 Tau, in Alzheimer disease, 144  
 Tazarotene, 835, 839  
 T-cell activation inhibitor, 530  
 Tedizolid, 675, 675t  
 Tegretol, 51  
 Telavancin, 668–669  
   black box warning, 669b  
 Telephone prescriptions, 8  
 Temeirolimus, 804  
 Tenecteplase, 877  
 Tenofovir, 737  
 Teratogenesis, 195  
   drug therapy during pregnancy and, 54  
   efavirenz and, 752–753  
   identification of, 54, 55f  
   lithium, 229  
   responding to exposure to, 57–58  
   selective serotonin reuptake inhibitors  
     and, 216  
   stage of development and, 54  
   sumatriptan and, 195  
 Teratogenic effect, 37  
 Teratogens, 37  
 Terazosin, 111–112, 454t  
 Terbinafine, 713  
 Teriparatide, 553b  
 Termination of transmission, 70  
   action, 71  
 Testosterone, 447–448, 472–474  
   for adult transgender males, 470  
   adverse effects, 473  
   biosynthesis and secretion of, 447  
   black box warning, 450b  
   choice, 472–473  
   formulations, 473t  
   mechanism of action of, 447  
   monitoring, 473–474  
   nasal gel, 451  
 Testosterone (*Continued*)  
   patient education, 452b  
   physiologic and pharmacologic effects, 447–448  
   precautions and contraindications, 473  
   and preexisting conditions, 474t  
   product equivalencies, 474t  
   reversible and permanent changes, 473t  
   therapeutic use, 472  
   for transgender man, 472–474  
 Tetanus, 486  
   vaccine, 490, 490t  
 Tetracyclines, 588, 670–672, 672b  
   adverse effects, 671  
   antimicrobial spectrum of, 670  
   drug and food interactions with, 671–672  
   major precautions of, 672  
   mechanism of action of, 670  
   patient-centered care across the life span, 672b  
   patient education on, 670b, 671b  
   pharmacokinetics, 670, 671t  
   routes of administration, dosing interval, and  
     dosage, 672t  
   therapeutic uses of, 670  
 Tetrahydrozoline, 581t  
 Tezepelumab-ekko, 567  
 Thalidomide, 809  
 Theophylline, 570–572, 570b  
 Therapeutic index, 30, 30f  
 Therapeutic lifestyle changes (TLC), 350  
 Therapeutic serum drug concentrations, 885, 885t  
 Thiamine, 618  
 Thiazide diuretics, 290–291  
   antihypertensive drugs, 316  
   dosages, 291t  
   for heart failure, 323  
   hydrochlorothiazide, 290–291  
   prescribing considerations, 291b  
   time course of effects, 291t  
 Thiazolidinediones, 407–408, 408b  
 Thienopyridines, 869  
 Thiocyanate toxicity, 880  
 Thionamides, 421–423  
 Thiopurine methyltransferase (TPMT), 50  
 Thiopurines, 609  
 Threadworm infestation, 774  
 Thrombocytopenia  
   cancer chemotherapy and, 787  
   ganciclovir and, 726  
 Thromboembolic events  
   androgens and, 450  
   oral contraceptives for, 439  
   patient education, 439b  
 Thrombolytic drugs, 370  
   acute care, 874–875, 876t  
 Thrombosis, 370  
   anticoagulants for, 370–377  
   direct factor XA inhibitors, 380–381  
   direct thrombin inhibitors for, 378–380  
   heparin for, 371–375  
   overview of drugs for, 370  
   patient education, 439b  
   warfarin, 375–377  
 Thrombotic thrombocytopenic purpura,  
   clopidogrel and, 383  
 Thymic stromal lymphopoietin blocker, 567  
 Thyroid  
    $\beta$ -blockers, 419  
   chemistry and nomenclature of, 416  
   disorders, drugs for, 416–424  
   function  
     iodine deficiency and, 416–417  
     regulation by hypothalamus and anterior  
       pituitary, 416  
   hormones  
     actions, 416  
 Thyroid (*Continued*)  
   preparations, 419t  
   synthesis and fate of, 416, 417f  
   pathophysiology, 418–419  
   physiology of, 416–417  
   radioactive iodine, 422–423  
   storm, 419  
   tests, 417–418  
 Thyroid-stimulating immunoglobulins (TSIs), 419  
 Thyroid toxicity, amiodarone (Pacerone), 343  
 Thyrotoxic crisis, 419  
 Ticagrelor, ST-segment elevation myocardial  
   infarction and, 869  
 Tigecycline, 675t  
 Time course of drug responses  
   benzodiazepines, 233  
   drug half-life, 23  
   for feminizing hormone therapy effects, 469  
   hydralazine, 309  
   loading *versus* maintenance doses, 24  
   local anesthetics, 177–178  
   loop diuretics, 290t  
   *d*-lysergic acid diethylamide, 278  
   for masculinizing hormone therapy effects,  
     470, 470t  
   3, 4-methylenedioxymethamphetamine  
     (MDMA), 279  
   organic nitrates, 362t  
   plasma drug levels and, 22  
   to plateau, 23  
   potassium-sparing diuretics, 292t  
   repeated doses and, 23–24, 23f  
   single-dose time course, 22f, 23  
   thiazide diuretics, 291t  
 Tinea capitis, 711  
 Tinea corporis, 711  
 Tinea cruris, 711  
 Tinea pedis, 711  
 Tinidazole, 588  
 Tirofiban, 875  
 Tirzepatide, 411–413  
 Tissue plasminogen activator, 876  
 Tissue rejection, prevention of, 513  
 Tizanidine, 174  
 Tobacco and marijuana smoke, 571  
 Tobramycin, 681, 681t  
 Tocilizumab (Actemra), 530–531, 530b  
 $\alpha$ -Tocopherol, 615  
 Tofacitinib, 531–533  
 Tolcapone, Parkinson disease and, 139  
   black box warning, 139b  
 Tolerance  
   alcohol, 260  
   amphetamine, 246  
   barbiturates, 237–238, 273  
   benzodiazepines, 234  
   buspirone, 242  
   central nervous system and, 125–126  
   defined, 253  
   *d*-lysergic acid diethylamide, 278  
   morphine and, 184  
   nicotine, 266  
   nitroglycerin, 362  
   opioids, 270–271, 815  
 Tolnaftate, 720  
 Tolterodine, 97t  
 Tonic-clonic seizures, 152  
 Topical anesthetics, for cancer pain, 816  
 Topical drugs  
   glucocorticoids, 830–831, 831t, 837–839  
   for hair loss, 853–854  
   local anesthetics, 178t  
   for skin, 830–832  
   testosterone, 451  
 Topiramate, 197

- Topoisomerase inhibitors, 792  
 Toremifene, 794  
 Torsades de pointes, 37, 39t, 339  
 Toxic epidermal necrolysis (TEN), 157–158  
 Toxicity  
   antipsychotics, 207  
   combined, 34  
   concentration, 22  
   defined, 36  
   digoxin, 329b  
   d-lysergic acid diethylamide, 278  
   effects of food on drug, 35  
   ferrous sulfate, 387  
   increase or decrease via metabolism, 20  
   lithium, 229b  
   methadone, 185b  
   monoclonal antibodies (MAbs) and, 781  
   morphine, 184  
   nicotine, 266  
   opioids, 271  
   organic solvents, 280  
   penicillin G, 659  
   reversal of  $\alpha_1$  agonist, 109  
   selective, 645  
   tricyclic antidepressants (TCAs), 220  
   vitamin A, 614  
 Toxic nodular goiter, 419  
 Toxicology  
   cholinesterase inhibitors, 90  
   muscarinic agonists, 86–87, 86b  
   muscarinic antagonists (MA), 98–99  
 Toxoids, 484  
   adverse effects, 489t  
   specific vaccines and, 488–494, 488t  
 Tramadol, 188–189  
 Trametinib, 804  
 Transdermal absorption, in neonates and infants, 60  
 Transdermal contraceptive patch, 442–443  
 Transdermal monoamine oxidase inhibitors, 223  
 Transdermal system, fentanyl, 185  
 Transdermal testosterone, 450–451  
 Transfeminine, 467b  
 Transgender, 467b  
 Transgender female, 467b  
 Transgender health, 466–474  
   clinical guidelines, 467t  
   gender-affirming hormone therapy  
     for adults, 469–470  
     for transgender adolescents, 468–469  
   terminology, 466, 467b  
   transitioning medications  
     estrogen, 471–472  
     GnRH analogues, 470–471  
     testosterone, 472–474  
 Transgender male, 467b  
 Transgender man, 466, 467b  
   drug therapy for, 448  
   testosterone for, 472–474  
 Transgender woman, 466  
   estrogen for, 471–472  
 Transmasculine, 467b  
 Transmucosal system, fentanyl, 185  
 Transport systems, 15  
 Transurethral insertion, alprostadil, 463  
 Trastuzumab, 51, 795  
 Traveler's diarrhea, 606–607  
 Trazodone, 239  
 Treatment resistant schizophrenia, 208  
 Trematodes, 773  
   infestations, 775  
 Tremor  
   albuterol and, 108  
    $\beta_2$  receptors activation, 104  
   lithium and, 229  
*Treponema pallidum*, 767  
 Tretinoin, 809, 834  
 Triamcinolone, 512t, 579t  
 Triamcinolone acetate, 535t  
 Triamterene, 292  
 Trichinosis, 774  
 Trichloroacetic acid (TCA), 846  
 Trichomoniasis, 768, 768t  
 Trichuriasis, 774  
 Triclabendazole, 775–776t  
 Tricyclic antidepressants (TCAs), 217, 218–220  
   adverse effects, 218  
   black box warning, 218b  
   for cancer pain, 816  
   chemistry, 218  
   clinical manifestations, 220  
   drug interactions, 218–220  
   drug selection, 220  
   epinephrine and, 106  
   mechanism of action, 218  
   for migraine prevention, 197  
   monoamine oxidase inhibitors (MAOI) and, 223  
   panic disorder, 243  
   patient education, 218b  
   pharmacokinetics, 218  
   prescribing considerations, 220b  
   promoting activation of serotonin  
     receptors, 216t  
   therapeutic uses, 218  
   toxicity, 220  
   treatment, 220  
 Trifluridine, 724t, 725  
 Triglycerides, high, 352  
 Trihexyphenidyl, 142  
 Trimethoprim, 683t, 684t, 685b, 686, 686b  
 Trimethoprim/sulfamethoxazole, 686–688  
   adverse effects, 687–688  
   antimicrobial spectrum, 687  
   drug interactions, 688  
   microbial resistance, 687  
   pharmacokinetics, 687  
   prescribing, 688b  
   sites of action, 686, 687f  
   therapeutic uses, 687  
 Triprolidine, 582t  
 Triptans  
   ergot alkaloids and, 195  
   and ergotamine interaction, 196  
   for menstrually associated migraine, 197–198  
   for migraine headache, 193–195  
   pharmacology, 194t  
   prescribing considerations, 195b  
   promoting activation of serotonin  
     receptors, 216t  
 Triptorelin, 798  
 Triterpenoids, 712t, 720  
 Trospium, 97t  
 Tuberculosis, 694–706  
   drug resistance and, 694  
   drug-sensitive, 695, 696f  
   drugs for  
     isoniazid, 699–701, 701b  
     pharmacology of, 699–703  
     prototype drugs, 699b  
   evaluating treatment, 697  
   extensively drug-resistant, 695  
   isoniazid- or rifampin-resistant, 695  
   multi-drug-resistant, 695, 696f  
   pathogenesis of, 694  
   patient-centered care across the life span, 695b  
   plus HIV infection, 696  
   primary infection, 694  
   prime directive, 694–695  
   treatment of, 697–699, 698t  
   vaccination against, 699  
 Tumor infiltrating lymphocytes (TILs), 810  
 Tumor necrosis factor (TNF) antagonists, 843  
 Tumor necrosis factor inhibitors, 527–529,  
   527t, 528b  
   indications for, 527t  
 Turmeric, 643  
 Twice-daily premixed regimen, 400  
 28-day-cycle schedules, oral contraceptives  
   and, 441–442  
 Tympanostomy tubes, 858  
 Type 1 diabetes (T1D), 393  
   characteristics, 394t  
   diagnosis, 394  
   dyslipidemia management, 394  
   glycemic control in, 395  
   hypertension management, 394  
   insulin replacement, 394  
   nephropathy management, 394  
 Type 2 diabetes (T2D), 393  
   characteristics, 394t  
   diagnosis, 395  
   drugs for, 402t  
   glycemic control in, 395  
 Tyramine, dietary, 220  
   hypertensive crisis, 221  
 Tyrosine kinase inhibitors, 780t, 781
- ## U
- Ubrogapant, 196  
 Ulipristal acetate emergency contraception  
   pill, 445  
 Ultraviolet radiation, 851, 852f  
 Undecylenic acid, 720  
 Unfractionated heparin, 371–374  
 Unstable angina, intravenous nitroglycerin for, 879  
 Urate-lowering therapy (ULT), 537–539,  
   538b, 539b  
 Uric acid oxidase, recombinant, 536t, 538–539  
 Uricosuric agents, 535t, 536t, 538  
 Urinary alkalinizers, 693  
 Urinary bladder, overactive. *See* Overactive  
   bladder, muscarinic antagonists for  
 Urinary retention  
   atropine, 94  
   baclofen and, 172  
   bethanechol for, 84  
   morphine and, 184  
 Urinary tract  
   antiseptics, 691–693, 692b  
   bethanechol and, 85  
 Urinary tract infections (UTI), 689–693  
   acute bacterial prostatitis, 691  
   acute cystitis, 689, 690f  
   acute uncomplicated pyelonephritis,  
     689–690  
   antibiotics specific for, 692t  
   complicated, 690  
   organisms that cause, 689  
   patient-centered care across the life span, 692b  
   recurrent, 690–691  
   regimens for oral therapy, 691t  
   sulfonamides for, 682  
   treatments for, 689–691  
   trimethoprim/sulfamethoxazole, 687  
   urinary tract antiseptics and, 691–693, 692b  
 Urogenital atrophy, in menopause, 431
- ## V
- Vaccination  
   definition of, 484  
   against tuberculosis, 699  
 Vaccine Adverse Event Reporting System  
   (VAERS), 485  
 Vaccine-preventable diseases, reporting of, 484

- Vaccines. *See also* Immunization, childhood  
 adverse effects, 489t  
 for chemoprevention, 810  
 contraindications to, 485t  
 COVID-19, 742, 743t  
 definition, 484  
 glucocorticoids and, 514  
 influenza, 493, 738–740, 739t  
   adamantanes, 740  
   administration of, 739–740  
   adverse effects of, 738  
   efficacy of, 738  
   neuraminidase inhibitors, 740–741  
   oseltamivir, 740  
   precautions, 738  
   types of, 738  
   zanamivir, 740–741  
 information statements, 485  
 killed *versus* live, 484  
 specific toxoids and, 488–494, 488t
- Vagina, contraceptive ring, 443
- Vaginosis, bacterial, 767–768, 768t
- Valacyclovir, 723, 724t
- Valerian, 643–644
- Valganciclovir, 726–727, 727t
- Valproate, bipolar disorder and, 230–231
- Valproic acid, 158  
   oxcarbazepine, 159–160
- Valsartan, 300, 325
- Valsartan in Acute Myocardial Infarction Trial (VALIANT), 300
- Vancomycin, 667–668, 668b, 680
- Vandetanib, 803–804
- Vardenafil, 460t, 462
- Varenicline, 266
- Variant angina, 360–361, 367  
   nitroglycerin for, 362
- Variation, in drug responses, 44–47  
 in absorption, 45  
 age, 44  
 bioavailability and, 45  
 body weight and composition and, 44  
 comorbidities, 46  
 gender- and race-related, 45  
 genetics and pharmacogenomics, 45–46  
 pathophysiology, 44  
 placebo effect, 45  
 social determinants of health (SDOH), 46, 47t  
 tolerance, 44–45
- Varicella zoster virus, 486–487  
 drugs for, 721–725, 722t, 723b, 725b  
 vaccine, 491
- Vascular smooth muscle (VSM), 304, 315–316  
 dihydropyridines and, 307–308  
 verapamil and diltiazem, 304–307
- Vascular system, drug exit from, 17–19
- Vasoconstriction, 80  
 angiotensin II, 293
- Vasoconstrictors, local anesthesia and, 178
- Vasodilation, adrenergic antagonists in, 117–119
- Vasodilators, 309–311  
 as antihypertensive drugs, 316  
 for heart failure, 326  
 histamine-1 stimulation as, 495  
 hydralazine, 309–310  
 intravenous, 879  
 minoxidil, 310–311  
 nitroglycerin, 361  
 patient education, 309b  
 person-centered care across the life span, 311b  
 preparations, dosage, and administration, 310t  
 prescribing considerations, 310b
- Vasomotor symptoms, in menopause, 427, 433–434
- Vasopressin receptor antagonists (Vaptans), 881–882
- Vasospastic angina, 360–361
- Vaughan Williams classification, antidysrhythmic drugs, 338t
- Vemurafenib, 804
- Venlafaxine, 217, 242
- Venous return, 283
- Venous thrombosis, 370
- Ventricular dysrhythmias, 339  
 digoxin-induced, 339  
 ST-segment elevation myocardial infarction and, 870
- Ventricular fibrillation, 339
- Ventricular tachycardia, 339
- Verapamil, 304–306, 343  
 acute care, 878  
 adverse effects, 306  
 digoxin and, 329  
 drug interactions, 306  
 hemodynamic effects, 305  
 nitroglycerin and, 362  
 pharmacokinetics, 305–306  
 prescribing considerations, 307b  
 therapeutic uses, 306
- Very-low-density lipoproteins (VLDLs), 346
- Vesicants, local injury from extravasation of, 789
- Vesicular monoamine transporter 2 (VMAT2) inhibitors, 205–206
- Viloxazine, 250–251
- Virilization, 450
- Viruses  
 antiviral agents, for non-HIV viral infections, 721–744, 722t, 723b  
   prototype drugs, 723b  
   attempted treatment of viral infection, 654  
   cytomegalovirus, 725–728, 726b, 726t  
   hepatitis. *See* Hepatitis  
   herpes simplex virus, 721–725, 722t, 723b, 725b, 768–769  
   influenza, 487  
     acute otitis media and, 858  
     prevention and treatment of, 858  
     vaccines, 493, 738–740, 739t  
   varicella, 486–487  
     drugs for, 721–725, 722t, 723b, 725b  
     vaccine, 491
- Vision. *See* Eyes
- Vitamin A, 614  
 deficiency, 613t
- Vitamin B<sub>1</sub>, 618  
 deficiency, 613t
- Vitamin B<sub>2</sub>, 617–618  
 deficiency, 613t
- Vitamin B<sub>3</sub>, 617
- Vitamin B<sub>5</sub>, 619–620
- Vitamin B<sub>6</sub>, 133, 618
- Vitamin B<sub>7</sub>, 620
- Vitamin B<sub>9</sub>, 619
- Vitamin B<sub>12</sub>, 388–391, 618–619  
 biochemistry and physiology of, 388  
 deficiency, 619  
   causes, 389  
   consequences, 389–390  
   diagnosis, 390  
   *vs.* folic acid deficiency, 390t  
   guidelines for treating, 390–391  
   long-term treatment, 391  
   neurological damage, 390  
   fate in body, 389  
   metabolic function, 389
- Vitamin C, 616–617
- Vitamin D, 541, 542t, 614–615  
 analogs, 839  
 deficiency, 544
- Vitamin D (*Continued*)  
 as a hormone, 544  
 patient education, 545b  
 pharmacokinetics, 544  
 physiologic actions, 544  
 preparations, dosage, and administration, 545–546, 545t  
 prescribing considerations, 546b  
 requirements, 544  
 sources, 544  
 therapeutic uses, 544  
 toxicity (hypervitaminosis D), 545
- Vitamin E, 615
- Vitamin K, 616  
 deficiency, 616
- Vitamin K epoxide reductase complex 1 (VKORC1), 50–51
- Vitamins, 611–620  
 adequate intake of, 611  
 basic considerations, 611–614  
 classifications of, 611  
 dietary reference intakes, 611  
 fat-soluble, 614–616  
 folic acid, 391, 619  
 multivitamin supplement, 611–613  
 niacin, 617  
 patient-centered care across the life span, 613b  
 pharmacokinetics of, 615t  
 protective antioxidant effects in, 613–614  
 riboflavin, 617–618  
 thiamine, 618  
 tolerable upper intake level of, 611
- Volume contraction, 863–864
- Volume, fluid  
 contraction, 863–864  
 disorders of osmolality and, 863–864  
 expansion, 864
- Vorapaxar, 383–384
- Vorinostat, 807
- Vulnerability of individual, substance use disorder and, 255
- Vulvovaginal candidiasis, 711
- W**
- Waist circumference, 621
- Warfarin, 375–377, 509  
 adverse effects, 376–377  
 contrasts with heparin, 377, 379t  
 drug interactions, 377  
 history, 376  
 levothyroxine metabolism, 420  
 mechanism of action, 376  
 monitoring treatment with, 376  
 patient education, 377b  
 prescribing considerations, 377b  
 therapeutic uses, 376  
 warnings and contraindications, 377
- Warts  
 agents used to remove, 845–846  
 anogenital, 771  
 common, 846  
 venereal, 845–846, 846t
- Water resistance, of sunscreen, 852
- Water retention  
 increased blood volume with heart failure and, 322  
 renal, 284–285
- Water-soluble vitamins, 616–620
- Weight gain  
 antipsychotic drugs and, 208–209  
 fluoxetine, 216  
 pathophysiology, 622–623  
 sulfonyleurea and, 405–406
- Weight loss. *See also* Obesity  
 amphetamine and, 247

- Weight loss (*Continued*)  
  biguanides and, 404–405  
Wernicke encephalopathy, 258  
Whipworm infestation, 774  
Whooping cough. *See* Pertussis  
Withdrawal syndrome, 234  
  alcohol, 262–263  
  baclofen and, 169  
  defined, 254  
  glucocorticoids and, 516  
  opioids and, 191  
  with selective serotonin reuptake  
    inhibitors, 216b  
Withdrawal techniques, barbiturates, 273  
World Health Organization (WHO), on cancer  
  pain management, 813, 813f
- Wound healing, impaired, glucocorticoids  
  and, 513  
Written instructions, 11  
Written prescriptions, 8  
Wuchereriosis, 774
- X**
- Xanthine oxidase inhibitors, 535t, 536t, 537–538  
Xerostomia  
  atropine, 94  
  centrally acting  $\alpha_2$  agonist, 121
- Y**
- Yuzpe Regimen, 445
- Z**
- Zafirlukast, 563–564  
Zaleplon, 235–236  
Zanamivir, 740–741  
Zevalin, 805  
Ziagen, 51  
Zileuton, 563  
Ziprasidone, 210  
Zoledronate, 796  
Zollinger-Ellison syndrome, 586, 589  
Zolmitriptan, 198  
Zolpidem, 235